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ABSTRACT 
 
 
The objective of the study is to demonstrate alleviation of pulmonary inflammation 
associated with acute lung injury (ALI) using novel surface modified nanoparticles. ALI 
is characterized by three main pathological events: I) pulmonary edema, II) excessive 
pro-inflammatory cytokines and chemokines production from alveolar epithelial and 
endothelial cells and III) leukocyte migration from blood circulation into alveoli. 
Currently, there is no FDA approved pharmacological treatment available except the 
supportive mechanical ventilation therapy. Numerous clinical trials involving 
pharmacological therapies aimed at different pathological targets turned unsuccessful. 
National Institute of Heart Lung and Blood Institute (NHLBI) cited underappreciation of 
drug delivery systems as one of the attributed drawbacks.  
 
During ALI, the αvβ6/αvβ5 integrins of alveolar epithelium and endothelium, 
respectively play a critical role in mediating pulmonary edema in interleukin-1  (IL-1 ) 
stimulated ALI models. A transient blockade of both integrins by antibodies (Ab) or small 
Arg-Gly-Asp (RGD) peptide sequences may provide new causal therapies for pulmonary 
edema. A transcription factor, nuclear factor-  (NF- B) is associated with the regulation 
of a battery of genes that encode for pro-inflammatory cytokines, chemokines and cell 
adhesion molecules (CAMs). Glucocorticoids (GCs) exert their anti-inflammatory effects 
by NF-  transcriptional interference mechanisms. Besides the above inflammatory 
mechanisms, leukocyte migration is another hallmark feature responsible for part of ALI 
pathogenesis. Leukocyte migration is dictated by sequential activation of adhesion 
molecules and their ligands on both leukocytes and endothelial cells (ECs). Intercellular 
adhesion molecule-1 (ICAM-1) located on alveolar endothelium plays a significant role 
in the recruitment of leukocytes into alveoli. Blockade of ICAM-1 receptors using anti-
ICAM-1 antibodies may impede leukocyte migration into alveoli. 
 
In view of high mortality associated with ALI, there is an urgent need for a drug delivery 
system that inhibits majority of pathological events. In drug targeting research, liposomes 
are considered as versatile for their ability to carry drug payloads and flexible enough to 
modulate their surface for targeting purposes. In the current investigation, I developed 
surface modified stable liposome formulation for delivery of methylprednisolone 
succinate (a glucocorticoid; MPS) to the lung. Liposomes were targeted to the disease 
sites through different routes of administration to avail the spatial expression of the 
receptors in response to IL-1  stimulus. MPS-L
cRGD
 targeted to v 6 integrins of 
alveolar epithelium attenuated pulmonary edema. MPS-L
Ab
 were able to modulate 
neutrophil migration. Moreover, MPS released from targeted liposomes inhibited the 
expression of pro-inflammatory cytokines and chemokines. The research work 
demonstrated the concept of using drug encapsulated and surface modified nanoparticles 
for therapeutic intervention of ALI. 
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CHAPTER 1. INTRODUCTION TO TARGETED LIPOSOMES 
 
 
1.1 Statement of Problem 
 
In 1967, at the Colorado General Hospital, Ashbaugh and colleagues were the first to 
describe patients with a variety of underlying illnesses characterized by tachypnea, 
hypoxemia resistant to oxygenation by regular ventilator support, decreased lung 
compliance, diffuse bilateral infiltrates on chest radiographs and surfactant abnormalities. 
Together, the above characteristics are defined as acute respiratory distress syndrome 
(ARDS).
1
 Another term, acute lung injury was used in synonymous with ARDS in most 
cases, but could only be applied to a broad range of pathological abnormalities in the lung 
where as ARDS should be reserved for the most severe cases of lung injury.
2
 
 
ALI is a major cause of acute respiratory failure with high morbidity and mortality in 
critically ill patients.
3
 Recent epidemiologic data indicate that the incidence of ALI 
defined by consensus physiologic criteria may account for 36,000 deaths per year in 
U.S.A.
4
 Although, there is evidence that mortality in patients with ALI may have declined 
over the last 10 to 15 years, it remains high (30-40%) and is an important cause of 
pulmonary and non-pulmonary morbidity in ICU patients.
5
 ALI develops in patients of all 
ages from a variety of clinical disorders. These conditions can be divided into two 
categories based on whether the insult was direct (pulmonary) or indirect (extra-
pulmonary). Direct injury can be described as a condition in which the lung epithelium is 
directly injured. Causes of such lung injury include pneumonia, aspiration of gastric 
contents, inhalation of toxic substances and pulmonary contusion.
6
 Direct causes of lung 
injury lead to a syndrome with more predictability and to a short latent period than do 
indirect causes.
7
 Indirect lung injuries are conditions that activate a systemic 
inflammatory response. Multiple trauma, burns, sepsis, fat emboli and hemorrhagic shock 
are all associated with a high risk of developing ALI. So far, mechanical ventilation is the 
lone supportive therapy for the alleviation of symptoms associated with ALI. 
 
 
1.2 Overview of Acute Lung Injury 
 
The most important pathological finding in the lung during the early stages of ALI is 
severe pulmonary edema, due to increased permeability of the alveolar endothelial and 
epithelial barriers. As illustrated in Figure 1.1, the morphological picture has often been 
labeled as diffuse alveolar damage and includes cellular necrosis, inflammation and 
fibrosis. Although, pathogenesis of ALI remains unclear, indirect evidence suggests that 
pulmonary edema occurs after a direct activation due to acute lung inflammation, or as 
the pulmonary manifestation of a systemic inflammatory response.
8
 The inflammatory 
response in both cases involves alveolar migration of leukocytes, (e.g. macrophages, 
monocytes and neutrophils) which are activated by pro-inflammatory cytokines and 
chemokines.
9
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Figure 1.1 Schematic representation of the normal alveolus and the injured alveolus 
in the acute phase of ALI/ARDS. 
 
In the acute phase of the syndrome (injured alveolus), sloughing of alveolar epithelial 
cells, with the formation of protein rich hyaline membranes on the denuded basement 
membrane is seen Neutrophils adhere to the injured capillary endothelium and 
extravasate into alveoli, which is filled with protein rich edema fluid. In the alveoli, 
alveolar macrophages secrete cytokines, which further stimulate chemotaxis and activate 
neutrophils. Neutrophils release oxidants, proteases, leukotrienes, and other pro-
inflammatory mediators, such as platelet activating factor. The influx of protein rich 
edematous fluid into the alveolus leads to the inactivation of surfactant. 
 
Reproduced with permission. Ware, L.B. & Matthay, M.A. The acute respiratory distress 
syndrome. N Engl J Med 342, 1334-1349 (2000).
4
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1.2.1 Pulmonary Cytokines and Inflammation in ALI 
 
A complex network of cytokines and other pro-inflammatory compounds initiate and 
amplify the inflammatory response in ALI. Different cell types, such as endothelial, 
epithelial and leukocytes produce cytokines and chemokines. Excessive or unregulated 
release of cytokines and chemokines might result in unwanted systemic and/or local 
effects that may cause ALI. The inflammatory process is regulated by the early response 
cytokines (e.g. tumor necrosis factor-  (TNF-α), IL-1β and IL-6), which are suggested as 
key mediators in the pathogenesis of ALI.
10
 These early response cytokines induce an 
intricate cascade of events, which include the production and release of chemokines (e.g. 
IL-8, monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory protein-1 
(MIP-1) and cytokine induced neutrophil chemoattractant-1 (CINC-1)) from endothelial 
cells, epithelial cells or leukocytes.
4,11-13
 In addition, cytokines and chemokines cause 
sequestration of leukocytes by inducing adhesion molecules (e.g. integrins, selectins and 
members of immunoglobulin superfamily) expression on epithelial and endothelial cells, 
and further activate the leukocytes, which trigger an extensive inflammation process.
14-17
 
 
 
1.2.2 Pulmonary Edema 
 
In the normal lung, fluid moves continuously outward from vessels to the interstitial 
space according to the permeability of the capillary membrane as well as the net 
difference between hydrostatic and protein osmotic pressures. Non-cardiogenic 
pulmonary edema occurs when the permeability of the alveolar epithelial/endothelial 
membrane increases because of direct or indirect lung injury resulting in a marked 
increase in the amount of fluid and protein leaving the vascular space. As illustrated in 
Figure 1.2, nature of the inflammatory stimulus/injury determines the mechanistic 
pathway for an increase in permeability across alveolar epithelium or endothelium, thus 
contributing to pulmonary edema. 
 
 
1.2.2.1 Alveolar Epithelial Integrin Receptors: Pulmonary Edema 
 
Pittet et al. showed that lipopolysaccharide (LPS) and IL-1  cause an increase in lung 
vascular permeability. Both the stimuli exert this effect through activation of 
transforming growth factor-beta (TGF- ) via v 6 integrin dependent mechanism in 
alveolar epithelium. Under normal conditions, TGF-  is latent and is non-covalently 
associated with latency associated peptide (LAP) and latent TGF-β-binding protein-1 
(LTBP-1). Activation of TGF-  by integrin receptors is critical in the propagation of lung 
edema in ALI.
18-20
 The v 6 integrin binds to RGD domain of the LAP of TGF-  
complex and activates latent TGF- .
19
 Although, the exact mechanism of v 6 integrin 
mediated TGF-  activation is still not clear, it is likely that the activation process 
involves multiple coordinated mechanisms. 
 
Pittet et al. demonstrated that αvβ6 integrin mediated TGF-β activation is dependent on 
cytoskeletal integrity. Inhibition of actin assembly by cytochalasin D and β6 subunit 
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Figure 1.2 Schematic illustration of the effect of interleukin-1β on the alveolar 
capillary barrier. 
 
The model demonstrates IL-1β signaling pathway that leads to an increase in lung 
epithelial and endothelial permeability. IL-1β causes an increase in RhoA activity leading 
to TGF-β activation via αvβ6 integrins. TGF-β activation induces an increase in 
permeability and an inhibition of the Na
+
 driven fluid transport in alveolar epithelial cells. 
In endothelial cells, IL-1β activates RhoA and increases lung endothelial permeability via 
the phosphorylation and endocytosis of β-catenin and αvβ5 integrin dependent stress 
fiber formation in lung endothelial cells. 
 
Reproduced with permission. Ganter, M.T. et al. Interleukin-1 {beta} causes acute lung 
injury via {alpha}v{beta}5 and {alpha}v{beta}6 integrin-dependent mechanisms. Circ 
Res 102, 804-812 (2008).
21
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cytoplasmic truncation mutants prevent integrin interaction with actin cytoskeleton, 
each abolishes TGF-β activation by αvβ6.19 Jenkins et al. demonstrated that upon external 
stimulus, PAR1 receptor signals to the αvβ6 integrins via RhoA and Rho kinase.20 
Because of the well-known effects of RhoA in re-organizing actin, these findings are 
consistent with the observation that αvβ6 mediated TGF-β activity is completely inhibited 
by an inhibitor of actin polymerization, cytochalasin D. In fact, blockade of any 
component in the sequence of events in actin polymerization leads to inhibition of TGF-β 
activity. A complete blockade of TGF-β activity was observed using αvβ6 antibodies. 
Recently, Ganter et al. demonstrated a complete inhibition of pulmonary edema using 
anti-αvβ6 integrin and anti-TGF-  antibodies in IL-1  instilled ALI model.21 
 
 
1.2.2.2 Alveolar Endothelial Integrin Receptors: Pulmonary Edema 
 
Physical passage of solutes through the endothelial barrier is thought to occur via 
paracellular pathways or through receptor activated transcytosis.
22
 Direct modification of 
actin cytoskeleton in endothelial cells is important for increasing paracellular 
permeability. One frequently cited model describes paracellular gap formation as a 
consequence of imbalanced competition between cytoskeletal, adhesive cell–cell and 
cell–matrix forces.23,24 Actomyosin mediated generation of tension leads to alteration of 
cell shape and formation of paracellular gaps. Stress fibers have been shown to form in 
endothelial cells, stimulated by several vasoactive mediators.
21,25,26
 In TGF-  stimulated 
model, TGF-  activates RhoA signaling cascade in endothelial cells. The TGF-  induced 
activation of the RhoA/Rho-kinase signaling cascade in endothelial cells increases F-
actin content, which contributes to an increase in stress fiber formation, interendothelial 
gap formation and subsequent decrease in endothelial monolayer resistance.
27
 Ganter et 
al. demonstrated that IL-1  activates RhoA, and increases lung endothelial permeability 
via v 5 integrin dependent stress fiber formation in lung endothelial cells. Furthermore, 
stress fiber formation induced by the agonists was attenuated by blockade of αvβ5 
integrin, suggesting a mechanism for αvβ5 integrins to regulate paracellular endothelial 
permeability in the lung. A complete inhibition of transendothelial permeability was 
observed using anti-αvβ5 integrin antibodies.21 
 
In summary, αvβ5/αvβ6 integrins play a critical role in mediating the development of 
pulmonary edema in LPS or IL-1  or TGF-  stimulated ALI models. Taken together, 
transient blockade of both integrins by antibodies or small RGD peptides may provide 
new causal therapies for pulmonary edema. 
 
 
1.2.3 Leukocyte Migration in Pulmonary Vasculature 
 
Circulating leukocytes infiltrate from blood circulation into tissues under both normal 
and pathologic circumstances. As illustrated in Figure 1.3, leukocyte migration from the 
vasculature occurs by a multi-step process, dictated by the sequential activation of 
adhesion molecules and their ligands on both leukocytes and ECs.
28,29
 Leukocytes  
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Figure 1.3 Schematic diagram of neutrophil and endothelial cell interactions in the 
pulmonary vasculature. 
 
E-selectin upregulation induces rolling of neutrophils, which adhere to endothelial cells 
activated by ICAM-1. Followed by transendothelial migration, neutrophils infiltrate into 
alveoli. Schematic diagram also shows various receptors and ligands involved in the 
neutrophil migration process. 
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infiltrate by these sequence dependent mechanisms but differ in their responses to 
chemotactic (e.g. MCP-1) and cytokine signals (e.g. TNF-  or IL-1 ), particularly in 
their qualitative and quantitative expression of adhesion molecules (e.g. selectins, 
integrins and members of immunoglobulin superfamily).
30-32
 Leukocyte trafficking in 
pulmonary circulation differs from systemic vasculature with respect to: I) the marginated 
pool of leukocytes, II) the site of transendothelial migration and III) requirements of 
adhesion molecules for leukocyte migration. Leukocyte migration begins with the 
“capture” by the vessel wall of leukocytes from flowing blood and is followed by their 
“rolling” to a small extent along the vessel wall. About 97% of pulmonary vascular 
leukocytes (7-8 µm) are found in the capillary network where vessels are too small to 
allow rolling (5-6 µm).
33
 Despite the lack of rolling in pulmonary capillaries, selectins 
may be involved in the leukocyte-endothelial cell interactions.
34-36
 Only after appropriate 
stimuli from alveolar capillary ECs, leukocytes become firmly adhered to ECs and are 
positioned for migration from blood vessels into lung parenchyma. 
 
The initiating signal for the next step of migration is firm adhesion, which is postulated to 
be either a receptor mediated event in response to pro-inflammatory 
cytokines/chemokines or an event propagated from signals from activated selectins.
36-38
 
Cytokines/chemokines on inflamed endothelium interact with their receptors on 
leukocytes. These interactions result in the activation of leukocyte integrins. Activated 
integrins interact with members of the immunoglobulin superfamily (e.g. ICAM-1) 
displayed on the inflamed endothelium, and these interactions cause the rolling cells to 
arrest on endothelium. Transmigration of arrested leukocytes across the endothelium is 
not as well understood. However, it is generally accepted that leukocytes migrate across 
the endothelium by penetrating junctions that lie within the intercellular cleft. Leukocytes 
move across blood vessel walls by passing between ECs (diapedesis).
39
 After 
transmigration, leukocytes move into the interstitium along a gradient of chemoattractant 
toward the source of the chemoattractant. In lungs, leukocytes then migrate across the 
epithelium to reach the apical side. Molecular requirements of transepithelial migration 
are not well understood but most likely involve a multi-step process that requires 
sequential interactions of leukocyte adhesion molecules with their ligands on the 
epithelial cells.
40,41
 
 
Leukocyte migration depends on: I) nature of inflammatory stimuli and II) route of 
exposure of stimuli to the alveolar capillary bed. Doerschuk et al. demonstrated that 
neutrophil migration occurs through at least two distinct pathways. One pathway requires 
2-integrins, whereas the other does not, and the distinction depends on the stimulus.
42
 
Gram negative bacteria (e.g. E.coli) or LPS elicit neutrophil migration via pathways 
predominately mediated by β2 integrins.42 Alveolar endothelial ICAM-1, which serves as 
a ligand for neutrophil β2 integrins is upregulated in response to LPS stimulus. In 
contrast, gram-positive bacteria (e.g. S.pneumoniae) elicit pulmonary neutrophil 
migration independent of β2 integrins.43 In a situation where neutrophil migration is β2 
integrin independent, antibody inhibition of β1 integrin or specific -subunits ( 2, 4, 
5 and 6) blocks neutrophil migration into alveoli.
44
 Moreover, gram-negative stimuli 
appear to elicit greater TNF-  production than do gram-positive stimuli. Taken together, 
integrin antibody studies and disparate cytokine production elicited by various stimuli 
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suggest that the adhesion molecule requirements for migration might depend on the type 
and quantity of cytokines and chemokines produced in response to inflammatory 
stimulus. 
 
Shang and Issekutz identified a role for β2 integrins, as well as 4, 5 and 6 1 
integrins.
45
 With a cocktail of blocking antibodies to these integrins, neutrophil migration 
was inhibited by 60%.
46
 Recently, a few studies indicated exceptions to the β2 integrin 
dependent neutrophil migration in LPS stimulated models. These studies reported the 
significance of 4 and/ or 5 integrins along with β2 integrins.47,48 Intratracheal (i.t.) 
instillation of LPS (E.coli) results in β2 integrin dependent migration, while intravenous 
administration results in sequestration that is β2-integrin independent.42,49 Airway 
instillation of stimuli via trachea would presumably induce inflammation along airway 
walls containing vessels of the bronchial circulation as well as pulmonary capillary beds. 
Conversely, models that use intralobular instillation may deliver inflammatory stimuli 
anatomically closer to alveolar regions, and may therefore induce relatively more 
neutrophil migration from the pulmonary vasculature. 
 
Clinical and experimental studies have provided circumstantial evidence of the 
occurrence of neutrophil mediated injury in ALI. Broncho-alveolar lavage fluid (BALF) 
in normal subjects yields normally only a few neutrophils.
50
 However, a subpopulation of 
circulating neutrophils is always present within the pulmonary microvasculature. 
Evidence shows that percentage of BALF neutrophils is markedly increased in ALI 
affected patients.
51
 The migrated neutrophils release myeloperoxidase (MPO) and 
reactive oxygen species (ROS) in alveoli, which can be potentially harmful to alveolar 
epithelium.
52
 When produced in excessive amounts or when anti-oxidant defense is 
insufficient, free radicals can damage DNA, lipids, proteins and carbohydrates.
53
 
Alongside neutrophils, monocytes play a critical role in the propagation of inflammatory 
response.
54,55
 From blood circulation, they migrate into lungs and differentiate into 
alveolar macrophages, which amplify the inflammatory response through the production 
and secretion of chemokines and other pro-inflammatory mediators. 
 
 
1.2.4 Relevance of ALI Models in Therapeutic Intervention 
 
Different animal models of ALI are in use to investigate pathological mechanisms of lung 
injury.
56
 However, none of the ALI models adequately reproduces the full characteristics 
of human ALI, and therefore, the choice of a particular model is made after considering 
the specific features of each model. Most ALI models target the primary tissues, alveolar 
epithelium or endothelium or both. Modeling strategies are an attempt to target specific 
tissue. From a practical standpoint, there are three general types of model systems: I) 
models in which the lung is injured directly by a noxious stimulus. These include 
intratracheal or intranasal administration of bacteria or bacterial products, such as LPS or 
pro-inflammatory cytokines, IL-1 ; administration of an acid, such as HCl to reproduce 
aspiration;
57,58
 administration of high inspired fractions of oxygen;
59
 depletion of 
surfactant by serial lavage with 0.9% NaCl
60
 or exposure to mechanical stretch using 
mechanical ventilation with high tidal volumes,
61
 II) models in which the lung is injured 
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indirectly. This category includes models based on reproducing sepsis, such as cecal 
ligation and puncture (CLP);
62
 systemic administration of LPS or bacterial infusion
63
 and 
III) combination models. Most commonly used model includes saline lavage followed by 
mechanical ventilation, or CLP followed by hemorrhage. 
 
Exposure to moderate doses of LPS is widely used as a prototypic ALI model,
64
 while 
administration of high doses of LPS is considered as a relevant model of ARDS.
65
 Early 
phase (4-6 h) of LPS instillation (i.t.) is characterized by an increase in BALF leukocytes, 
albumin and pro-inflammatory cytokines/chemokines, and late phase (24–48 h) is 
characterized by normalization of BALF cytokines and increase in BALF leukocyte 
counts.
66
 Systemic administration of LPS in animals induces a septic shock resulting in 
injury to various organs, including the liver
67
 and the lung.
68
 Following the systemic 
administration of LPS, the capillary endothelium is the initial site of injury, which results 
in apoptosis of endothelial cells.
69
 Neutrophil migration occurs before epithelial 
permeability changes or alveolar barrier disruption.
70
 Other hallmark features include 
elevated concentrations of cytokines/chemokines in blood circulation and coagulation 
abnormalities.
71
 Altogether, these animal models clearly demonstrate that direct 
(pulmonary) or indirect (systemic) challenges by endotoxins may cause lung tissue 
damage that are severe enough to qualify as ALI/ARDS. In addition, animal models 
provide a critical method for testing potential new therapies in a proof-of-principle 
fashion. 
 
 
1.2.5 Pharmacological Interventions of ALI in Preclinical and Clinical Trials 
 
The pathophysiology of ALI is increasingly well understood; however, very little success 
was achieved with regard to new treatment modalities. The spate of trial failures may 
relate to participant heterogeneity or to intervention strategy. Important considerations for 
trial failures are the timing of intervention (pre-ALI, the early exudative phase, the 
intermediate fibro-proliferative phase or later), mechanism of drug delivery (intravenous, 
enteral, inhaled or intrapulmonary instillation). As new information regarding the 
pathogenesis of ALI evolves, more specific therapies are being studied, including 
separate considerations for direct or indirect forms of ALI. Table 1.1 is a summary of the 
therapies under preclinical and various phases of clinical development. 
 
 
1.2.5.1 Anti-inflammatory Strategies: Corticosteroids 
 
Transcription factor, NF-kB is associated with the regulation of a battery of genes that 
encode for cytokines, chemokines and adhesion molecules.
72,73
 NF-κB is a heterodimeric 
protein composed of the DNA binding proteins, p65 and p50 constitutively present in the 
cytoplasm in an inactive form stabilized by the binding to the inhibitory protein, IκBα.74 
Cellular activation by adverse stimuli leads to phosphorylation and degradation of 
IκBα.75 The liberated NF-κB then translocates into the nucleus and binds to promoter 
regions of target genes to initiate the synthesis of the pro-inflammatory cytokines, 
chemokines and adhesion molecules. 
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Table 1.1 Pharmacological agents in preclinical and clinical phases of drug 
development. 
 
Stage of study Pharmacological intervention 
Preclinical Cyclooxygenase inhibitors: Eltenac 
 Keratinocyte growth factor (KGF) 
 Neutrophil elastase inhibitors: EPI-HNE-4 
Phase I Anti-oxidant: OxSODrol 
 Cytoprotective therapies: CPC-111 
 Soluble complement receptors: TP-20 
Phase II Anti-coagulants: NAPc2 
 Anti-inflammatory: PAF-AH/Pafase™ 
 Inhaled nitric oxide 
 β2-agonists 
 Soluble complement receptors: TP-10 
 Liquid ventilation: LiquiVent™ 
 Albumin and furosemide 
 Nutrition 
Phase III Surfactants: Venticute™, HL-10, lucinactant 
 Prostaglandins: Prostacyclin/PGI2, PGE1/TLC C-53 
 Growth Factors: GM-CSF/leukine 
 Anti-coagulants: rhAPC/drotrecogin alfa, TFPI 
 Corticosteroids 
 
G-CSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte macrophage 
colony-stimulating factor; hLS: Human lung surfactant; HNE: Human neutrophil 
elastase; KGF: Keratinocyte growth factor; NAC: N-acetylcysteine; NAP: Anti-
coagulation protein; rhAPC: Recombinant human activated protein C; PAF-AH: Platelet 
activating factor acetylhydroxylase; TFPI: Tissue factor pathway inhibitor. 
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Glucocorticoids mediate NF-  transcription interference by one of the following 
mechanisms:
75
 I) physically interacting with the p65 subunit and formation of an inactive 
(GR-NF-κB) complex,76 II) inducing the transcription of the inhibitory protein, IκBα,76-78 
III) impairing TNF-α induced degradation of IκBα79 and (IV) competing for limited 
amounts of GRα co-activators, such as steroid receptor co-activator-1.80 Through one of 
the above mechanisms, GCs suppress the production of cytokines by target cells (e.g., 
endothelial, epithelial and leukocytes) in response to inflammatory stimuli. Furthermore, 
they downregulate the expression of chemokines and adhesion molecules on these 
cells.
72,81-83
 Studies in vitro demonstrate a direct effect of GCs on cultured ECs and 
isolated neutrophils to inhibit expression of adhesion molecules.
84-86
 Several case series 
reports
87,88
 suggested that glucocorticoids could lower mortality in some patients with 
severe ALI when administered several days after ALI onset. In a small, randomized, 
placebo-controlled trial important clinical outcomes were better in patients randomized to 
receive methylprednisolone in the late phase of ALI.
89
 
 
 
1.2.5.2 Prostaglandin Agonists/Inhibitors 
 
Prostaglandin E1 is a vasodilator that blocks platelet aggregation and decreases 
neutrophil activation. This agent showed promise in experimental and preliminary 
clinical studies of lung injury.
90
 However, a multi-center study
91
 reported no evidence of 
reduced mortality in those treated with prostaglandin E1. Liposomal delivery of 
prostaglandin E1 was also not beneficial in a phase II study.
92
 Ketoconazole, a potent 
inhibitor of thromboxane and leukotriene synthesis was reported to prevent the 
development of ALI in high risk surgical patients. However, an NIH-sponsored multi-
center phase III trial
93
 showed no decrease in mortality for ketoconazole treatment (35%) 
vs. the placebo group (34%). 
 
 
1.2.5.3 Phosphodiesterase Inhibitors 
 
Pentoxifylline is a phosphodiesterase inhibitor that inhibits neutrophil chemotaxis and 
activation.
94
 In animal studies, lisofylline inhibited release of TNF- , IL-1  and IL-6, and 
attenuated shock induced lung injury in mice.
95
 However, phase III trial
96
 by the NIH-
ARDS Network in ALI patients showed no beneficial effects of lisofylline. 
 
 
1.2.5.4 Anti-oxidants 
 
Evidence suggests that ROS plays a major role in mediating injury to the endothelial 
barrier of the lung in ALI.
97
 In normal individuals, oxidant productions are normally 
balanced by a number of anti-oxidants, including water soluble molecules, such as 
glutathione and lipid soluble molecules, such as Vitamin E (α-tocopherol).98,99 N-
acetylcysteine (NAC), a synthetic anti-oxidant mediates its effect as a precursor for 
gluthatione.
98
 NAC was shown to protect lung tissue against oxidative damage in 
preclinical models.
100
 However, clinical studies failed to improve survival in ALI 
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patients.
101
 Vitamin E, considered as the principal anti-oxidant improved immune 
responsiveness, and reduced the incidence and severity of infectious diseases.
102
 
 
 
1.2.5.5 Anti-IL-8 Therapy 
 
One approach is to reduce the number of neutrophils that migrate into the extravascular 
space of the lung by interfering with neutrophil adhesion to the lung endothelium or by 
reducing the release of chemotactic factors in the extravascular space. Monoclonal 
antibodies that neutralize IL-8 reduced acid-induced lung injury in rabbits.
103
 Clinical 
trials of anti-IL-8 therapy for prevention in high risk patients or in early ALI may soon be 
warranted. 
 
 
1.2.5.6 Surfactants 
 
Surfactant is a lipoprotein complex produced by alveolar type II cells. Alveolar surfactant 
secretion reduces surface tension, and prevents alveoli from collapsing.
104
 Whether 
reduced in amount or dysfunctional in condition, surfactant abnormalities may lead to 
problems, such as ventilation-perfusion mismatch, hypoxemia and reduced lung 
compliance.
105
 Surfactant replacement therapy in animal models of ALI improved 
oxygenation, lung mechanics and survival.
104,106
 
 
 
1.2.5.7 Miscellaneous Therapies 
 
Many other therapeutic interventions are under preclinical and clinical investigations. 
Partial liquid ventilation uses perfluorocarbons to maintain open lung units and improve 
oxygenation.
107
 The use of activated protein C
108
 and GM-CSF
109
 are all moving forward 
in large scale clinical trials. β2 agonists110 and fluid balance manipulation111 appear 
promising despite varied conclusions from previous trials. Various ligand based 
pharmaceuticals (e.g. inhibitors of the upregulated receptors on alveolar epithelium or 
endothelium or leukocytes) are in different stages of drug development.  
 
Citing the multiple pathways involved in ALI pathogenesis, an „all-out‟ therapy that 
contributes to the resolution of edema, and inhibition of leukocyte migration and pro-
inflammatory mediators‟ production is most desirable rather than just limiting one or the 
other. 
 
 
1.2.6 Significance of Drug Delivery in ALI Pathogenesis 
 
Numerous clinical trials involving pharmacological therapies aimed at different 
pathological targets turned unsuccessful. One of the attributed drawbacks is the under-
appreciation of drug delivery systems in the management of ALI. Very few investigations 
were directed at drug delivery perspective in the treatment of ALI. However, the results 
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are promising both in the alleviation of the syndrome and improving the survival of 
patients. As described previously, the alveolar epithelium and endothelium play an 
important role in the vicious circle of production of pro-inflammatory mediators and 
leukocyte recruitment. An attractive therapeutic approach is to selectively target anti-
inflammatory drugs to activated epithelium/endothelium, thereby increasing the 
effectiveness of the targeted drug and simultaneously diminishing systemic side effects. 
To selectively deliver drugs into activated alveolar epithelial/endothelial cells, integrins 
and ICAM-1 receptors are suitable targets because of spatial and temporal expression in 
response to inflammatory stimulus. Furthermore, both integrin and ICAM-1 receptors are 
internalizing molecules, which results in the intracellular degradation of the drug-
targeting systems and drug release, thereby leading to local anti-inflammatory activity. 
Thus, targeting to integrin/ICAM-1 receptors facilitates multi-purpose: I) specific 
delivery of drugs for inhibition of pro-inflammatory mediators‟ production and II) 
blockade of receptors for inhibition of pulmonary edema/leukocyte migration. 
 
Optimal targeted drug delivery systems incorporate the ability to preferentially recognize 
and localize to sites of injury, while simultaneously avoiding uptake into normal tissue 
beds.
112
 Therefore, active targeted drug delivery systems are investigated to improve 
therapeutic efficiency and reduce side effects associated with systemic administration. 
Liposomes are studied extensively as potential vehicles for selective drug targeting, 
achieved by modulation of specific and non-specific cellular and molecular interactions. 
Liposomal drug delivery systems have received considerable attention due to their 
specific advantages: I) encapsulation of small and large molecules with a wide range of 
hydrophobicity levels and pKa values, II) prolong and target therapeutic agents by 
modification of liposome surface and III) minimize clinical drug dose and reduce toxicity 
effects. The surface chemistry of liposomes can be controlled by the selection of 
particular phospholipid moieties to incorporate several different molecules in well 
defined molar ratios. As a result, liposomes can be engineered to provide great diversity 
of structures with exceptional design control. Liposomes also have a relatively high 
encapsulation volume available for carrying therapeutic agents compared with other drug 
carrying nano sized vehicles.
113
 Therefore, liposomes are considered as potential targeted 
drug delivery systems. 
 
In the current investigation, we will apply the liposome drug delivery perspective to the 
pathological mechanisms, and improve therapeutic benefits in the treatment of ALI. It is 
perhaps this requirement that is most tenuous, but the one with the great potential. 
 
 
1.3 Overview of Liposome Literature 
 
Most of the medical applications of liposomes are in cancer and inflammation areas. 
Ligand targeted liposomes perform best against targets in the vasculature or readily 
accessible from the vasculature, e.g. as an adjuvant therapy in the treatment of residual 
and micro-metastatic disease following primary therapy of solid tumors by surgery or 
radiation.
114
 Over the next decade, the number of liposome based pharmaceutical 
products will continue to expand, justifying the investment in research and development 
  14 
over the previous years. Table 1.2 illustrates the liposome products in preclinical and 
clinical phases of development. 
 
 
1.3.1 Basic Liposome Composition 
 
Liposomes are spherical self-closed vesicular structures. The size of a liposome ranges 
from 20 nm to 1-5 m, and they may be composed of one or several concentric 
membranes, each with a thickness of about 4 nm. Liposomes possess unique properties 
owing to the amphipathic character of the lipids, which make them suitable for drug 
delivery. Liposomes, prepared using a lipid or combination of lipids carry water soluble 
drugs in their aqueous compartments and lipid soluble drugs in their lipid bilayers. The 
amphipathic phospholipid molecules, with distinct hydrophobic and hydrophilic domains, 
spontaneously form bilayers in aqueous media as a consequence of the interaction 
between the polar head group of the phospholipid and water. The charge, phase transition, 
hydrogen-bonding capacity, membrane rigidifying potential and functional groups of 
phospholipids all affect the retention of the encapsulated drug. 
 
The inclusion of cholesterol (CHOL) stabilizes liposomal phospholipid membranes 
against disruption by plasma proteins
115,116
 and results in decreased binding of plasma 
opsonins responsible for rapid clearance of liposomes from circulation.
117
 Cullis and 
coworkers
118
 showed that CHOL-free liposomes bound 3-4 times more protein than 
CHOL containing liposomes. This increase in CHOL caused a substantial increase in 
clearance from the blood of mice. CHOL-free liposomes were shown to aggregate rapidly 
in the absence of steric stabilization, and further leads to increased clearance.
119
 The 
fluidity of the membrane also affects the rate of clearance, with non-pegylated liposomes 
composed of unsaturated phospholipids and CHOL display rapid clearance rates than 
those containing saturated phospholipids.
120-122
 In the absence of CHOL, neutral 
phosphatidylcholine liposomes composed of saturated lipids were cleared more 
rapidly.
118
 However, high CHOL concentrations (30 mole%) resulted in the formation of 
a highly ordered crystalline state, which decreased protein binding and dramatically 
increased circulation life times.
118
 The rate of liposome clearance varied positively with 
the phase transition temperature of the phosphatidylcholine.
118
 This is likely due to 
increased protein binding to exposed hydrophobic domains originating from packing 
defects in gel phase membranes. Substitution of sphingomyelin for the high phase 
transition distearoyl phosphatidylcholine (DSPC) increased circulation life times in 
CHOL containing liposomes.
123
 This is likely due to the highly cohesive membranes
124
 
formed as a result of intermolecular hydrogen bonds between sphingomyelin and 
neighboring CHOL
122,125,126
 or even other sphingomyelin
127
 molecules. Liposomes 
composed of hydrogenated sphingomyelin and CHOL were shown to improve circulation 
life times of vincristine encapsulated liposomes.
128
 
 
Charged lipids affect liposome clearance, although the relationship is often very 
complex.
122
 In general, low concentration of charged lipids provide sufficient 
electrostatic repulsion to prevent liposome aggregation upon addition of hydrophobic 
drugs to the membrane.
129
 However, the inclusion of high concentration of either anionic  
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Table 1.2 Liposome products in clinical and preclinical studies. 
 
Product Application Company; trial phase 
Clinical studies   
Drug delivery   
Caelyx Bladder cancer Schering Plough; EU 
Doxil Ovarian cancer Ortho Biotech 
Doxil+VAD Myeloma Millennium 
Doxil+VAD Multiple myeloma Millennium; III; J&J; III 
Doxil+Yondelis Ovarian cancer J&J; III 
Myocet Breast cancer Sopherion Therapeutics; III 
Liposomal cisplatin Recurrent ovarian cancer Sequus; II 
Aroplatin™ B-cell lymphoma Antigenics; I 
Annamycin Leukemia Aronex Pharm; II 
Paclitaxel Head and neck cancer Neopharm; II and III 
Vincristine  Lung cancer Inex Pharm; II 
Topoisomerase inhibitor Lung and ovarian cancer OSI Pharm; II 
Mitoxanthrone Other cancers Neopharm; II 
Nystatin Leukemia Pfizer; III 
DNA delivery   
Interleukin-2 plasmid DNA  Kidney and prostate cancer Vical; II 
Antigen delivery   
MUC-1 peptide; BLP25 Lung cancer Merck; III 
   
Preclinical studies    
Drug delivery   
Adriamycin Sarcoma  
Doxorubicin Neuroblastoma  
Vincristine B-cell lymphoma  
Prednisolon Autoimmunity  
Clodronate Autoimmunity  
Glucocorticoids Arthritis  
Glucocorticoids ALI  
Budesonide Asthma  
Tacrolimus Skin disorders  
Interleukin-2 Immunotherapy  
DNA delivery   
Bcl-2 antisense ODNs Cancer  
Interferon-b DNA Glioma   
 
VAD denotes vincristine, adriamycin and doxorubicin (DXR) combination 
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or cationic lipids into liposomal membrane increases clearance of liposomes from the 
circulation. High concentration of anionic lipids increases accumulation in liver and 
spleen.
122,130
 In addition to liver and spleen, cationic lipids enhance uptake by vascular 
endothelial cells of lung,
131
 tumor vasculature
132
 and blood brain barrier.
133
 In anionic 
liposomes, net negative charge of liposomes is dependent on the specific anionic lipid 
utilized in the formulation, with low concentrations of anionic gangliosides, 
phosphatidylglycerol (PG), phosphatidylinositol (PI) and PEGylated 
phosphatidylethanolamine (PEG-PE) result in substantial reduction in 
clearance.
120,122,130,134
 The presence of anionic lipids, such as phosphatidic acid (PA), 
phosphatidylserine (PS) and cardiolipin (CL) caused an increase in the rate of clearance 
from the blood.
122,130,135
 This discrepancy is in part due to the differences in 
protein/opsonins binding to membranes containing different anionic lipids. Liposomes 
comprised of the anionic lipids exhibited high plasma protein binding, while liposomes 
composed of PG, PI and PEG-PE show less protein binding.
130
 The presence of PS on 
liposomal surface resulted in receptor-mediated clearance.
136
 Therefore, caution should 
be exercised in the selection of charged lipid components in liposomal therapeutics. 
 
The phase transition temperature (Tm) of the phospholipid component influences drug 
retention. The phospholipid undergoes a shift from a well ordered gel phase to a fluid and 
disordered liquid crystalline state at its phase transition temperature. In general, liposome 
membranes are more permeable above the Tm of the particular phospholipid. For 
unsaturated phospholipids, physiological temperature is above the phase transition, and 
therefore, the drug retention is compromised. On the other hand, saturated phospholipids, 
such as DSPC or hydrogenated soy phosphatidylcholine (HSPC) have a phase transition 
temperature (50-58 C) above the physiological temperature, and therefore, the liposome 
formulations are stable. The clearance rates of doxorubicin loaded pegylated liposomes 
were correlated with the Tm of the phosphatidylcholine (EggPC>DPPC>HSPC), 
reflecting the increased membrane permeability, and thus leakage of doxorubicin for the 
EggPC and dipalmitoyl phosphatidylcholine (DPPC) formulations.
137
 
 
Sphingomyelin stabilizes membranes in the presence of CHOL. It imparts compact 
packing of membrane lipids
138
 with a decrease in permeability to water and other 
solutes.
139
 The high cohesiveness and reduced permeability of the membrane could be 
due in part to the strong hydrogen bonds between the amide nitrogen of sphingomyelin 
and the hydroxyl group of CHOL.
126
 In addition, due to the amide linkage in its 
backbone, sphingomyelin is also less sensitive to pH-dependent hydrolysis.
140
 
Substitution of dihydrosphingomyelin for sphingomyelin was shown to improve the 
stability of vincristine encapsulation. Thus, the ability of sphingomyelin and 
dihydrosphingomyelin to reduce the membrane permeability of certain drugs can play an 
important role in regulating the rate of drug release for certain small molecule drugs.  
 
 
1.3.2 Physico-chemical Properties of Drugs: Liposome Encapsulation 
 
The physico-chemical properties of the drug to be incorporated into liposomes play an 
important role in determining its rate of release. Encapsulated drugs are classified as: (I) 
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water insoluble hydrophobic drugs, (II) amphipathic weak bases, (III) amphipathic weak 
acids, (IV) highly water and membrane impermeable small molecular weight drugs and 
(V) polyions, such as nucleic acids. The most commonly studied drugs are the 
amphipathic weak bases (e.g. camptothecins, anthracyclines). Typically, weak bases are 
loaded into liposomes using ammonium sulfate gradient method, which even 
significantly improved the pharmacokinetics of the encapsulated drug. However, within a 
given class of drugs, the drug release rates can vary dramatically. Doxorubicin has an 
improved toxicity and anti-tumor efficacy profiles. However, another member of the 
same class, mitoxantrone is released more slowly compared to doxorubicin, its activity is 
compromised and requires a modified lipid composition to promote release of the drug 
and improve efficacy.
141
 Weakly acidic drugs can be loaded using reverse pH gradients 
(i.e., pH lower on liposome exterior), including acetate gradient method.
142
 Drugs that 
contain both weakly basic and weakly acidic groups pose a challenge, but are often 
overcome depending on the pKa and number of the various ionizable groups. A drug that 
contains both a weakly basic amine and a phenolic hydroxyl group, with its relatively 
high pKa, is still viable for gradient method. The presence of low pKa acids, make it 
difficult to find a pH where both the acid and the amine would be neutralized, enabling 
the drug to readily penetrate the liposomal membrane and accumulate in the liposome 
interior. Hydrophobic drugs represent a third class of drugs that are formulated in 
liposomes. Lipophilic drugs rapidly transfer between liposomal membranes and various 
biological interfaces, including cellular membranes and plasma proteins.
143
 Therefore, 
these liposomes often demonstrate some improvement in pharmacokinetic parameters. 
Highly water soluble molecules include both small molecules and polyionic compounds, 
such as nucleic acid based therapeutics. Encapsulation of highly water soluble agents 
may not be amenable to gradient-based drug loading methods due to their minimal 
membrane permeability. However, nucleic acids, although highly water soluble can be 
efficiently complexed with cationic lipids to form highly condensed lipidic 
nanoparticles.
144
 These examples illustrate the barriers and opportunities for delivery of 
various classes of drugs. 
 
 
1.3.3 PEGylation of Liposomes 
 
Conventional liposomes formed by natural phospholipids and CHOL are generally 
recognized by the body‟s immune system as foreign bodies and are often destroyed 
before significant amounts of drug reach the intended disease site. Liposomes are 
engulfed by phagocytic cells of the reticular endothelial system (RES), and therefore, 
drugs accumulate in the liver, spleen or bone marrow. Attachment of ligands, such as 
polyethylene glycol (PEG) to a liposome surface results in the formation of sterically 
stabilized liposomes, which prolong drug residence time in blood circulation.
145,146
 This 
is the patented delivery form, termed stealth® liposomes (ALZA). As shown in Figure 
1.4, targeted liposomes usually involve coating with functionalized ligands that bind 
specifically with receptors on cell surface. The stealth® liposomes maintain chemical 
stability of the drug in the body and lengthen drug circulation half-life.
147,148
 Therefore, 
incorporation of steric stabilizing surface functional moiety became an essential 
component of liposome formulation development. Among the various ligands  
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Figure 1.4 Schematic representation of various classes of liposomes. 
 
Conventional liposomes are PEGylated to obtain long circulating liposomes. 
Conventional liposomes or PEGylated liposomes are surface modified with proteins (e.g. 
antibodies) to obtain targeted liposomes. Cationic liposomes are obtained by 
incorporation of cationic lipids (e.g. lipofectamine). 
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investigated for improving the blood circulation half-life of liposomes, PEG is the most 
widely used stabilizer in pharmaceutical applications because of its advantages, including 
non-biodegradability, high solubility in aqueous solution, ability to bind to a large 
number of water molecules, high flexibility of its polymer chain, and non-immunogenic 
and limited accumulation in RES system.
121
 In addition, PEG prevents the adsorption of 
proteins (opsonins) responsible for phagocytic removal, and thus provides the ability to 
adjust the liposome physico-chemical (such as drug loading and leakage) and biological 
properties (e.g. blood circulation and tissue distribution).
149,150
 
 
 
1.3.4 Liposome Targeting 
 
 
1.3.4.1 Passive Targeting 
 
Targeting of drugs to specific cells and substrates is a critical objective of drug delivery. 
The size control of liposomes and nature of liposome surface (e.g. surface/steric effect) 
may be used to optimize passive targeting.
122
 The enhanced accumulation of liposomes at 
inflammation and tumor sites is due to the leaky vasculature system,
151,152
 which is 
unable to prevent small species (<100 nm) crossing the capillary membrane. Even 
though, only a small fraction of liposomes eventually accumulate at target sites, 
prolonged circulation indirectly enhances accumulation of liposome associated drugs in 
the targeted tissues. 
 
 
1.3.4.2 Active Targeting 
 
Active targeting of liposomes to specific cell receptor sites involves modifying the 
liposome surface with the incorporation of specific ligands, e.g. peptides, antibodies, 
immunoglobulins, lectins and other proteins.
153
 A number of key issues must be 
addressed before active targeting of liposomes using ligand-receptor interactions in 
vivo.
154
 Targeted liposomes must circulate in blood long enough to perfuse into the target 
organ and eventually interact with cells. Otherwise, liposomes will be cleared without 
making contact with the cell targets.
155
 Targeted cell receptor expression should be high 
compared to non-targeted cells, and receptors must provide sufficient specificity and 
affinity. Therefore, knowledge of the density of the receptors in target tissue compared 
with non-targeted sites and the degree of blood perfusion are useful to design targeted 
liposomes.
122
 In addition, targeting moieties coupled to the surface of liposomes must be 
sufficiently stable in vivo. In some cases, PEG incorporated into liposomes affects the 
targeting action and interferes with target (e.g. receptor) recognition. To overcome the 
barrier of PEG, attachment of targeting ligand to the distal end of a PEG molecule 
precludes steric hindrance and improves targeting properties of liposomes.
156,157
 For 
example, attachment of a targeting ligand to the maleimide residue of DSPE-PEG-
maleimide.
119,158
 The PEG-PE liposomes with targeting moieties retain long survival 
times in blood circulation and demonstrate target recognition in vivo.
159
 In addition, 
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reports suggested that PEG chain length and charge density are crucial for targeted 
liposomes.
119
 
 
 
1.3.5 Methods for Attaching Targeting Ligands to Liposomes 
 
Over the years, different strategies evolved to impart active targeting to liposomes. All 
these strategies are based on two chemical methods for attaching ligands to the liposomal 
surface: covalent and non-covalent coupling. Figure 1.5 describes various covalent 
reactions used for coupling targeting ligands to liposome surface. Generally, ligands are 
bound to the surface of liposomes through hydrophobic anchors with functional groups. 
Long-chain fatty acids, such as palmitic acid
160
 and phospholipids, such as PE
161,162
 are 
generally used as anchors. These anchors are incorporated into liposomal bilayers during 
the formation of liposomes. There are two approaches to covalently attach the ligand to 
the anchor. The first consists of carrying out the reaction between the ligand and the 
anchor, and mixing the resulting ligand with other constituents of the liposome.
163
 In the 
second case, the anchor is already included in the liposome bilayer, and the coupling 
reaction occurs on the surface of preformed liposomes.
164
 
 
 
1.3.5.1 Coupling of Ligands to the Surface of Liposomes Using thio-ether Bonds 
 
The reaction between thiol and maleimide groups is an efficient reaction that gives a 
stable thio-ether bond. Native thiol groups are present in some proteins, but in many 
others, thiol functions are either absent or present in insufficient amounts. Thiol groups 
are added either via hetero-bi-functional cross-linking agents
165,166
 or by reducing 
disulfide bonds. N-hydroxysuccinimide 3-(2-pyridyldithio)propionate (SPDP) and 
succinimidyl-S-acetylthioacetate (SATA)
165,167
 are commonly used as crosslinkers. Both 
offer one primary reactive amine residue for coupling with the ligand. In both cases, thiol 
functions are not directly available, and a deprotection of these functions under mild 
conditions is necessary before the reaction with liposomes. In the case of SPDP, 
dithiothreitol (DTT) or an alternative reducing reagent is used to reduce the disulfide 
bond to thiol function. SATA offers one protected thiol function, which is deacetylated 
with hydroxylamine. N-(4-(p-Maleimidophenyl)butyryl)phosphatidylethanolamine 
(MPB-PE) is another commonly used functionalized anchor.
168
 The extended spacer arm 
between the phospholipid head group and the maleimide moiety reduces the possibility of 
a steric hindrance at the bilayer interface, and thereby ensures favorable thiol reactivity. 
Once the liposomes with maleimide groups are formed, the ligands with thiol functions 
are coupled to the liposomes by simple addition reaction.
166,168
 Now, there is commercial 
abundance of functionalized lipids with terminal maleimide groups for ease of 
conjugation with thiol groups of antibodies. 
 
Immunoliposome technology can be combined with sterically stabilized liposomes to 
give long circulating vesicles capable of delivering antibodies/immunoglobulins to target 
cells. There are two ways of obtaining immunoliposomes: (I) antibodies are bound to the 
surface of liposome in parallel with PEG
168
 and (II) antibodies are linked to the distal end  
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Figure 1.5 Schematic representations of different coupling methods used for surface 
modification of liposomes. 
 
Reaction between maleimide and thiol functions (A), formation of a disulfide bond (B), 
reaction between carboxylic acid and primary amine group (C), reaction between 
hydrazide and aldehyde functions (D), cross-linking between two primary amine 
functions (E). 
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of PEG chains.
169
 For both approaches, PEG is incorporated into the bilayer via an 
anchor, such as distearoyl phosphatidylethanolamine (DSPE).
168,170
 When antibodies are 
coupled to the termini of PEG, (maleimidomethyl)cyclohexanecarboxylate-PEG-DSPE 
(MCC-PEG-DSPE) or maleimido-phenylpropionate-PEG-DSPE (MP-PEG-DSPE) are 
used.
171,172
 Thiol groups of the Fab  fragments
171
 or monoclonal antibodies (entire IgG) 
are then attached to the distal end of PEG chains via the maleimide groups. It is also 
possible to link maleimido antibodies to liposomes offering thiol functions.
170, 173
 
Antibodies can also be attached either directly to the surface of the vesicles via PDP-
dioleoyl phosphoethanolamine (PDP-DOPE)
170
 or to the PEG terminus via PDP-PEG-
DSPE
170
 or PDP-PEG-PE.
169
 Maleimido antibodies are obtained using a hetero-bi-
functional cross-linker, succinimidyl 4-[p-maleimidophenyl]butyrate (SMPB)
169,170,173
 
that is reactive with amino and sulfhydryl groups of antibodies. High coupling efficiency 
is possible when ligands are coupled to the distal ends of PEG chains.
170
 
 
 
1.3.5.2 Attachment of Ligands to Liposomes via a Disulfide Linkage 
 
One of the most rapid and easy coupling chemistries involves the conjugation of two thiol 
functions to form a disulfide bond. However, disulfide bonds are relatively unstable 
under the reductive conditions in serum.
174
 For this reason, the disulfide linkage is 
progressively replaced by other more stable ones. As seen before, thiolated ligands are 
generated either by reduction of disulfide bonds
174
 or using SATA or SPDPlinkers.
175
 The 
thiolated ligands are then made to react with the pyridyldithio moiety of the anchor (PE-
PDP) to form a disulfide linkage. Several studies demonstrated that the coupling method 
is efficient in attaching antibody to the liposomes without denaturation of the ligand.
175
 
 
 
1.3.5.3 Cross-linking between Carboxylic Acid Functions and Primary Amines of the 
Ligand 
 
Ligands are attached to the surface of liposomes by an amide bond using an anchor 
functionalized with carboxylic acid end groups. Distearoyl-N-(3-carboxypropionoyl 
poly(ethylene glycol)succinyl)phosphatidylethanolamine (DSPE-PEG-COOH) offers 
carboxylic acid groups at the distant end of PEG chains.
156,176
 The coupling reaction is 
carried out in the presence of N-hydroxysulfosuccinimide (NHS) and 1-ethyl-3-(3-
dimethylamino-propyl)carbodiimide (EDC) to form an acyl amino ester, which will 
subsequently react with the primary amine of the ligand, yielding an amide bond.
176, 177
 
The advantage of this method is that no prior ligand modification is required, thus 
reducing the risk of denaturation and loss of specific activity. 
 
 
1.3.5.4 Binding of Ligands to Liposomes via Hydrazone Bond 
 
Antibodies are covalently bound through their carbohydrate moieties to hydrazide groups 
grafted onto the liposomal surface to form a hydrazide bond. A mild oxidation of the 
carbohydrate groups on the constant region of the heavy chain of the immunoglobulin is 
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required to produce aldehyde groups. These react with hydrazide groups of the anchor.
178
 
The carbohydrate groups are oxidized either by galactose oxidase or by sodium 
periodate.
178
 Once the oxidized antibodies are formed, they are either directly coupled to 
the lipid bilayer containing a hydrazide-hydrophobic anchor, such as lauric acid 
hydrazide
178
 or to the distal end of the PEG chains of sterically stabilized liposomes.
170,179
 
In the latter case, a functionalized PEG-lipid hydrazide, Hz-PEG-DSPE
180
 is used. This 
coupling method is not very efficient because only a small percentage of antibodies 
(17%) were attached to the liposomal membranes.
170
 
 
 
1.3.5.5 Cross-linking between Primary Amines on Liposomes and Primary Amines of the 
Ligand 
 
In this method, direct amine-amine cross-linking is performed. Two homo bi-functional 
cross-linkers are used: glutaraldehyde and suberimidate.
181
 The advantage of this 
coupling approach is that no prior modification is required to add functional groups to the 
ligand. The coupling method consists of first activating the primary amine of PE on the 
liposome surface via the cross-linker and subsequently coupling the ligand. High 
coupling efficiency (60 mole%) of antibodies to liposomes was reported.
182
 Despite the 
fact that the coupling reaction is efficient, the use of homo bi-functional cross-linkers is 
rarely exploited owing to the uncontrollable homo-polymerization of ligand during the 
cross-linking reaction. 
 
 
1.3.5.6 Multi-step Attachment Using the Avidin-Biotin Interaction 
 
The avidin-biotin strategy is a popular and versatile tool for active targeting.
157,183,184
 
Anita et al demonstrated the use of a biotinylated PEG-DSPE linker to form a non-
covalent bond between streptavidin-conjugated monoclonal antibody (mAb) (e.g. OX26 
mAb raised against the rat transferrin receptor) and liposomes.
184
 Furthermore, 
biotinylated antibodies are easily obtained.
185,186
 Huwyler et al demonstrated specific 
targeting of daunomycin to the rat brain using OX26 antibody conjugated liposomes.
157
 
 
 
1.3.5.7 Non-covalent Methods 
 
An alternative means to conjugate ligands to liposomes is the use of non-covalent 
methods. The advantage of these methods is easy to be carried out without the need of 
aggressive reagents. A simple method is to merely add the ligand to the mixture of 
phospholipids during the preparation of the liposomes. However, the percentage of ligand 
attached to the carrier is relatively low (4-40%) and aggregation of the liposomes is 
frequently observed. Furthermore, the amount of ligand linked to the liposome is not 
easily controllable and the correct orientation of the antibodies is not ensured. Finally, 
detachment of the antibody in vivo might occur. 
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1.3.6 Preparation of Liposomes 
 
 
1.3.6.1 Passive Loading 
 
Over the last 60 years, numerous methods are reported for the preparation of liposomes. 
On a small scale, Bangham method is the commonly employed method. In this method 
the lipid film is hydrated with drug solution/suspension to encapsulate or incorporate 
drug moieties.
154
 Usually, hydrophilic drugs should have a large encapsulated volume. On 
the other hand, the encapsulation efficiency of hydrophobic drugs depends on the 
quantity and quality of lipids.
187,188
 In an appropriate preparation method, concentration 
of lipids and drugs, drug/lipid ratio, presence of functionalized lipids, pH, buffer and 
process parameters play a critical role in the encapsulation efficiency of drugs.
122
 
 
 
1.3.6.2 Active Loading: Gradient Loading Strategies 
 
The drug encapsulation method is important in determining the in vivo stability of 
liposomes. Hydrophobic drugs are usually encapsulated passively by hydration of the 
lipid film with drug solution.
189,190
 Some therapeutic agents, including small molecules 
and proteins can be complexed with charged lipid components.
144,191
 However, one of the 
most widely used encapsulation methods employs transmembrane gradients to efficiently 
load and subsequently stabilize weakly basic amphipathic drugs inside the core of 
liposomes. These include: (I) simple pH gradients using citric acid solutions,
192,193
 (II) 
ammonium ion gradients employing citrate
194
 or sulfate,
195
 (III) alkyl,
196
 (di-alkyl) or tri-
alkyl ammonium salts,
197
 (IV) transition metal concentration gradients (Cu
2+
, Mn
2+
, 
Zn
2+
and Mg
2+
)
198-200
 and (V) transmembrane gradients of drug solubility.
201
 The cation 
entrapped in the liposome interior plays a role either in establishing a pH gradient across 
the membrane that drives the accumulation of weakly basic drugs into the liposome 
interior, or directly exchanging with the drug molecule. The counter ion plays an 
important role in stabilizing the formulation to premature leakage of encapsulated drugs. 
Figure 1.6 depicts an example of active loading and subsequent stabilization process of  
doxorubicin using ammonium sulfate gradient method.
202
  
 
Liposomal formulation of the camptothecin prodrug, irinotecan, displayed a different 
pharmacokinetic behavior in lieu of the encapsulation method.
203
 Using manganese 
sulfate gradient method, Bally et al.
203
 prepared irinotecan liposome formulation, whose 
drug release half-life improved from 8.3 h to 56.8 h.
197
 The intraliposomal drug 
concentration also affects the stability of liposomal drugs prepared using gradient loading 
methods. At low drug/lipid ratio, doxorubicin was retained in the liposomes due to the 
strength of the residual gradient in the carrier.
203
 A high drug/lipid ratio resulted in the 
exhaustion of pH-gradient across the membrane leading to an increased leakage of the 
drug. Similarly, studies with high ionic concentration gradient using ammonium sulfate 
improved doxorubicin formulation stability.
202
 Insoluble drug precipitates formed due to 
the complexation of drug and intraliposomal ions may acquire desirable zero-order 
release rates. This could be due to the fact that the dissolved drug maintains constant  
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Figure 1.6 Schematic representation of the liposomal loading of weak bases (A) and 
weak acids (B). 
 
In the former case, liposomal aqueous core is acidic, which causes the formation of a gel-
like precipitate of DXR. In the latter case, unionized MPS diffuses across the lipid 
bilayers and forms an insoluble calcium-MPS complex inside the liposome core.
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equilibrium with the precipitated drug fraction of the liposomes.
204
 In addition, the 
potency of the drug determines the selection of drug/lipid ratios for the preparation of 
liposomes. Many liposome formulations display dose-dependent pharmacokinetics; 
therefore, a high drug/lipid ratio will result in low lipid doses, and thus may contribute to 
rapid clearance of liposomes. Even pegylated liposomes are vulnerable for fast clearance 
from the body. Therefore, high drug/lipid ratios may be viable for low to moderate 
potency drugs, such as the prodrugs,
197
 but not for potent drugs. 
 
Low concentration of anionic lipids was shown to enhance the stability of encapsulated 
drugs using transmembrane electrochemical gradient.
205,206
 Fluoxuridine retention 
increased upon inclusion of only 20 mole% of distearoyl phosphatidylglycerol (DSPG) in 
DSPC liposomes, and in a separate study, the inclusion of 15-55 mole% of DSPG in 
liposomes improved the retention of vincristine using a methyl ammonium gradient.
206
 It 
was hypothesized that the inclusion of negatively charged lipids increased the membrane 
partition coefficient of weakly basic drugs and improved their retention in liposomes 
maintaining a transmembrane pH-gradient. However, the presence of a negative charge at 
the membrane interface in other formulations caused leakage of encapsulated drug.
207
 
Therefore, physico-chemical properties of drugs and phospholipids play a critical role in 
the selection of active loading strategy for encapsulation of drugs. 
 
 
1.3.7 Liposome In Vivo Kinetics: Systemic Administration and Aerosolization 
 
The rate of in vivo drug release is an extremely important parameter since it influences 
the rate of clearance of the drug from the general circulation, bioavailability, and activity 
of the drug at its site of action and targeting ability of the drug.
122
 In vivo encapsulated 
drug concentration can be determined either directly by measuring purified liposomal 
drug in plasma
197,208
 or indirectly by assuming that the clearance rate of the 
unencapsulated drug is sufficiently faster than the clearance rate of the liposomes (by 
simply following changes in the plasma drug-to-lipid ratios). 
197
 However, challenges 
pose for hydrophobic drugs that demonstrate significant protein binding. For some drugs, 
the rate of in vivo drug release can be controlled by manipulation of physico-chemical 
properties of the liposomes. 
 
Different applications may require distinct release kinetics and different particles sizes.
209
 
Following an intravenous injection, the first capillaries to be encountered by a delivery 
vehicle are in the lung tissue, which tends to mechanically entrap large particles, such as 
multilamellar vesicles (MLVs). The lung thus represents a unique site for drug delivery if 
large liposomes are employed, but care has to be taken to avoid pulmonary emboli. 
Administration of liposomal formulations to the epithelial cells in the lower airways of 
the lung by nebulization requires smaller particles ( 300 nm) that are in the respirable 
range.
210
 To deliver imaging agents, a rapid burst will achieve maximum contrast 
between the circulation system and the target tissues. 
 
The „„first pass‟‟ organ to be encountered after systemic administration is the liver, which 
can thus be targeted with fast-release liposomes. Large vesicles are generally more 
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rapidly eliminated from the bloodstream, whereas small ones circulate for longer, 
especially those with neutral or positively charged, rigid bilayers. Liver, lung and spleen 
may be circumvented using stealth liposomes. Usually, liposomes do not pass through the 
endothelial barrier of the vascular system; however, under pathological conditions, small 
particles (<100 nm) are able to extravasate through the poorly formed neovasculature of 
some solid tumors.
211
 Regardless of the circulation time of an intravenously injected 
liposomal dose, the majority will eventually be taken up by the mononuclear phagocyte 
system. Using alternate parenteral routes, such as intraperitoneal, subcutaneous or 
intramuscular, large liposomes generally tend to be retained longer at the site of injection, 
while small ones are mainly taken up by the draining lymph system. 
 
Aerosolized liposomal preparations became a feasible route for delivering drugs to the 
lung. A combined aerosol of liposomal paclitaxel and cyclosporin A achieved better 
results in the treatment of pulmonary metastases of renal-cell carcinoma.
212
 Spray-dried 
liposome powder formulations were used as carriers for superoxide dismutase (SOD).
213
 
Improved delivery of rifampicin by aerosolized liposomes to alveolar macrophages might 
become significant in the treatment of tuberculosis.
214
 Aerosolized liposomal budesonide 
is effective against experimental asthma in mice.
215
 Aerosol formulations of liposomal 9-
nitrocamptothecin are non-toxic, and efficiently treated melanoma and lung metastases in 
mice.
216
 Liposomal paclitaxel in aerosol effectively treated pulmonary metastases in a 
murine renal carcinoma model.
217
 Nebulization was recently proposed as a means to 
deliver liposomal aerosols.
218
 
 
 
1.3.8 Liposomes: Clinical and Diagnostic Applications 
 
Recent advances in liposome technology have led to the development of “stealth 
liposomes” whose prolonged circulation lifetime improved the therapeutic benefits. For 
cancer and inflammation diseases, therapeutic potential could be improved by receptor 
specific targeting and cell specific delivery of therapeutic moieties. Despite some 
progress, one of the current challenges is the targeting specificity and affinity of the 
binding motif to the disease sites. In an ideal targeted delivery system, high binding 
specificity avoids adverse effects to the surrounding tissues within the vessel and/or 
downstream of the injury site, while high binding affinity enables competition with 
natural ligands. As targeted liposomal drug delivery systems are now becoming feasible, 
it offers significant potential for local delivery of anti-cancer, anti-inflammatory, anti-
coagulants. 
 
In addition to clinical applications, liposome formulations are used for as contrast agents 
for experimental diagnostic imaging of liver, spleen, brain, cardio-vascular system, 
tumours, inflammation and infections. Gamma-scintigraphy, near infrared fluorescence 
imaging (NIRF) and magnetic resonance imaging (MRI) require a sufficient quantity of 
radionuclide or fluorescent dye or paramagnetic metal to be associated with the liposome. 
There are two possible routes to improve the efficacy of liposomes as contrast mediums 
for gamma-scintigraphy or MRI or NIRF: I) increasing the quantity of carrier-associated 
marker and II) enhancing the signal intensity. To increase the load of liposomes with 
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reporter metals, amphiphilic chelating polymers, such as N,α-(DTPA-polylysyl)glutaryl 
phosphatidyl ethanolamine were introduced. These polymers easily incorporate into the 
liposomal membrane and markedly increase the number of chelated Gd or In atoms 
attached to a single lipid anchor. In the case of NIRF, fluorescent dyes are incorporated 
into the lipid bilayers of liposomes. Imaging approach using contrast liposomes allows 
the visualization of pathological areas. Liposomes loaded with imaging agents are also 
used for the in vivo monitoring of tissue pharmacokinetics of liposomal drugs. 
 
 
1.3.9 Stability of Liposomes 
 
The shelf-life of liposomes is determined by physical and chemical aspects of 
liposomes.
122
 Physical processes, such as aggregation and fusion result in loss of 
liposome encapsulated drug and changes in size. In principle, this process is reversible; 
however, fusion of liposomes further triggers coalescence of liposomes. As coalescence is 
an irreversible process, liposomes cannot be retrieved. 
 
 
1.3.9.1 Physical Stability 
 
Stable liposome suspensions require a repulsive interaction that is at least comparable to 
the magnitude and range of vander Waals forces.
219,220
 Repulsive interactions at the 
surface of liposomes are a function of: I) electric potential (zeta potential, ) at the plane 
of shear and II) surface charge density ( ). The zeta potential is calculated from 
electrophoretic mobility by Equation 1.1
154,221
 
 
ζ = η/εoεr Equation 1.1 
 
The surface charge density calculation is based on Gouy-Chapman double layer 
theory.
222-225
 The theory is applicable to unabsorbed particle surfaces. However, ions 
adsorb on the surface of liposomes giving rise to a Stern layer so that the double layers 
must be described by the Gouy-Chapman-Stern theory (Figure 1.7).
225
 Later on, the  
problems associated with the distortion of the electrical double layers due to the motion 
of the charged liposomes (e.g. PE/PEG-PE liposomes) and the influence of surface 
conductivity on electrophoretic mobility superceded the Gouy-Chapman-Stern theory 
with Derjaguin-Landau-Verwey-Overbeek (DLVO) theory.  
 
Jones
223
 stated that the classic DLVO model is applicable for determining the stability of 
liposomes, considering that many of the physico-chemical properties of liposomes 
resemble that of conventional colloidal particles. The total interaction potential is a 
function of the repulsive and the attractive components. The short range attractive forces 
between liposomes are of van der Waals forces, while the long range repulsive forces are 
electrostatic repulsive forces. These forces are calculated using the Poisson-Boltzmann 
equation. The repulsive force arising from the overlap of the electrical double layers 
surrounding charged liposomes is the main reason for the stability of liposome 
dispersion.
226
 The electrical forces increase exponentially as liposomes approach one  
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Figure 1.7 Schematic diagram of the Gouy-Chapman-Stern diffuse double layer 
theory. 
 
The theory states that ions do have finite size so cannot approach the surface closer than a 
few nm. The first ions of the Gouy-Chapman diffuse double layer are not at the surface, 
but at some distance away from the surface. This distance will usually be taken as the 
radius of the ion. According to Stern, it is possible that some of the ions are specifically 
adsorbed by the surface in the plane of shear and this layer has become known as the 
Stern Layer. The potential at the OHP is considered as the zeta potential. The double layer 
is formed in order to neutralize the charged surface, and in turn causes an electrokinetic 
potential between the surface and any point in the mass of the suspending liquid. This 
voltage difference is on the order of millivolts, and is referred to as the surface potential. 
The magnitude of the surface potential is related to the surface charge and the thickness 
of the double layer. From the surface, the potential drops off linearly in the Stern layer 
and then exponentially through the diffuse layer, approaching zero at the imaginary 
boundary of the double layer. The potential curve indicates the strength of the electrical 
force between the particles and the distance. The particle (liposome) mobility is related to 
the dielectric constant and viscosity of the suspending liquid, and to the electrical 
potential at the boundary between the moving particle and the liquid. 
 
Adapted with permission. Jones, M.N. The surface properties of phospholipid liposome 
systems and their characterisation. Adv Colloid Interface Sci 54, 93-128 (1995).
223
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another, and the attractive forces increase as an inverse power of separation. Other forces 
also contribute to the interaction between liposomes. Addition of other interactions 
expands the DLVO model to an extended DLVO interparticle model. According to the 
extended DLVO theory, the total force (FT) between the liposomes is given by Equation 
1.2: 
 
FT = Fvdw-Fhfo+Fest+Fund+Fhgd+Fsteric Equation 1.2 
 
As described previously, Fvdw and Fest represent van der Waals and double layer repulsive 
forces between colloidal particles.
225
 For neutral liposomes e.g. EPC liposomes, the 
bilayers can approach within the order of 5-20 nm, and under these conditions, the 
repulsive hydration force (Fhgd) is the major repulsive interaction between lipid bilayers. 
At small separations, a repulsive interaction may arise from out of plane motions or 
undulations which give rise to an undulation force (Fund). Fund is only of importance for 
fluid bilayers, e.g. egg lecithin bilayers account for approximately 25% of the van der 
Waals forces.
227
 The hydrophobic force (Fhfo) is a long-range force and operates at a 
greater distance than Fvdw.
228
 
 
The electrophoretic mobility of PEGylated liposomes is very low when compared to non-
pegylated liposomes, and the electrophoretic mobility show little variation with DSPE-
PEG levels of liposomes in the range 5-10 mole%. The inclusion of CHOL has little or no 
effect on the mobility. The low electrophoretic mobility corresponds to low zeta 
potentials. For PEGylated liposomes, a steric force will arise when the surface polymer 
chains interact. Several theoretical approaches to the interaction between surfaces with 
adsorbed polymers were proposed.
229-231
 There are two limiting cases of repulsive forces; 
at low polymer density where the polymer separation exceeds the polymer coil size 
('mushroom model'), and at high polymer density when the polymer chains take up 
extended conformations ('brush model'). It is noted that bridging between two polymer 
coated surfaces involves polymer interdiffusion and entanglements that lead to attractive 
interaction.
232-234
 Needham et al.
235
 reported that steric stabilization is a result of the 
combination of electrostatic and steric forces. 
 
The electrostatic component results from a net charge on the liposome surface and/or the 
charge associated with the adsorbed polymer (e.g. PEG chains). And the steric component 
arises from the chain-chain exclusion of adsorbed polymeric material on one surface from 
the other surface. The coalescence kinetics in colloidal systems was performed by von 
Smoluchowski.
236, 237
 The total number of vesicles at time t, N may be approximated by 
Equation 1.3: 
 
N = 6φ/πd3 Equation 1.3 
 
Where d is vesicle diameter and φ is the liposome volume fraction. For liposome 
systems, the entrapped aqueous volume is estimated by NVOL method.
238
 The aggregation 
process in colloidal systems is a second-order process. Mean diameter (Dt) of liposomes 
at time, t is determined from Equation 1.4: 
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Dt = [d
3
+(6kφ/π)t]1/3 Equation 1.4 
 
Where d0 is the initial vesicle diameter at t = 0 and Dt is the liposome diameter at time t. 
From DLS studies, mean liposome diameters can be estimated. By plotting d
3
 versus 
time, we can calculate the rate constant for aggregation, k = 6kφ/π. 
 
 
1.3.9.2 Chemical Stability 
 
As phospholipids form the backbone of the bilayer, their chemical stability is important. 
Two types of chemical degradation reactions affect the performance of phospholipid 
bilayers: hydrolysis of the ester bonds linking the fatty acids to the glycerol backbone and 
peroxidation of unsaturated acyl chains. The oxidation and hydrolysis of lipids may lead 
to the appearance of short-chain lipids, and then soluble derivations will form in the 
membrane resulting in the decrease of the quality of liposome products. The chemical 
stability of liposomes is improved by inclusion of anti-oxidants, such as -tocopherol and 
saturated phospholipids. 
 
 
1.3.10 Lyophilization: Stabilization of Liposomes 
 
Lyophilization of liposomes can prevent hydrolysis of the phospholipids and physical 
degradation of liposomes during storage. In addition, it may stabilize the particle size and 
leakage of drugs encapsulated inside the liposomes. Lyophilization of liposomes results 
in an elegant dry cake, which can be reconstituted to obtain the original liposomal 
suspension. On the other hand, the lyophilization process may induce physical changes in 
liposomes, such as leakage of the encapsulated drug and changes in the vesicle size. The 
interaction between the hydrophilic phospholipid head groups and water molecules plays 
a key role in the formation of liposomal bilayers. Thus, removing water from the 
liposomes by lyophilization presents a challenge. Evidence suggests that excipients, such 
as disaccharides (e.g. sucrose and trehalose) protect the liposomes during the 
lyophilization process (lyoprotectants).
239
 As illustrated in Figure 1.8, lyophilization 
process is comprised of three phases: (I) freezing cycle, (II) primary drying and (III) 
secondary drying. The parameters of each phase depend on the selected formulation. In 
the freezing phase, buffer components and lyoprotectants form an amorphous matrix in 
and around the liposomes that prevents fusion, and protects the liposomes against rupture 
due to the growth of ice crystals. As the temperature of the frozen matrix is lowered, the 
viscosity of the frozen matrix increases, until it forms a glass with low molecular 
mobility. The temperature at which this occurs is called Tg‟, glass transition temperature 
of the frozen matrix. The Tg‟ is a function of frozen matrix composition, but liposomes 
do not contribute to the value of Tg‟.241,242 The freezing cycle carried at a slow rate 
allows formation of pores and facilitates sublimation during primary drying phase. This 
in turn minimizes the leakage of contents from liposomes after rehydration of the 
lyophilized sample. Another option to increase water evaporation at the sublimation front 
is annealing process. 
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Figure 1.8 Schematic representation of different stages of a lyophilization cycle. 
 
It describes the relation between the product‟s (green solid line)/shelf (blue solid line) 
temperatures to the chamber pressure inside the lyophilizer. The product is frozen below 
the glass transition temperature of the amorphous product matrix (Tg‟). Primary drying is 
also carried below Tg‟ to avoid product cake collapse and crystallization of the product 
matrix. Secondary drying is performed to remove residual moisture of the product. 
Vacuum during the primary drying is usually 100-300 mTorr and 50 mTorr in secondary 
stage.  
 
Adapted with permission. Gea, G.H. Thermodynamic Lyophilization Control-TLC. 
Process Analytical Technology 12, 1-9 (2008).
240
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Crystallization of the ice can be optimized further by „„annealing‟‟ of the frozen samples: 
the samples are heated to a temperature above Tg‟ and are cooled again before the start of 
the lyophilization process. The energy that becomes available for the frozen matrix may 
induce further crystallization of unfrozen water in the amorphous matrix 
(„„devitrification‟‟). In addition, small crystals may re-crystallize into larger ones. The 
result of annealing is often an increase in sublimation rate during primary drying.
243
 In 
addition, liposomes may be better protected against lyophilization stress. The effect of 
annealing may depend on the specific formulation (e.g., excipients, lipid composition, 
and vesicle size).
244
 
 
During primary drying, the ice crystals are sublimated, resulting in the porous cake 
structure of the freeze-concentrated matrix. The temperature at the sublimation front is 
maintained 5 C below Tg‟. The product temperature at the sublimation front is 
determined by local pressure, according to the ice vapor pressure-temperature. The set 
point of the chamber pressure is chosen at a value that corresponds to an ice temperature 
of about 4 C below Tg‟. The shelf temperature should be higher than the ice temperature 
in order to transfer the heat to the sublimation front for drying. The driving force of the 
drying process is the difference in temperature, and therefore, difference in water vapor 
pressure between the condenser of the lyophilizer and the sublimation front. Heat transfer 
from the shelf to the sublimation front occurs via conduction by glass and ice as well as 
by gas molecules.
245
 In conclusion, careful control of chamber pressure and shelf 
temperature as well as knowledge of the sample Tg‟ are prerequisites for successful 
lyophilization. 
 
In the secondary drying phase, the residual water content of the amorphous matrix is 
further decreased. Followed by the primary drying phase, when the product temperature 
approaches the shelf temperature, the secondary drying phase can be initiated. In the 
secondary drying phase, the pressure is reduced to a minimal value and the shelf 
temperature can be gradually increased. Reduction of the water content of the cake occurs 
during primary drying, but the cake is further dried to <1% w/w of the total moisture 
content. Reduction of the water content increases the glass transition temperature (Tg) of 
the cake, and this allows for a gradual increase in shelf temperature. The shelf 
temperature is a key parameter for obtaining low residual water content. Vials can be 
closed under vacuum or after (partially) releasing the vacuum with nitrogen gas or argon.  
 
The optimal liposome size for high retention of a water soluble compound after freeze-
drying is 0.1–0.2 m.246 Rigid liposomes are more vulnerable to high cooling rates 
(0.5 C/min) than liposomes with flexible bilayers, but give a high retention (70–90% 
w/v) of the encapsulated hydrophilic compounds. Rigid liposomes are usually composed 
of saturated phospholipids. Addition of CHOL (e.g. 30 mole% of the total lipid content) 
may increase the resistance of liposomal bilayers to lyophilization stress. Lyoprotectants 
form an amorphous, glassy matrix in and around the liposomes. Interaction between the 
lyoprotectant and the phospholipid head groups is important for preventing leakage 
during rehydration of liposomes.
247
 Recently, a different mechanism
247-249
 was proposed 
by which sugars may reduce the stress on bilayers during drying. Bilayers dried without 
lyoprotectant approach each other and the suction of water by the phospholipid causes a 
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lateral compressive stress. The mere presence of a glass between adjacent bilayers during 
drying provides spacing between the bilayers, and in combination with the attraction of 
water by the sugars (osmotic properties), the compressive stress on the bilayers is 
reduced. The preferred lyoprotectants are disaccharides, such as sucrose and trehalose. 
Trehalose has a high Tg (100-115 C) in the dried state (<0.5% w/w residual water) than 
sucrose (70 C), which may be an advantage for the storage stability of the dried product. 
Lyoprotectants provide optimal protection of the liposomes if present at high 
sugar/phospholipid ratios. In addition, the lyoprotectant should be present on both inside 
and outside the liposomes.
250
 A total solute concentration of more than 30% w/v may 
hinder the drying process. The use of crystallizing excipients, such as glycine and 
mannitol is not recommended for the lyophilization of liposomes.
251
 A crystalline 
excipient can facilitate the primary drying process and improve the appearance of the 
freeze-dried cake. However, the successful use of crystalline excipients for the 
lyophilization of liposomes is not reported so far, and the lack of an amorphous phase in 
and around the liposomes may damage the bilayers. The use of low molecular weight 
excipients, such as sodium chloride, glucose and amino acids should be minimized. Such 
excipients lower the Tg‟ of the freeze-concentrate and further, the Tg of the lyophilized 
cake. A low Tg‟ requires lyophilization at a low product temperature, which is an 
inefficient process. A decrease in product temperature of 5 C may double the primary 
drying duration. 
 
An acceptable shelf-life is a pre-requisite for successful introduction of liposome 
formulations into therapy. With advances in formulation and lyophilization process 
research, the shelf-life of the specialized targeted liposomes could be improved. 
 
 
1.4 Summary and Rationale 
 
Pulmonary edema, pro-inflammatory mediators‟ production and leukocyte migration are 
the hallmark features of acute lung injury. In the current investigation, human ALI 
features were mimed in IL-1  stimulated rat model. Pulmonary edema and leukocyte 
migration are mediated via v 6 integrin and ICAM-1 receptors upregulated on alveolar 
epithelium or endothelium, respectively. This poses a serious challenge to find a common 
ground for targeting to each of the receptors. Citing a spatial and disparate expression of 
receptors, the current problem was addressed using different targeting motifs 
administered by nebulization and systemic routes of administration. In response to IL-1  
stimulation, v 6 integrins of alveolar epithelium interact with RGD domain of the LAP-
TGF-  complex inducing an increase in permeability across alveolar epithelium. 
Therefore, RGD sequence was identified as the targeting motif to intervene the 
interaction of v 6 integrins with LAP-TGF-  complex.  
 
Our first strategy is to utilize the cRGD-peptide as the targeting motif on the liposome 
surface. Due to the apical expression of v 6 integrins on the alveolar epithelium, MPS-
L
cRGD
 were nebulized to exert direct impact on epithelium for inhibition of pulmonary 
edema. Also, ICAM-1 receptors are upregulated on alveolar endothelium to aid in the 
neutrophil migration into alveoli during ALI. An anti-ICAM-1 antibody might disrupt the 
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interaction of ICAM-1 receptors with 2 integrins of neutrophils, and thus impedes 
neutrophil migration. Our second strategy is to conjugate antibody on the MPS 
encapsulated liposomes to target ICAM-1 receptors, which are accessible by systemic 
administration. Both the strategies deliver MPS to the targeted tissues for inhibition of 
pro-inflammatory cytokine and chemokine production. Each of these strategies has the 
potential to modulate ALI pathogenesis. The success of the strategies depends on the 
answers of the following central questions: (I) how efficient are the conjugation reactions 
of MPS-L
cRGD
 and MPS-L
Ab
, (II) how efficient are the MPS-L
cRGD
 and MPS-L
Ab
 to 
interact with their counter receptors, (III) how efficient are the MPS-L
cRGD
 and MPS-L
Ab
 
to internalize in the targeted cells and (IV) how stable are the MPS-L
cRGD
 and MPS-L
Ab
 
in vitro and in vivo. Through addressal of each of these critical issues, the underlying ALI 
pathogenesis can be resolved. 
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CHAPTER 2. CENTRAL HYPOTHESIS AND SPECIFIC AIMS 
 
 
2.1 Central Hypothesis 
 
The overall goal of the proposed research is to reduce inflammation associated with ALI. 
To achieve the goal, I propose to design new liposome drug delivery systems that 
selectively target and deliver methylprednisolone succinate to the inflamed alveolar 
epithelium and endothelium. It is well accepted that RGD domain and ICAM-1 receptors 
play a critical role in mediating pulmonary edema and neutrophil migration respectively. 
Based on this, the proposed research is focused on the design and development of 
liposomes that utilize the cRGD-peptide and anti-ICAM-1 antibody tethered to the 
liposome surface as the targeting motifs. The proposed research is based on the central 
hypothesis that “methylprednisolone succinate encapsulated targeted liposomes bind to 
integrin or ICAM-1 receptors and modulate ALI pathogenesis”. 
 
Completion of these studies provided a promising drug delivery system for receptor 
mediated inflammatory diseases.Therefore, in order to test the hypothesis, I propose the 
following specific aims: 
 
 
2.2 Specific Aims 
 
 
2.2.1 To Develop MPS Encapsulated Targeted Liposomes 
 
The purpose of this specific aim was to prepare MPS encapsulated liposomes, surface 
modified by cRGD-peptide and anti-ICAM-1 antibody. In the former case, (DSPE-
PEG2000-maleimide)-cRGD-peptide conjugate was synthesized by Michael addition 
reaction and the conjugate was incorporated into MPS encapsulated liposomes by post-
insertion method. In the latter case, anti-ICAM-1 antibody was fragmented, and the 
generated mFab‟ fragments were coupled to the distal ends of MPS encapsulated 
liposomes. Since stable colloidal properties of liposomes are critical for the application, 
size distribution and zeta potential of the prepared liposomes were characterized by 
dynamic light scattering studies. 
 
 
2.2.2 To Lyophilize and Develop Stable MPS Encapsulated Targeted Liposomes 
 
The purpose of this specific aim was to improve the shelf-life of the targeted liposomes. 
MPS-L
cRGD
 and MPS-L
Ab
 formulations were prepared in the presence of intra and 
extraliposomal lyoprotectants. The formulations were then subjected to lyophilization 
process to preserve the liposomes as dry powder. As a result of lyophilization, the original 
liposome properties were retained with minimal or no damage to the reconstituted 
liposomes. 
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2.2.3 To Modulate Pulmonary Edema via MPS-LcRGD Targeting to v 6 Integrins 
 
An IL-1  instilled rat ALI model was used to investigate the effect of MPS-L
cRGD
 on 
pulmonary edema. MPS-L
cRGD
 were nebulized to bind to v 6 integrins of alveolar 
epithelium and inhibit pulmonary edema. Simultaneously, the effect of MPS on inhibition 
of pro-inflammatory mediators production was investigated. BALF samples were 
collected for analysis of protein, cytokines, chemokines and neutrophils. 
 
 
2.2.4 To Impede Neutrophil Migration via MPS-LAb Targeting to ICAM-1 Receptors 
 
MPS-L
Ab
 were targeted to ICAM-1 receptors of alveolar endothelium to attenuate 
neutrophil migration into alveoli. In this study, MPS-L
Ab
 were administered by 
intravenous route prior to IL-1  instillation in rats. MPS-L
Ab
 disrupt the interaction of 2 
integrins of neutrophils with endothelial ICAM-1 receptors, and thereby attenuate 
neutrophil migration. BALF samples were collected for analysis of neutrophils and 
protein content.
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CHAPTER 3. HPLC METHOD FOR DETERMINATION OF LIPIDS IN 
LIPOSOMES 
 
 
3.1 Introduction 
 
Liposomes are lipid vesicles prepared by dispersing lipids in an aqueous phase. 
Liposomes were used as a carrier of drugs.
252
 One of the most significant advantages of 
using liposomes as a drug delivery carrier is the reduced toxicity and improved 
therapeutic efficacy. While different lipids could be used for formulating drugs in 
liposomes; invariably most formulations contain phospholipids and CHOL. Most 
commonly used phospholipids are egg phosphatidylcholine, hydrogenated soy 
phosphatidylcholine, 1, 2-distearoyl-sn-glycero-3-phosphocholine and 1, 2-dipalmitoyl-
sn-glycero-3-phosphocholine. Several liposome formulations contain different anti-
cancer agents, e.g., paclitaxel, doxorubicin and amphotericin.
253, 254
 These formulations 
contain HSPC, CHOL and α-tocopherol in product-specific ratios. There are several 
reported high performance liquid chromatography (HPLC) methods in the literature that 
use silica columns with UV detection, wide and varied mobile phase compositions of 
organic solvents (acetonitrile, hexane, methanol and isopropanol) and water for detection 
and estimation of phospholipids.
255,256
 Separation of several classes of phospholipids was 
achieved using silica column by gradient elution with hexane-isopropanol-water mobile 
phase.
257,258
 While estimation of CHOL and other phospholipids in liposome formulation 
has been reported,
259,260
 some methods require lipid extraction from samples prior to 
injecting into HPLC system,
261
 whereas others use complicated gradient elution for 
separation.
259
 Recently, evaporative light scattering detection (ELSD) has been used for 
estimation of CHOL and other phospholipids in liposome based formulations.
262
 While 
the methods that use ELSD are considered universal, they are cumbersome to reproduce, 
calibration of standards require non-linear regression analysis due to varying sensitivity 
of the detector and often give results with high variations compared to UV detection 
methods. In this report, we describe a rapid HPLC method for separation and 
simultaneous estimation of HSPC and CHOL components of liposome formulations. This 
method uses a C8 column, isocratic mobile phase and UV detection at 205 nm. The 
results generated show that this method can also be used to quantitate α-tocopherol, an 
anti-oxidant used in liposome formulations. 
 
 
3.2 Experimental Section 
 
 
3.2.1 Materials 
 
CHOL used for calibration standard was purchased from National Institute of Standards 
and Technology (NIST, Gaithersburg, MD). HSPC and CHOL were purchased from 
Avanti Polar Lipids (Alabaster, AL) and were of research grade. Anti-oxidant, α-
tocopherol was purchased from Sigma (St.Louis, MO). HPLC grade methanol, water, 
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monobasic ammonium phosphate and 85% w/v phosphoric acid (H3PO4) were purchased 
from Fisher Scientific (Suwannee, GA). 
 
 
3.2.2 Methods 
 
 
3.2.2.1 High Performance Liquid Chromatography 
 
The HPLC system was equipped with Waters Alliance System (Waters®, Milford) 
consisting of vacuum degasser, temperature controlled well-plate auto-sampler, column 
thermostat, quaternary pump and photo diode array detector. Chromatographic analysis 
was performed using a Hypersil BDS C8 (15 cm×4.6 mm i.d., 5 µm particle size, 80°A 
pore size) column (Alltech, Deerfield, IL) at column temperature, 60 C. The analytical 
column was protected with a disposable pre-column (Alltech, Deerfield, IL). Mobile 
phase flow rate was set to 1.0 mL/min with a run time, 30 min. The diode array detector 
was operated at 205 nm with 4 nm of bandwidth and slit setting, off reference mode and 2 
s response time setting. Injection volume was set at 50 µL. An isocratic mobile phase 
containing 50 mM solution of ammonium phosphate buffer (pH 3.0)-methanol (15:85 % 
v/v) was used. 
 
 
3.2.2.2 Preparation of Reagents 
 
Ammonium phosphate buffer (50 mM, pH 3.0) was prepared by dissolving ammonium 
phosphate in water and adjusting the pH to 3.0 with 85% w/v H3PO4. The clear solution 
was filtered through a 0.45 µm nylon membrane filter and stored at room temperature. 
Mobile phase was prepared by mixing the buffer solution and methanol in 15:85% v/v. 
Standard stock solutions of CHOL (1.0 mg/mL) and HSPC (2.0 mg/mL) were prepared 
using methanol. Intermediate stock solutions were prepared by mixing the stock solutions 
of CHOL and HSPC in the product-specific ratio to bracket the target concentration for 
analysis. Calibration standards were prepared by further diluting the intermediate 
solution. Five levels of calibration standards were prepared by diluting the intermediate 
solution. Mobile phase was used as diluent for intermediate and calibration standard 
solutions. The calibration standards used for liposome based MPS analysis were prepared 
in the range of 20-200 and 40-400 µg/mL for CHOL and HSPC, respectively. For other 
drug formulations, similar preparations were made based on the lipid ratio in the 
particular formulation. 
 
 
3.2.2.3 Preparation of Liposome Formulations for HPLC Analysis 
 
Liposome based formulations were prepared as described elsewhere. The samples for 
HPLC injections were prepared by diluting the liposome formulations with mobile phase. 
To bring the concentration of the samples into the calibration range, the required dilution 
depends on the expected concentration of CHOL and HSPC in samples. 
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3.3 Results and Discussion 
 
The HPLC method described here was developed for estimation of CHOL and HSPC 
(Figure 3.1) following the FDA and international conference on harmonization of 
technical requirements for registration of pharmaceuticals for human use (ICH) 
guidelines.
263,264
 Linearity, accuracy, precision, specificity, quantitation limit and 
robustness of the method were tested to ensure that the method is suitable for 
identification and quantitation of CHOL and HSPC components of liposome 
formulations. Chromatographic performance data for a typical run are presented in Table 
3.1. Resolution of 2.0 or greater is desired for critical band pair. Critical resolution of 
2.543 was observed between CHOL and HSPC peaks. Tailing factors for both CHOL and 
HSPC are <1.20. Retention factor in the range of 0.5<k‟<20.0 is desired to separate the 
first peak from void time and to avoid higher retention time for the last band. Retention 
time of 4.316 and 6.205 were found for CHOL and HSPC, respectively. Retention factors 
of the CHOL and HSPC peaks were optimized by varying the mobile phase composition. 
However, it was necessary to increase column temperature to 60 C to achieve acceptable 
resolution between critical band pair of CHOL and HSPC. 
 
 
3.3.1 Linearity and Range 
 
Linearity of the calibration standards was tested in the concentration rage, 20.0-200.0 and 
40.0-400 µg/mL for CHOL and HSPC, respectively. Five levels of calibration standards 
were prepared at various concentration levels. Correlation coefficients (r) were found to 
be >0.999 for both CHOL and HSPC (Table 3.2). Typical chromatogram of a standard 
solution is shown in Figure 3.2. 
 
 
3.3.2 Accuracy 
 
The accuracy study was performed to determine the closeness between the true 
concentration value and the experimental results. CHOL and HSPC were spiked into the 
excipients that include other lipids, anti-oxidant and MPS, expected to be present in the 
formulations. Spike recovery was performed at three levels (500, 100 and 150%) of the 
target concentration. For each level, three preparations were performed. Table 3.3 
summarizes the results from accuracy experiments. Average recovery of 99.80 and 
100.14% were observed for CHOL and HSPC, respectively, which is within ±2.0% of 
normally accepted value. 
 
 
3.3.3 Precision 
 
Instrument precision was performed as part of each sequence run at the beginning of the 
sequence. Six injections of the target level of calibration standard were performed and the 
data were evaluated. Table 3.4 shows the mean retention and area response for both 
CHOL and HSPC. Relative standard deviations (RSDs) for both CHOL and HSPC are  
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Figure 3.1 Chromatogram of calibration standards of CHOL and HSPC. 
 
 
Table 3.1 Chromatographic performance data of the method. 
 
Analyte Retention time (min) Tailing factor
a
 Retention factor
b
 Plate count
c
 
Resolution between 
critical band pair 
CHOL 4.316 1.025 7.362 5440 2.543 
HSPC 6.205 1.206 11.41 6826 - 
 
a
Tailing is defined as W0.05/2tw, where W0.05 is peak width at 5% of peak height (min), tw is distance between peak front and peak 
retention measured at 5% of the peak height (min). 
b
Retention factor is defined as (tR-t0)/t0, where tR is retention time of peak (min) 
and t0 is void time (min). Void time = 0.5 min for the method. 
c
Plate count is defined as 16(tR/WB)
2
, where WB is the tangent peak 
width (min). 
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Table 3.2 Summary of linear regression data for calibration standards. 
 
 Linear regression parameters 
Analyte Intercept Slope Correlation coefficient (r) Coefficient of determination (r
2
) 
CHOL 6.641 11.239 0.99998 0.99995 
HSPC 3.689 5.604 0.99999 0.99999 
 
 
 
 
 
Figure 3.2 Typical chromatogram of linearity of standards containing CHOL and HSPC. 
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Table 3.3 Summary of method accuracy results. 
 
Analyte 
Recovery solution at 
target level (%) 
Theoretical 
concentration ( g/mL) 
Recovered average 
concentration ( g/mL) 
RSD (%) 
Analytical 
recovery
a
 (%) 
CHOL 
50 81.95 81.73 (0.449) 0.268 99.73 
100 163.900 163.71 (0.507) 0.115 99.88 
150 245.850 245.651 (0.598) 0.080 99.91 
HSPC 
50 112.682 112.931 (0.416) 0.220 100.22 
100 225.363 225.509 (0.683) 0.100 100.06 
150 338.044 338.540 (0.543) 0.146 100.14 
 
a
Results are based on six data points. Standard deviation is given in parenthesis. 
 
 
Table 3.4 Summary of method precision results. 
 
 Analyte Average concentration
a
 (mg/mL) RSD (%) 
Day 1 CHOL 22.433 (0.276) 1.16 
 HSPC 31.692 (0.730) 0.216 
Day 2 CHOL 21.887 (0.050) 0.096 
 HSPC 31.888 (0.307) 1.075 
Between days 1 and 2 CHOL 22.705 (0.236) 0.919 
 HSPC 31.609 (0.367) 1.245 
 
a
Based on 12 data points. Standard deviation is given in parenthesis. 
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<2.0%, which indicates sufficient instrument reproducibility of the method. For sample 
precision measurements, six replicate samples were prepared and analyzed on the first 
day. For each sample preparation, three injections were performed. On the second day, 
the same analyst prepared a second set of six samples from the same sample vial and 
independently analyzed on the same system. The RSD values are found to be <2.0% for 
both CHOL and HSPC on each day and <2.0% between days 1 and 2. These results 
clearly indicate sufficient sample repeatability with this method. 
 
 
3.3.4 Quantitation Limit 
 
There are at least four different ways to determine quantitation limits of analyte, and 
signal-to-noise ratio (S/N) is one of the most commonly used procedures. We used this 
procedure for determining quantitation limits of CHOL and HSPC. Stock solutions of 
individual lipid components, CHOL and HSPC were progressively diluted and signal-to-
noise ratios for CHOL and HSPC were determined until a minimum S/N ratio of 10 was 
achieved. Quantitation limits of 0.5 and 10.0 µg/mL were observed for CHOL and HSPC, 
respectively. Previously, a detection limit of 1.5 µg/mL was reported for CHOL in 
liposome formulations.
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3.3.5 Robustness 
 
Robustness is the capacity of a method to remain unaffected by small, deliberate 
variations in method parameters and measures reliability of the method. To test the 
robustness of the method, we deliberately varied four parameters, pH of the buffer, 
column temperature, mobile phase composition and flow rate. The buffer solutions with 
pH values of 2.8, 3.0 and 3.2 were used to study the effect of pH variation on the 
performance of the method. With each variation of buffer pH, analysis of a sample 
solution was performed and the chromatographic results were evaluated. Data were 
collected at three column temperature settings, 58, 60 and 62 C to study the effect of 
column temperature variation on the performance of the method. With each variation of 
column temperature, analysis of a sample solution was performed and the 
chromatographic results were evaluated. The mobile phase flow rates were set at 1.3, 1.5 
and 1.7 mL/min to study the effect of mobile phase flow rate variation on the 
performance of the method. Three different mobile phase compositions (13:87, 15:85 and 
17:83 (v/v) of buffer-methanol) were used to study the effect of varying the mobile phase 
composition on the performance of the method. Robustness data from the above 
experiments are summarized in Table 3.5. The retention times for both CHOL and HSPC 
decreased with increasing column temperature, mobile phase flow rate and pH of the 
buffer, which is expected. The chromatographic performance of the method does not 
change significantly. The retention times for CHOL and HSPC increased with increasing 
polarity of the mobile phase composition. However, it is important to note that the overall 
performance of the method remained unaffected. 
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Table 3.5 Summary of robustness of the method. 
 
Parameters 
Critical 
resolution 
Tailing factor Plate count Overall RSD
a
 (%) 
Correlation 
coefficient (r) 
   CHOL HSPC CHOL HSPC CHOL HSPC CHOL HSPC 
Column 
temperature ( C) 
58 3.68 1.02  6026 7136 1.24 1.36 0.99992 0.99978 
 60 3.60 1.02 1.24 5884 6927 0.98 0.41 0.99988 0.99989 
 62 3.40 1.04 1.23 5436 6638 1.69 0.38 0.99975 0.99971 
Flow rate 
(mL/min) 
1.3 3.66 1.02 1.23 5997 7206 1.85 1.47 0.99984 0.99963 
 1.5 3.60 1.02 1.21 5883 6927 0.87 0.94 0.99996 0.99981 
 1.7 3.38 1.03 1.21 5513 6505 0.65 1.02 0.99977 0.99978 
Mobile phase 13:87 3.45 1.03 1.21 5201 6498 1.74 1.15 0.99983 0.99984 
 15:85 3.60 1.02 1.21 5884 6927 0.89 1.62 0.99993 0.99993 
 17:83 4.25 1.02 1.22 4986 6334 1.60 0.71 0.99971 0.99987 
Buffer pH 2.8 3.38 1.04 1.22 5115 6728 1.29 0.68 0.99987 0.99975 
 3.0 3.60 1.02 1.22 5884 6928 0.71 0.95 0.99992 0.99989 
 3.2 3.36 1.04 1.22 4970 6725 0.80 1.09 0.99986 0.99977 
 
a
For each sequence run, a calibration standard solution was injected at the beginning of the sequence, after the five levels of 
calibration standards (two injections) and at the end of the sequence (two injections) to verify the system suitability of the overall run 
sequence. The %RSD data are based on the response (area) of these 10 system suitability injections for each run.  
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3.3.6 Conclusions 
 
A rapid isocratic HPLC method for simultaneous quantitation of CHOL and HSPC in 
liposome formulations was developed. The method is linear, precise, accurate, sensitive, 
robust and specific for quantitation of CHOL and HSPC in liposome formulations. In 
addition, this method is applicable to several of the liposome formulations for 
quantitation of CHOL and HSPC, and does not require preprocessing of the samples. This 
method also improved the quantitation limits of CHOL compared to other reported 
methods.
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CHAPTER 4. MPS ENCAPSULATION AND SURFACE MODIFICATION OF 
LIPOSOMES 
 
 
4.1 Introduction 
 
Methylprednisolone sodium succinate treatment is widely used in the treatment of 
inflammatory diseases.
85,265
 MPS is more effective anti-inflammatory agent than are non-
steroidal anti-inflammatory drugs. However, the systemic administration of MPS is often 
accompanied by substantial side effects, especially when long-term treatment is used. 
Due to the fast clearance of MPS from the body, frequent high-dose intravenous (i.v.) 
and/or oral administration is required to achieve efficacy, but this affects many tissues 
and causes serious side effects. Therefore, improvement of the therapeutic efficacy would 
be beneficial. A systemic “targeted” administration will bring the MPS selectively to the 
inflamed areas and increases the therapeutic index of MPS. This can be achieved by MPS 
delivery via liposomes. Although, MPS delivery via liposomes is one of the earliest 
attempts to use liposomes as drug carriers, until now no liposomal MPS formulation has 
reached clinical application. A systemic liposome formulation needs to fulfill several key 
requirements in order to be efficacious enough to justify development as a drug: I) 
liposome formulation should accumulate at the inflammation site as a result of prolonged 
circulation due to reduction in uptake by the RES, II) low drug leakage rate during the 
circulation, III) liposomal formulation should be chemically and physically stable during 
storage, IV) liposomes should have a high [drug/lipid] ratio to avoid toxicity induced by 
high liposome dose and V) high drug encapsulation is required. Herein, I describe the 
development of MPS liposome formulations using passive and active loading strategies. 
In both the strategies, the influence of formulation composition and process variables 
were investigated comprehensively to improve the MPS encapsulation efficiency and 
meet the above criteria. However, the formulation based on a novel acting loading 
approach, calcium acetate transmembrane gradient efficiently loaded MPS into 
liposomes. Approximately, 63% w/v MPS encapsulation efficiency was achieved using 
the acetate gradient method. In addition, MPS-L were surface modified with cRGD-
peptide by post-insertion method to exert control on the incorporation of targeting ligand. 
In this method, an incorporation efficiency of 45.3% (molar) was achieved. 
 
In this chapter, the influence of formulation composition, process parameters and loading 
strategies were investigated to obtain an optimized MPS encapsulated formulation for use 
in in vivo studies. 
 
 
4.2 Materials 
 
HSPC, 1, 2-dipalmitoyl-sn-glycerophosphoethanolamine-poly (ethylene glycol)2000-
amine (DSPE-PEG2000), 1, 2-dipalmitoyl-sn-glycerophosphoethanolamine-poly (ethylene 
glycol)2000-maleimide (DSPE-PEG2000-maleimide) were obtained from Avanti Polar 
Lipids (Birmingham, AL). MPS and CHOL were purchased from Sigma (St.Louis, MO). 
cRGD-peptide was purchased from Peptide International Inc. (Louisville, KY). PBS and 
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HEPES buffers were purchased from cellgro Inc. (Herndon, VA). All other chemicals 
were obtained from Sigma or Fisher Scientific. 
 
 
4.3 Methods 
 
 
4.3.1 Preparation of MPS-L by Passive Loading (Bangham Method) 
 
Liposomes were prepared with a composition of HSPC: CHOL: DSPE-PEG2000 in 50: 45: 
3: 2 molar ratios. The lipids were solubilized in chloroform-methanol solution and 
subjected to evaporation to form a thin lipid film. Hydration of the lipid film was carried 
with HEPES buffer (50 mM, pH 6.5) containing MPS at 100 mg/mL. The resulting 
MLVs were extruded through 100/200 nm sandwiched polycarbonate membrane filters 
using liposome extruder (LIPEX™, Northern Lipids, Canada). MLVs were subjected to 
the required number of extrusion passes to form small unilamellar vesicles (SUVs) in the 
size range, 100-120 nm. This was followed by the incubation of SUVs with cRGD-
peptide solution, pH 6.5, overnight at 25 C. The conjugation reaction was quenched with 
100 µL of 1 µM of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC; Sigma, MO). 
Unconjugated free RGD-peptide and free MPS were isolated by dialysis at 4 C for 6 h 
using equilibrium chambers (Harvard Apparatus, MA), separated by a 10,000 Da MWCO 
membrane. The dialysate was subjected to HPLC analyses to determine MPS 
encapsulation and cRGD-conjugation efficiency. The surface modified liposomes were 
stored at 4 C until further use. 
 
 
4.3.2 Active Loading of Amphipathic MPS into Liposomes 
 
Remote loading was performed using calcium acetate transmembrane gradient method. 
Ca.acetate]liposome >> [Ca.acetate]medium transmembrane gradient was used as the driving 
force for the remote loading of MPS, an amphipathic weak acid. Such a gradient is 
characterized by an excess of the membrane-impermeable Ca
+2
 ions over the membrane-
permeable acetic acid; the leakage of acetic acid of the liposomes leads to creation of a 
pH gradient in which the pHliposome >> pHmedium. In such liposomes, the amphipathic weak 
acid, such as MPS in its unionized form is diffused into the slightly alkaline 
intraliposomal aqueous phase. Inside the aqueous core, it is de-protonated and becomes 
negatively charged. Now, the ionized MPS forms a poorly soluble calcium-MPS 
complex, which precipitates in the intraliposomal aqueous phase. The loading process 
continues till the exhaustion of intraliposomal acetate ion concentration. Lipids, 
HSPC/CHOL/DSPE-PEG2000 were dissolved in ethanol and then were hydrated with 200 
mM calcium acetate at 65°C. The large MLVs formed upon lipid hydration were extruded 
at 65°C through sandwiched polycarbonate filters (100/200 nm). Approximately, 100-120 
nm sized liposomes were obtained. To create the transmembrane calcium acetate 
gradient, the calcium acetate of the external liposome medium was replaced by 0.9% 
NaCl (w/v) at 4°C by dialysis. MPS was dissolved in 0.9% NaCl to a concentration of 19 
mM (9 mg/mL) and mixed with preformed liposome dispersion (30 mM phospholipids) 
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in which a transmembrane calcium acetate gradient was created. The remote loading was 
achieved by incubation of the liposome dispersion at 48°C (near the Tm of HSPC, i.e. 
52 C) for 6 min, and then liposomes were cooled to 4°C and dialyzed against 0.9% NaCl 
to remove any residual traces of acetate ion. After dialysis, MPS and phospholipid 
concentrations were 12.03 mM and 27.2 mM, respectively. 
 
 
4.3.3 Synthesis of DSPE-PEG2000-maleimide-cRGD Conjugate 
 
DSPE-PEG2000-maleimide-cRGD conjugate was synthesized and incorporated into MPS 
encapsulated liposomal bilayers for targeting to lungs via the integrin receptors. The 
conjugate was synthesized as described in Figure 4.1. Briefly, 11.34 mg of DSPE-
PEG2000-maleimide and 1.16 mg of cRGD peptide were dissolved in 100 µL of HEPES 
buffer (50 mM, pH 6.5) containing TCEP and 1 mM disodium EDTA. The reaction was 
carried overnight at 25 C on a tube shaker (Barnstead/Thermolyne, IA). The product was 
dialyzed in 1000 Da MWCO Slide-A-Lyzer® dialysis cassettes (Pierce, Rockford, IL) 
against HEPES buffer (pH 6.5) at 4 C for 6 h. Followed by dialysis, the product was 
subjected to further de-salting on micro bio-spin chromatography columns (Bio-Rad, 
Hercules, CA). The product was then lyophilized and stored at -20 C until further use. 
The product was characterized by vMALDI. For vMALDI analysis, the product ( 1 nM) 
was purified with a ZipTip C18 spin column using the procedure recommended by the 
manufacturer (Millipore, Billerica, MA). The purified product solution was eluted with 2 
L of α-cyano-4-hydroxycinnamic acid (α-CHCA) matrix solution (2.5 mg/mL in 
ACN/Water/TFA mixture) on a micro-column. The product/matrix mixture was spotted 
on a vMALDI plate and air-dried at room temperature. The product was analyzed with 
vMALDI–LTQ mass spectrometer (ThermoFinnigan, San Jose, CA) operated in positive-
ion mode. For the vMALDI source, the crystal-positioning system and auto spectrum 
filter (ASF) were enabled and ASF threshold was set at 500 counts for an MS scan. 
Automatic gain control (AGC) was enabled to adjust the number of laser shots and 
maintain the quality of vMALDI spectra. For an MS scan, high-mass range (m/z 500–
4000) and normal scan rate were used. Product spectra were acquired and analyzed using 
Xcalibur software (ThermoFinnigan, San Jose, CA). The amount of residual free cRGD 
peptide was determined by Ellman reaction,
266
 which quantifies the sulfhydryl groups of 
cRGD peptide. 
 
 
4.3.4 Insertion of DSPE-PEG2000-maleimide-cRGD Conjugate into Liposomes 
 
DSPE-PEG2000-maleimide-cRGD conjugate was micellized and inserted into liposomes 
to exert control on the number of targeting ligands per liposome. A micellar solution of 
the conjugate was prepared by a procedure described elsewhere.
267,268
 Briefly, 28.9 mg of 
the lyophilized conjugate was solubilized in 1000 L of water to form micellar solution. 
The resulting micellar solution was lysed in 5% w/v Triton-X surfactant solution and the 
total cRGD peptide content was determined by Ellman reaction. Based on the liposome  
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Figure 4.1 Schematic representation of Michael addition reaction between the lipid, 
DSPE-PEG2000-maleimide and cRGD-peptide. 
 
The reaction was carried between equimolar concentrations of the lipid and the peptide. 
The synthesized conjugate was de-salted, and futher purified using dialysis cassettes 
(MWCO, 1000 Da) at 4 C for 6 h. The peptide and phospholipid contents were estimated 
by Ellman reaction and phosphorus assay to determine the conjugation efficiency. The 
lipo-peptide conjugate was qualitatively characterized by MALDI-MS in positive ion 
mode. 
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number, a specific micellar concentration of the conjugate was added to liposome 
suspension to obtain the required number (1,500) of targeting ligands per liposome. The 
number of liposomes was determined by NVOL method.
238
 As illustrated in Figure 4.2, 
both micellar conjugate and liposomes were incubated together at 48°C for 6 min and 
stored overnight at 4°C. The liposome formulation was then centrifuged (1,500xg, 15 
min) in mini bio-spin chromatography columns to remove any unincorporated conjugate. 
Followed by centrifugation, liposome formulation was lysed with 5% w/v Triton-X 
surfactant solution, and cRGD peptide content was determined to estimate the conjugate 
incorporation efficiency. 
 
In active loading strategy, MPS encapsulation was evaluated with respect to formulation 
composition and process parameters, before surface modification with cRGD-peptide. 
 
 
4.3.5 Chemical Characterization of Liposome Dispersion 
 
The total and intraliposome concentrations of MPS were quantified using RP-HPLC 
method. The concentrations of HSPC and CHOL were determined using HPLC method 
as described in Chapter 3. 
 
 
4.3.6 Physical Characterization of Liposome Dispersion 
 
Mean diameter (Zavg) and zeta potential of liposomes were evaluated by dynamic light 
scattering (DLS) studies using zetasizer® (Malvern Inc., Westborough, MA) equipped 
with a 4.5 mW diode laser as a light source operating at 670 nm. Particle scattered 
photons were detected at 173 . Medium refractive index, 1.335; medium viscosity, 1.0 
mPa; and a dielectric constant of 80.0 were used as reference parameters for experimental 
investigations. Samples were suitably diluted with 0.22 µm filtered HPLC water to avoid 
multi-scattering phenomena for Zavg and zeta potential determination. A Smoluchowski 
constant of 1.5 was used to measure zeta potential values from electrophoretic mobility. 
The mean diameter and zeta potential of liposome formulations were expressed in 
nanometers (nm) and millivolts (mV), respectively. Morphology was determined by 
negative staining of the SUV specimens on carbon support films by the single droplet 
procedure. 2% w/v aqueous solution of uranyl acetate (pH 6.5) was employed to stain the 
specimens. Specimens were studied using transmission electron microscope, functioning 
at 200 kV (JEOL-FX 2000). A magnification of 50,000x was employed to acquire the 
electron micrograph. 
 
 
4.3.7 MPS Encapsulation Efficiency 
 
MPS encapsulation efficiency studies were carried to evaluate the MPS loading as a 
function of composition and process parameters. In passive loading strategy, formulation 
composition parameters include drug/lipid ratios, CHOL fraction and PEGylated lipid 
fraction. Process parameters include primarily, the effect of extrusion passes and pressure  
  52 
 
 
 
Figure 4.2 Schematic representation of the insertion of the targeting conjugate by 
post-insertion technique. 
 
The micelles of the conjugate were incubated with MPS encapsulated liposomes to yield 
targeted liposomes, MPS-L
cRGD
. All targeting ligands on the external leaflet of the 
liposomes are presumed to be available for targeting. The conjugate insertion efficiency 
into liposomes was determined to be 34% (molar) as determined by Ellman reaction and 
phosphorus content analysis. 
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on MPS encapsulation. Extrusion parameters do not have a significant influence on MPS 
encapsulation in active loading strategy as preformed small unilamellar liposomes were 
used for MPS incorporation. MPS encapsulation efficiency (% EE) was calculated using 
the Equation 4.1 
 
% EE = (At-Af/At) Equation 4.1 
 
Where At is the total amount of drug used for encapsulation and Af is the amount of free 
drug left in solution. 
 
 
4.3.8 In Vitro Leakage Kinetics of MPS from Liposomes 
 
The kinetics of MPS leakage in buffers was quantified using dialysis cassettes (MWCO, 
10000 Da) equilibrated with HEPES buffer (pH 7.4, 50 mM). At definite time points, 
aliquots were taken and analyzed for MPS leakage. 
 
 
4.3.9 Mathematical Models 
 
Mathematical models were applied to describe the MPS release kinetics in liposome 
formulations. Higuchi and Korsenmeyer-Peppas (K-P) models were applied to describe 
the diffusion kinetics of MPS from liposomes, prepared by passive loading method. For 
active loading method (See Figure 1.6B), a mathematical model based on Rippie‟s 
assumptions was proposed to describe the drug release diffusion kinetics in liposomes 
(Figure 4.3). The same model was used to estimate the encapsulated drug (At-Af) in 
liposomes prepared by active loading method. 
 
 
4.4 Results and Discussion 
 
 
4.4.1 Passive Loading Strategies 
 
 
4.4.1.1 MPS Encapsulation Efficiency (% EE): Influence of Drug/Lipid (D/L) Ratios 
 
Initial work was devoted for selection of phospholipid and characterizing its effect on 
MPS retention. Further work was extended to study the influence of D/L ratios on MPS 
encapsulation. HSPC/CHOL (55/45 mole%; 27.2 mM total lipids) liposomes were 
prepared with increasing amounts of MPS corresponding to D/L ratios from 0.1 to 0.8. 
The liposomes were then dialyzed at 4 C for 6 h to remove unencapsulated drug, and the 
D/L ratio was measured after quantitation of MPS inside the liposomes.As shown in 
Figure 4.4, D/L ratio as high as 0.6 (molar) was achieved. However, a stable 
encapsulation could not be achieved, and a substantial fraction ( 92% w/v) was desorbed 
into the external medium in 6 h. 
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Figure 4.3 Schematic representation of the mathematical model based on Rippie‟s 
assumptions. 
 
The model can be used to predict the drug diffusion in and out of particulate cores, where 
pH transmembrane gradient is maintained across the membranes. 
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Figure 4.4 Graph depicting the MPS encapsulation efficiency as a function of 
drug/lipid ratios. 
 
Each level is a mean SEM of n = 3 samples. Total lipid content of MPS-L was 27.2 mM. 
* p<0.05 in comparison to [D/L] at 0.1 or 0.2. Statistical analysis was performed using 
Newman-Keuls test for multiple comparison (one-way ANOVA). 
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4.4.1.2 Influence of CHOL Incorporation on MPS encapsulation 
 
Basic composition of liposomes includes HSPC and CHOL. Being a saturated lipid, 
HSPC is stable to chemical degradation and avoids premature leakage of encapsulated 
drug from the liposomes in comparison to unsaturated phospholipids. CHOL was 
included in the formulation to enhance the rigidity of phospholipid bilayers. However, 
with CHOL, MPS entrapment efficiency was reduced, which may be due to phase 
separation of CHOL from the liposome formulation during hydration and extrusion 
processes. Phase separation and CHOL crystallization may induce pore formation in 
phospholipid bilayers and cause extensive drug leakage.As shown in Figure 4.5, 
formulation composition of HSPC/CHOL at 55/45 mole% showed a % EE of 8.94. 
Though, HSPC/CHOL at 65/35 mole% showed the highest entrapment, a substantial 
amount of MPS leaked out in 6 h at 37 C. 
 
 
4.4.1.3 Influence of PEG Incorporation on MPS Encapsulation 
 
PEG-lipids were incorporated into the liposome membrane to enhance the in vivo 
circulation half-life of liposomes. As shown in Figure 4.6, % EE values containing 1-10 
mole% of PEGylated lipid in the liposome formulations are in the range of 2-8% w/v of 
the MPS used for encapsulation. MPS encapsulation showed no significant effect till 5 
mole% of the incorporated PEGylated lipids. Usually, the PEGylated lipid concentration 
is limited to 5 mole% in long circulating liposome formulations. In this range, MPS 
encapsulation efficiency is independent of PEGylated concentration.  
 
 
4.4.1.4 MPS Encapsulation: Influence of Extrusion Pressure 
 
Characteristics of the extrusion procedure (applied pressure, flow rate and pore size) as 
well as physical properties of the lipids and the lipid suspension (surface tension, bending 
modulus and concentration) may all play a role in the size and polydispersity of the 
vesicles produced. Understanding the role of these factors will contribute to the 
reproducibility achieved and should lead to production of more ideal vesicle solutions. 
Size and polydispersity of vesicles produced by extrusion depend on the number of times 
the solution is extruded, pore size of the extruded filters,
269
 lipid properties
270
 and 
pressure.
271
 Optimization of extrusion pressure and cycles is critical for drug 
encapsulation. As shown in Figure 4.7, MPS encapsulation reduced with extrusion 
pressure. 
 
 
4.4.1.5 Drug Release Models 
 
The drug release data was analyzed with mathematical models, such as the Higuchi 
model and the Korsmeyer-Peppas equation.
272
 One of the most often used mathematical 
equations to describe the release rate of drugs from drug delivery systems is the Higuchi 
model,
273
 which is described by Equation 4.2: 
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Figure 4.5 Graph depicting the MPS encapsulation efficiency as a function of CHOL 
fraction. 
 
Each level is a mean SEM of n = 3 samples. Total lipid concentration was 27.2 mM. 
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Figure 4.6 Graph depicting the MPS encapsulation efficiency as a function of 
PEGylated lipid incorporation. 
 
Each level is a mean SEM of n = 3 samples. From the graph, it is observed that there is 
no significant difference in MPS encapsulation as a function of PEGylated lipid 
concentration. 
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Figure 4.7 Graph depicting the MPS encapsulation efficiency as a function of number 
of extrusion cycles. 
 
For all the levels of lipid content, an extrusion pressure of 250 psi was maintained. Each 
level is a mean SEM of n = 3 samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  59 
Mt/A = [D(2C0-CS)CSt]
0.5
 for C0>CS Equation 4.2 
 
The Higuchi equation was originally applied to dissolution and growth from solid 
particles.
273
 However, the Higuchi law was extended to colloid systems, such as 
emulsions.
274,275
 The K-P equation organizes the cases of the drug release from a dosage 
form, and the cumulative drug amount, Mt, released at time t is given by the Equation 
4.3: 
 
Mt/M0 = kt
n
 up to Mt/M0≤0.07 Equation 4.3 
 
where M0 is the initial amount of drug in the liposomes at time t = 0, k is the release 
constant and n is the release exponent, indicative of the drug release mechanism. If n = 1, 
the release is zero order. If n is between 0.5 and 1, the release follows an anomalous 
transport (non-Fickian) mechanism, which is controlled by factors other than diffusion, 
including the drug encapsulation matrix and liposome membrane structure. If n = 0.5, the 
drug release is controlled by Fickian diffusion, and the drug release can be modeled using 
Higuchi‟s law. All the factors influencing the relationships between Mt and t in Equation 
4.2 are represented by the release rate constant k in Equation 4.3. The rate limiting steps 
in MPS release include (I) MPS diffusion to the inside surface of the liposome and II) 
MPS diffusion through the lipid bilayer. 
 
 
4.4.1.6 Influence of PEG Incorporation on the Release Mechanism 
 
The percentage cumulative MPS release (Mt/M∞) x 100%) from liposomes containing 
PEGylated lipid was shown in Figure 4.8. As shown in Table 4.1, good correlation was 
obtained between experimental data and the K-P equation with r
2
 values greater than 
0.97. The release rate constant, k and the release exponent, n were obtained from the 
intercept and slope, respectively, of the plot of Ln (Mt/M∞) versus Ln (t). It was found 
that the value of n increased with PEG content in the liposomes. It is concluded that 
Fickian diffusion (n = 0.5) is the main release mechanism for liposomes with less than or 
equal to 2.5 mole% DSPE-PEG2000 in liposome formulations. While the release 
mechanism followed non-Fickian diffusion mechanism at DSPE-PEG2000 greater than or 
equal to 5 mole%. This data shows that MPS release is controlled by the interfacial 
structure of the liposomes with tethered PEG chains at the surface. 
 
In this case, liposomes can be considered as reservoir systems, where the drug was 
surrounded by a barrier,
276
 e.g. MPS molecules in liposomes composed of lipid 
membrane and PEG chains.Narasimhan et al.
277
 suggested that diffusion through the 
polymer (such as PEG) is the rate-limiting step. If the Fickian diffusion law is obeyed for 
MPS release from liposomes, the diffusion rate is proportional to: (I) membrane 
permeability, therefore, DSPE-PEG2000 in liposomes can reduce the diffusion rate because 
HSPC bilayers are less rigid than PEG layers, (II) thickness of the bilayer; hence MPS 
diffusion from PEGylated liposomes. PEGylated liposomes exhibited high release rates. 
The phospholipid membrane generally is ~2-4 nm,
278
 whereas the PEGylated coat of the 
liposome is ~5 nm, (III) drug concentration gradient across the liposome bilayer leads to  
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Figure 4.8 Graph depicting the MPS release from liposome formulations containing 
different fractions of DSPE-PEG2000. 
 
The release studies were performed at 25 C using dialysis cassettes (10,000 Da MWCO). 
All the values are a mean SEM of n=3 samples. 
 
 
Table 4.1 Parameters in the K-P equation for MPS release kinetics from MPS-L. 
 
DSPE-PEG2000 mole% n Release mechanism k (min
-n
) r
2
 
0 0.51 Fickian diffusion 0.12 0.98 
2.5 0.53 Fickian diffusion 0.05 0.98 
5 0.68 Non-Fickian diffusion 0.3 0.99 
10 0.71 Non-Fickian diffusion 0.01 0.97 
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a high diffusion rate for high MPS encapsulation and (IV) surface area of liposomes, i.e. 
size of the liposomes.  
 
Silvander et al.
279
 indicated that the PEGylated lipids impose restrictions on the 
molecular motion in the outer as well as the inner parts of the hydrocarbon region of the  
lipids. PEGylated lipids may cause an increased packing order at the water/hydrocarbon 
interface. At 5 mole%, both diffusion and PEGylated surfaces of liposomes controlled 
MPS release. The release rate constant, k decreased dramatically as the PEG was 
incorporated, and k values were not significantly different when the PEG-lipid in 
liposomes was >5 mole%. The MPS release from liposomes with PEGylated lipid less 
than 5 mole% followed a t
0.5
 dependence (Higuchi law) rather than a t
0.7
 law (for PEG-
lipid >5 mole% in liposomes). 
 
 
4.4.1.7 Influence of Mean Size of Liposomes on the Release Kinetics 
 
Liposome diameter has been reported to influence the pharmacokinetics and disposition 
of a drug, such as doxorubicin into the RES.
280
 The MPS release kinetics from PEGylated 
liposomes of different sizes is shown in Figure 4.9. The data was fit by the Higuchi law, 
which showed a good correlation of this model to MPS release from PEGylated 
liposomes (r
2
 is 0.97-0.99). Higuchi law shows that the surface area of liposomes exposed 
to the release medium is part of the release rate constant, k calculated from the 
relationship between the cumulative drug release amount and t
0.5
. Therefore, MPS release 
is related to the size/surface area of liposomes. The MPS release rate increased with 
decreasing liposome size because the total surface area (TSA) of liposomes was 
increased. TSA is equal to the average surface area (S) of liposomes multiplied by the 
number of liposomes in suspension, which is equal to the inverse of the volume of a 
liposome (V). Therefore, TSA is proportional to (A/V), i.e. (4 π r2)/(4/3 π r3) = 3/r (r is 
the average radius of PEGylated liposomes). The MPS release rate constant as a function 
of 3/r is shown in Figure 4.10. An increase in the surface area of liposomes led to an 
increase in k values due to the increase in total surface area exposed to the release 
medium, and also led to an increase in MPS diffusion from liposomes. For a PEGylated 
liposome, Higuchi law is followed during the MPS release, and the release rate constant 
is proportional to the inverse of liposome radius. In Figure 4.10, the relationship is, k = 
(3.9/r)+0.0135. When r → ∞, k is 0.0135 min-0.7, which is the situation of MPS release 
from a flat surface. 
 
 
4.4.1.8 Influence of Temperature on the Release Kinetics 
 
Temperature of the release medium may alter the viscosity of the liposome suspension, 
and thereby change the solubility and diffusion rate of drugs incorporated in 
liposomes.
281
 Figure 4.11 shows that MPS release as a function of temperature of the 
medium. Release data was fit to Equation 4.3 with n = 0.7 for PEGylated (5 mole%) 
liposomes. As shown in Table 4.2, temperature (25 vs.37 C) has a significant effect on 
MPS release. An increase of temperature increases the value of the diffusion coefficient,  
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Figure 4.9 Graph depicting the MPS release from PEGylated liposome formulations 
with mean diameters of 100, 200, 400 and 800 nm. 
 
The total lipid content in all the formulations was 27.2 mM, and the studies were carried 
at the same stirring speed (50 rpm) at 25 C. All the values are a mean SEM of n=3 
samples. 
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Figure 4.10 Graph depicting the MPS release rate constant of the liposome 
formulations with varied mean diameter, calculated from K-P equation. 
 
The release rate constant is related to radius of the liposomes. The rate constants were 
obtained from the slopes of the MPS release from different sized liposome formulations.  
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Figure 4.11 MPS release rate from PEGylated liposomes stored at different 
temperatures 4 (■), 25 (□), 30 (Δ), 37 (▲) and 40 C (*). 
 
The MPS release rates were fit to K-P equation. 
 
 
Table 4.2 Values of k from the t
0.7
 law for MPS-L at different temperatures. 
 
Temperature (
o
C) k (min
-0.7
) 
4 0.02 
25 0.04 
30 0.04 
37 0.08 
40 0.12 
 
The release study was conducted at pH 7.4 and, the buffer has no added salt. 
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D, which relates the diffusion process to temperature (T) and viscosity (η),282 In 
Equation 4.4, kB is Boltzmann‟s constant and r is the liposome radius. The temperature 
effect on the D value is also described by Equation 4.5. 
 
D = kBT/(6πηr) Equation 4.4 
 
D = D0e
(-Ead/RT)
 Equation 4.5 
 
Where D0 is a constant, Ead is the activation energy for the diffusion process (J/ mol), R 
is the universal gas constant (J/ mol K) and T is the absolute temperature. From Equation 
4.4, D increases with increase in T, which is in agreement with the experimental value. As 
shown in Figure 4.11, over the temperature range, 4 to 40
o
C, MPS release showed 
Arrhenius behaviour. The activation energy, Ea for MPS release through the liposome 
bilayer was calculated from the temperature dependence of the release rate constant using 
the Arrhenius equation.
283
 For PEGylated liposomes, the diffusion process is not the only 
mechanism and Ea is larger than Ead. However, PEG chains impeded the drug diffusion. 
 
 
4.4.1.9 Summary for Passive Loading Strategy 
 
MPS encapsulation efficiency was ~8% w/v using passive loading process. The K-P 
equation (n = 0.7) and the Higuchi model (n = 0.5) provided good fits for the 
experimental data of MPS release/leakage from PEGylated liposomes at PEGylated lipid 
concentrations, <2 and >5 mole%, respectively. The high surface area of small liposomes 
led to increased MPS release. Changes in pH and salt concentration significantly 
influenced the MPS release rate, indicating that electrostatic forces between liposomes or 
between liposome and MPS molecules affect the drug release. In contrast to the 
assumption that PEG incorporation into the liposome formulation reduces MPS release 
rate, PEGylation increased the MPS release rate. A high molar ratio of PEGylated lipid in 
the liposome formulations resulted in increased release rate. In addition, the release 
mechanism was transformed from diffusion control to interfacial control based on the K-
P equation. These findings may be utilized for the improvement of the formulation, and 
gives an insight into the actions of PEGylated liposomes in the body. 
 
 
4.4.2 Active Loading Strategies 
 
 
4.4.2.1 Dynamic Light Scattering (DLS) Studies for Particle Size and Zeta Potential 
 
The average diameter and zeta potential of extruded liposomes were 120 13 nm and -
27 4.7 mV, respectively as determined by DLS studies, which indicate the formation of 
small and stable liposomes. MPS-L
cRGD
 were stable at 4 C. 
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4.4.2.2 Encapsulation of MPS by the Use of Salt Gradients 
 
MPS liposomes loaded with gradients of calcium acetate showed a higher EE than those 
loaded by sodium salts (Figure. 4.12). The liposomes showed a constant particle size and 
low polydispersity index during the loading process (data not shown). The EE declined in 
the line: calcium>sodium>ammonium. Among the acetate salts, only calcium showed a 
high MPS loading. All salt gradients resulted in active MPS loading, when compared to 
the passive loading, which is calculated by the ratio of encapsulated MPS amount to the 
total MPS concentration. 
 
 
4.4.2.3 Influence of Intravesicular Acetate Concentration on MPS Encapsulation 
 
Dried lipid was hydrated with various buffers containing 50, 100, 200, 300 or 400 mM 
calcium acetate (pH was adjusted to 7.0 with 0.1 N NaOH). The size of the liposomes 
after extrusion was around 100-120 nm. External acetate was removed using de-salting 
columns. After incubation of MPS with preformed liposomes at 48 C, the encapsulation 
efficiency (EE) increased up to 63% w/v with a [drug/lipid] ratio of 0.4 at an acetate 
concentration of 200 mM inside the liposomes. The lowest MPS EE (3.1% w/v) was 
achieved with 50 mM HEPES buffer, containing no acetate ions. (Figure 4.13) 
 
In the study, a stable pH gradient over the loading period is maintained in situ by 
generation of acetate gradient, i.e. by a high intraliposomal acetate concentration and an 
acetate ion-free, extraliposomal buffer. Due to the acetate gradient, the pH value 
decreases outside the liposome from pH 4.3 to a lower pH, even though the 
extraliposomal buffer was set to a pH of 4.3. The in situ generation of the pH gradient 
from the higher permeation coefficient of acetic acid caused basification of the liposome 
interior. In the absence of an acetate gradient, there is no decrease in extraliposomal pH 
value. Instead, the internal pH adjusts to that of the outer pH. Due to de-protonation and 
precipitation of MPS, high encapsulation efficiency was achieved. Due to the interaction 
of MPS with calcium ions, negatively charged MPS precipitates with calcium ions to 
form a gel-like structure within the liposomes.
187, 195, 284
 The solubility studies showed 
consistently poor solubility of MPS in a 200 mM acetate solution in the investigated pH 
range of values close to the pKa of MPS (pKa=4.3), where solubility drops to almost 
zero. 
 
 
4.4.2.4 MPS Encapsulation via Calcium Acetate Gradient with Different Interior pH 
Values 
 
Liposomes were prepared with intraliposomal calcium acetate buffer (200 mM) of 
various pH values (pH 3, 4.3, 5, 6 and 7.0). Loading liposomes with MPS via acetate 
gradient is a new, potent and alternative remote loading method. Loading of MPS by 
means of salt gradients includes two synergistic effects, both of which result in the fact 
that MPS can no longer pass the lipid membrane. On one hand, loading is driven by de-
protonation and charging of MPS within the liposome, and on the otherhand, by  
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Figure 4.12 Histogram of MPS encapsulation driven by various acetate salt gradients 
in PEGylated liposomes. 
 
The lipid formulations were prepared with a [drug/lipid] ratio of 0.4. The lipid film (27.2 
mM phospholipid concentration) was hydrated with 200 mM salt solution adjusted to pH 
7.0 (n = 3). *** indicates significant levels at P<0.001 (ANOVA) in comparison with 
minimum EE. 
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Figure 4.13 Histogram of MPS encapsulation as a function of different ionic strengths 
of calcium acetate inside the lipoosmes. 
 
All the values are a mean±SEM (n = 3). ** indicates significant levels at P<0.01 
(Bonferroni‟s one way ANOVA) in comparison with minimum EE. 
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precipitation of MPS in the hydrophilic interior of the vesicle when the concentration of 
MPS solubility is exceeded. By means of a stable pH-gradient, MPS is de-protonated in 
the basic interior of the liposome. When the extraliposomal pH is low, only a small part 
of the MPS is de-protonated. The free uncharged acid is then able to pass the membrane 
so that there is intra and extraliposomal adjustment in the concentration of the free acid of 
the drug. When the intraliposomal pH value is higher, the free intraliposomal MPS acid is 
de-protonated and new extraliposomal, unionized MPS can diffuse into the liposome 
according to the concentration gradient. Therefore, a “proton pool” outside the liposomes 
is necessary as a driving force for MPS loading.  
 
As shown in Figure. 4.14, high pH values resulted in a higher EE of MPS. At pH values 
<4.3, the solubility of MPS decreases. After protonation of MPS in the liposome aqueous 
core, the complex is nearly insoluble in the calcium acetate solution. By using calcium 
acetate gradients with various pH values, it could be demonstrated that with the 
synergism of de-protonation and precipitation of MPS, higher encapsulation efficiencies 
can be achieved. 
 
 
4.4.2.5 Leakage of MPS Liposomes Loaded via Acetate Gradient 
 
MPS leakage from liposomes was examined under different pH conditions at 25 C. These 
include contact with physiological fluids at pH 7.0, pH 6.0 of tumor tissues
285
 and pH 5.0 
after uptake into endosomes. The drug leakage properties of liposomes, which were 
loaded via transmembrane acetate gradient differ completely from vesicles, which are 
loaded with other ion gradients. The MPS release of liposomes, which were loaded via an 
acetate gradient showed a negligible leakage at low pH, but leakage increased with pH 
(Figure 4.15). At pH 6.0 and 7.0, the drug release is influenced by the extraliposomal 
ratio of negatively charged MPS to neutral MPS. Furthermore, release experiments have 
been performed with these liposomes at 37°C (data not shown). pH dependent release 
from the liposomes significantly increased, which might be due to increased MPS 
solubility and/or membrane fluidity. 
 
Besides efficient loading, the release of the drug is also a critical factor for a drug 
delivery system. As shown, the release of MPS from liposomes is highly dependent on 
the extraliposomal pH value. In this study, pH values, 7.0, 6.0 or 5.0 similar to the 
situations in most tissues, tumors and endosomes were chosen to imitate the various pH 
environments of the liposome from the point of application to the reaching of the target. 
In the case of MPS liposomes, a high extraliposomal pH value results in facilitated MPS 
release, whereas liposomes are not significantly influenced by the low extravesicular pH 
value. 
 
 
4.4.2.6 (DSPE-PEG2000-maleimide)-cRGD Conjugate Synthesis and Micelle Formation 
 
(DSPE-PEG2000-maleimide)-cRGD conjugate was micellized for later insertion into the 
preformed liposomes at well defined numbers of targeting ligands. Final product yield  
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Figure 4.14 Histogram of MPS encapsulation in liposomes as a function of 
intravesicular pH. 
 
Liposomes were prepared with 200 mM calcium acetate buffer of different intravesicular 
pH (n=3). * and ** indicate significant levels at P<0.05 and P<0.01, respectively in 
comparison with MPS encapsulation at pH 3.0 (Bonferroni‟s one-way ANOVA). 
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Figure 4.15 MPS release from liposomes as a function of pH of the external medium at 
25 C. 
 
MPS was encapsulated by calcium acetate gradient. The drug release was analyzed in 50 
mM HEPES, 140 mM NaCl buffers, pH 4.0, 5.0, 6.0 and 7.0 at 25 C. Data points are a 
mean±SEM of n=3 samples. 
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was 34% (molar), as determined by Ellman reaction and phosphorus content of the lipid. 
The product was analyzed qualitatively by MALDI-MS. As shown in Figure 4.16, the 
peak corresponding to the lipid-peptide targeting conjugate was observed at 3458.29 Da. 
Mass spectra for the starting materials were 586 Da for cRGD-peptide and 2941 Da for 
DSPE-PEG2000-maleimide (data not shown). 
 
 
4.4.2.7 (DSPE-PEG2000-maleimide)-cRGD Conjugate Insertion into MPS-L 
 
In order to construct MPS-L bearing defined number of targeting ligands, (DSPE-
PEG2000-maleimide)-cRGD conjugate was incorporated into the lipid bilayers of MPS-L 
by the „post-insertion‟ technique. Following dialysis, the unincorporated (DSPE-PEG2000-
maleimide)-cRGD conjugate was estimated as described elsewhere. The number of 
cRGD peptides per liposome was determined by subtraction method. From the peptide 
and phospholipid analysis, the number of targeting ligands intended for insertion was 
1500 cRGD peptides per liposome. From the analysis, approximately 680 ligands were 
inserted into liposomes. This is equivalent to 45.3% (molar) of the targeting conjugate 
insertion efficiency. 
 
 
4.4.2.8 Summary for Active Loading Strategy 
 
The development of MPS-L for treating inflammatory diseases has been a long-sought 
goal, as evident from numerous studies starting in the 1970s and continuing to this day. 
However, although much progress has been made, some major limitations and restrictions 
still prevent the pharmaceutical development of MPS-L formulations for clinical use. 
From a historical perspective, in the early stage of research related to MPS-L, the main 
idea was to utilize their lipophilic nature and to encapsulate them in the liposome 
membrane. This form of encapsulation has encountered a major limitation of stability, 
since most GCs are not lipophilic enough, as is obvious from their logD and mass 
aqueous solubility. For instance, CHOL, one of the liposome membrane components, has 
a logD of 9.85 at pH 7.0 and mass solubility of 6x10
-9
 gm/L, while hydrocortisone has a 
much lower logD of 1.43 at pH 7.0 and mass solubility of 0.16 gm/L.
282
 Therefore, such 
GCs are not suitable for “encapsulation” in the liposome bilayer, since upon dilution they 
will desorb to the aqueous medium. Mishina et al.
195
 demonstrated that 50% w/v of 
encapsulated methylprednisolone was released to the bulk medium during 10 days of 
storage. In the present study, obstacles associated with passive loading approach were 
overcome with active remote loading of MPS. 
 
It seems that the cosmotropic properties of the counter-ion contribute to the solubility of 
MPS. The salts used for loading, i.e., ammonium, sodium and calcium are all components 
of the Hofmeister or lyotropic series.
286,287
 This series reflects the ranking of ions 
according to their binding strength of bulk water and to the concomitant decrease in the 
hydration of other compounds. The precipitation caused by these compounds is then 
termed as salt-out effect. This also explains the requirement of the high salt concentration 
of 200 mM for liposome loading, since this concentration is necessary to withdraw the  
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Figure 4.16 MALDI-MS spectra of the (DSPE-PEG2000-maleimide)-cRGD-peptide 
conjugate. 
 
The product was characterized by vMALDI. For an MS scan, high-mass range (m/z 500–
4000) and normal scan rate were used. Product spectra were acquired and analyzed using 
Xcalibur software. MADLI-MS analysis was performed in positive ion mode, and 
therefore, the mass obtained on the spectra is usually M+1. 
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hydration shell of MPS. This salt-out effect plays a role not only for proteins but for 
amphiphilic substances as well, which has been shown in other studies.
288
 The 
withdrawal of the hydration shell also explains the self-aggregation of MPS driven by 
hydrophobic interactions, which is highly dependent on the respective buffer 
composition. 
 
In conclusion, the active loading process of MPS in liposomes via acetate gradient 
depends on various factors: intraliposomal salt concentration, water binding potential of 
the salt, the pH value in the liposome and the presence of acetate pool. The loading of 
MPS in liposomes via calcium acetate gradient represents a potent alternative procedure 
to the methods used to date. It allows fast and effective loading of the MPS into 
liposomes at 48 C. Although, there is evident release of MPS at 37°C, under long term (3 
months) storage conditions at 4°C, there is a minimal (8% w/v) release of MPS. We were 
able to demonstrate that the novel active loading method facilitates dual purposes: I) 
MPS encapsulation (63% w/v encapsulation efficiency) and II) high targeting ligand 
insertion (45.3% molar) into lipid bilayers. 
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CHAPTER 5. PROTECTION OF COLLOIDAL PROPERTIES OF MPS-LCRGD 
 
 
5.1 Introduction 
 
Liposomes have been successfully employed for the encapsulation of a range of synthetic 
drugs and biologicals.
289,290
 However, the potential application of liposomes as 
therapeutic tools is still challenged by their inherent physical and chemical instabilities, 
which can result in increased bilayer permeability, subsequent drug loss and vesicle 
aggregation/fusion. These instabilities can be stimulated by chemical degradation (e.g. 
lipid oxidation and hydrolysis) and physical factors, such as heating or freezing.
291
 For 
instance, changes in the arrangement of phospholipids within the bilayer of small vesicles 
have been attributed to the loosely packed head-groups and tightly packed alkyl chains in 
the outer layer, with the opposite arrangement in the inner layer of the bilayer.
292
 This 
leads to a thermodynamically unstable state, which favors aggregation and/or fusion of 
the vesicles. Therefore, it is clear that the composition of the lipid bilayer, bilayer-drug 
interactions and the storage conditions of the liposomes will all influence liposome 
stability.
293-295
 To circumvent these problems and achieve long term stability of 
liposomes, lyophilization has been used as an effective approach to render liposomes 
stable without compromising their physical state or encapsulation capacity. However, 
lyophilization of liposome systems without appropriate stabilizers will again lead to 
fusion of liposomes; a factor exploited by the dehydration-rehydration method.
296
 To 
promote liposomes stability during the lyophilization process, lyoprotectants, including 
saccharides (e.g. sucrose, trehalose) and aminoacids (e.g. lysine) are employed.
297,298
 A 
detailed review by Crowe and Crowe
295
 outlines the mechanism of stabilization offered 
by the saccharides. Briefly, the increase in liposome size and leakage of the encapsulated 
material in non-lyoprotected liposomes during lyophilization is attributed to two factors: 
phase separation of lipids around their gel-fluid transition temperature and fusion of the 
liposome membranes. Thus, aggregation of liposomes could be prevented by the 
formation of stable boundaries between the liposomes. The ability of lyoprotectants to 
form these stable boundaries has been attributed to their ability to replace the bound 
water around the bilayer via interaction with the polar region of the lipid head group 
(water replacement hypothesis).
295,299
 Alternatively, Koster et al.
300
 proposed the 
formation of a vitreous layer (glass formation around the bilayer) of the lyoprotectant 
around the bilayer, which depresses the transition temperature of the phospholipids thus 
preventing any drug leakage during gel to fluid phase transformations. 
 
The role of various saccharides (glucose, sucrose, trehalose, etc.) has been investigated 
thoroughly as stabilizing lyoprotectants.
250
 Despite the detailed investigations, these 
systems have not been fully optimized, and in order to achieve effective lyoprotection 
and reproducible formulation parameters, high concentrations (30 mole%) are required. 
Therefore, the aim of this work is to assess various lyoprotectants, including 
disaccharides and aminoacids as stabilizing moieties during the lyophilization of 
liposomes. Crowe et al. investigated the influence of disaccharides and aminoacids as 
lyoprotectants.
301
 It has been shown that sugars are able to protect membranes during 
dehydration. In addition, very little has been reported on the ability of sugars to stabilize 
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targeted liposomes, whose surface is modified with peptides or proteins. The present 
study investigates the ability of disaccharides to protect lyophilized peptide or antibody 
conjugated liposomes. Parameters, such as particle size distribution, drug leakage and 
gel-to liquid phase transitions after rehydration were analyzed to investigate if the 
lyophilized formulations could be reconstituted without physico-chemical changes. Also, 
amino acids were investigated for use as lyoprotectants in simple liposome formulations. 
 
 
5.2 Experimental Section 
 
 
5.2.1 Materials 
 
HSPC1, DSPE-PEG2000, DSPE-PEG2000-maleimide were purchased from Avanti Polar 
Lipids (Birmingham, AL). CHOL, arginine, histidine, lysine, trehalose, sucrose and MPS 
were obtained from Sigma (St. Louis, MO). cRGD peptide was purchased from Peptide 
International Inc. (Louisville, KY). IgG antibody was purchased from Chemicon 
(Minneapolis, MN). Acetonitrile was purchased from Fisher Scientific (Suwannee, GA). 
All chemicals used were of analytical grade. 
 
 
5.2.2 Methods 
 
 
5.2.2.1 Preparation of Liposomes 
 
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate 
gradient method. Liposomes were prepared with a lipid composition of HSPC, CHOL, 
DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45: 3: 2 molar ratios. Lipid (27.2 
mM total phospholipids) solution in chloroform-methanol solution (3:1% v/v) was 
subjected to vacuum drying at 40 C to form a thin dry film, which was hydrated with 
calcium acetate buffer (200 mM) at 65 C to form MLVs. These vesicles were extruded 
through 200/100 nm sandwiched polycarbonate membrane filters using LIPEX
TM
 
extruder The MLVs were subjected to 6 extrusion passes to obtain liposomes with a mean 
diameter of 100-120 nm. To create a transmembrane calcium acetate gradient across the 
liposomes, the extraliposomal calcium acetate buffer was replaced with 0.9% saline 
solution by dialysis (10,000 Da MWCO). Followed by generation of calcium acetate 
gradient, liposomes were mixed and incubated with MPS solution [19 mM] at 48°C for 6 
min and then cooled to 4°C. Unencapsulated MPS and any traces of calcium acetate were 
removed by dialysis of MPS-L at 4°C for 6 h. cRGD peptide-lipid conjugates were 
inserted into lipid bilayers for formation of targeted liposomes. Detailed procedure for 
preparation of targeted liposomes was described elsewhere. Empty liposomes were 
prepared by Bangham method without MPS encapsulation. 
 
 
5.2.2.2 Lyophilization of Liposomes 
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Liposomes were mixed with different lyoprotectants (trehalose, sucrose, lysine, histidine 
and arginine) to obtain [lyoprotectant/lipid] ratios at 2, 4, 6 and 8:1. The liposome 
suspensions were then subjected to lyophilization. Vials were loaded into a lyophilizer 
(Virtis Genesis ES25) and run according to the protocols listed elsewhere. 
 
 
5.2.2.3 Determination of MPS Encapsulation and Retention in Liposomes 
 
The amount of MPS encapsulated in liposomes was determined after dialysis at 4 C. 
Purified liposomes were dissolved and suitably diluted with ethanol before analysis. MPS 
determination was performed by RP-HPLC using a Nova-pak® C-18 column (3.9x150 
mm, 4 µ) (Waters, MA). An isocratic method was run with a mobile phase comprised of 
sodium acetate: acetonitrile in 67: 33% v/v. The pH of the mobile phase was adjusted to 
4.8 with glacial acetic acid. The retention time of MPS was between 5-6 min with 
absorbance maximum at 250 nm. 
 
 
5.2.2.4 DLS Studies for Particle Size and Zeta Potential 
 
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as 
described elsewhere.  
 
 
5.2.2.5 Transmission Electron Microscopy 
 
Morphology of liposomes was determined by negative staining of the SUV specimens on 
carbon support films by the single droplet procedure. 2% w/v aqueous solution of uranyl 
acetate (pH 6.5) was employed to stain the specimens. 
 
 
5.2.2.6 Differential Scanning Calorimetry (DSC) 
 
The gel-to-liquid phase transition temperature of the undiluted vesicles in liposome 
suspension was determined using DSC. Thermograms were obtained using a Q2000 
series DSC (TA Instruments, New Castle, DE). Samples were run at 10°C/min from -
45°C to 80°C. Q2000 series software was used for data analysis. The first of three scans 
of each sample (n=3) was used for data analysis. 
 
 
5.2.2.7 Stability Studies of Lyophilized Liposomes 
 
To investigate the stability offered by the addition of lyoprotectants, lyophilized 
liposomal formulations were tested for their particle size and MPS retention for a period 
of 4 weeks. The lyophilized formulations were stored at 25 C. The samples were then 
hydrated and drug leakage was studied.  
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5.2.2.8 Moisture Content Analysis using Karl Fisher Titration 
 
Residual moisture content of the lyophilized cakes was measured using the Karl Fisher 
titration method.
302
 A minimum of 100 mg of pulverized cake was dispersed into an 
anhydrous methanol bath and titrated with Karl Fisher reagent (Acros, NJ). 
 
 
5.2.2.9 Statistical Analysis 
 
Statistical analysis was carried out by analysis of variance followed by Bonferroni t-test 
using GraphPad Prism™ software. 
 
 
5.3 Results and Discussion 
 
 
5.3.1 Disaccharides as Lyoprotectants: Evaluation of Appearance of MPS-LcRGD 
 
In the present study, MPS-L
cRGD
 were lyophilized in the presence of sucrose or trehalose 
at various concentrations. The lyophilized formulations were examined by visual 
inspection. A uniform cake matrix was obtained after lyophilization of MPS-L
cRGD
 in the 
presence of trehalose or sucrose at concentrations ranging from 200 to 400 mM or at 
[lyoprotectant/lipid] ratios, 4:1 or 8:1. At lower concentrations (<100 mM), a collapse of 
the cake was observed indicating that these concentrations of sugars were insufficient to 
prevent aggregation of MPS-L
cRGD
. This collapse is illustrated in Figure 5.1 with pictures 
of cakes containing 400 mM and 50 mM trehalose. The collapse was more pronounced 
for the formulations containing sucrose (data not shown). Formulations containing 200 
mM trehalose and 400 mM sucrose were readily rehydrated, and the process occurred 
within 10 min with no visual sign of aggregates (Figure 5.2). Formulations with lower 
concentrations of sugar were rehydrated more slowly, and the formulations with the 
lowest concentrations showed signs of aggregates even hours after rehydration. These 
results suggest that with sufficient amounts of trehalose or sucrose, it is possible to 
lyophilize MPS-L
cRGD
 and create a stable dry cake. Furthermore, insufficient amounts of 
lyoprotectant cause slow rehydration. A successful lyophilization should enable the 
product to rapidly reabsorb solvent, and restore the substance to its original state. 
 
 
5.3.2 Effect of Lyoprotectants on Particle Size 
 
The particle size of MPS-L
cRGD
 was analyzed to determine which sugar concentration 
was sufficient to preserve the average particle size upon lyophilization. The average 
particle size of MPS-L
cRGD
 prior to lyophilization was 120±13 nm. The average particle  
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Figure 5.1 Representative samples of the MPS-L
cRGD
 lyophilized with high (400 mM; 
left) and low (50 mM; right) concentrations of trehalose. 
 
 
 
 
 
Figure 5.2 Transmission electron micrographs ofMPS-L
cRGD
 before and after 
lyophilization (i.e. reconstituted) with trehalose. 
 
Micrographs depict the morphology of the targeted liposomes lyophilized with 200 (1:4) 
and 400 (1:8) mM of trehalose. 
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size of the lyophilized formulations was measured 10 min after rehydration. The 
formulations with above 200 mM trehalose regained their normal particle size after 10 
min of rehydration (P>0.01). This was not the case for the formulations with lower 
concentrations of trehalose indicating that these liposomes were not fully rehydrated or 
that the membrane structures were not preserved during lyophilization. For sucrose, only 
at a concentration of 400 mM sucrose, rehydration of the MPS-L
cRGD
 took place in 10 
min. The particle size increase of the lyophilized formulations containing less than 100 
mM sugar was 8-12 times over the original size. At low levels of sugar concentrations, 
not even 24 h of rehydration resulted in a normal particle size suggesting that aggregation 
is irreversible. Since MPS-L
cRGD
 is a monodisperse formulation, it was important to 
analyze if any changes in the particle size distribution could be detected. 
 
As illustrated in Figure 5.3, MPS-L
cRGD
 with 200 mM trehalose or 400 mM sucrose, the 
particle size distribution did not change suggesting that the size distribution was 
preserved upon lyophilization. Formulations containing 400 mM trehalose or sucrose 
were found to be more monodisperse than MPS-L
cRGD
 lyophilized formulations with low 
sugar concentrations. The results thus show that at trehalose concentrations 200 mM, 
the formulation can be reconstituted within 10 min without change in average particle 
diameter as well as particle size distribution, whereas sucrose only preserves the particle 
size at the highest concentration (400 mM). The results also confirm the conclusion from 
the visual inspections, that much more sucrose than trehalose is needed to obtain a quick 
rehydration of lyophilized formulations. 
 
 
5.3.3 Effect of Lyoprotectants on the Thermotropic Phase Behaviour of HSPC before 
Lyophilization 
 
The thermotropic phase behaviour of HSPC in the presence of trehalose or sucrose was 
determined before lyophilization to investigate the effect of sugars on the liposome 
dispersions. The thermograms obtained are shown in Figure 5.4. The phase transition 
temperature for HSPC was observed at 52.62±0.02°C. Low concentration trehalose 
slightly increased the Tm to 54.02±0.08°C in non-lyophilized MPS-L
cRGD
 formulation. 
There was no apparent difference between Tm of the formulations containing different 
concentrations of trehalose. Addition of sucrose also did not affect the main gel-to-liquid 
phase transition temperature of HSPC. However, at 100 mM trehalose, a shoulder was 
observed on the high temperature side of the peak, which developed into a distinct peak 
at 67.68°C with 400 mM trehalose. The same pattern was observed with sucrose, though 
not so pronounced. The small increase in Tm for the formulations containing trehalose 
and the shoulder on the high temperature side of the peak could be explained by direct 
interaction.
303
 Direct interaction of trehalose with the polar head-group of the lipids could 
cause the formation of a depletion layer around the liposomes in which the concentration 
of water is lower than in the bulk phase.The polar head-groups of trehalose, with 
hydroxyl groups are available for hydrogen bonding. HSPC of MPS-L
cRGD
 would 
therefore have this sugar available on the membrane surface for interaction with 
cosmotropic molecules like trehalose and sucrose. The cosmotropic effect can cause a de-
structuring of the H-bond network of bulk water, which affects the dynamic properties of  
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Figure 5.3 Mean diameter of MPS-L
cRGD
 as a function of lyoprotectant concentration. 
 
MPS-L
cRGD
 formulations containing sucrose (red) and trehalose (blue) before (open 
symbols) and after (closed symbols) lyophilization. All the formulations are a 
mean SEM, n=2 samples. AL indicates after lyophilization and BL indicates before 
lyophilization. 
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Figure 5.4 Thermograms of MPS-L
cRGD
 containing increasing concentrations of 
trehalose (A) and sucrose (B) prior to lyophilization. 
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water and reduces the amount of water in the solvation layer surrounding the liposome 
membranes.
304,305
 This could cause the Tm of the liposome membrane to change due to 
lower flexibility and higher thermal stability, and thus explains the shoulder on the high 
temperature side of the peak.
304
 Another explanation for the shoulder on the high 
temperature side of the peak could therefore be that a phase separation in HSPC local 
domains with high concentrations of highly ordered HSPC with elevated phase transition 
temperatures. This phase separation would lead to a lowering of the gel-to-fluid phase 
transition of these areas. No reduction of Tm was observed suggesting that phase 
separation cannot explain the shoulder on the high temperature side of the peak. More 
investigations are required to explain this behaviour further. 
 
 
5.3.4 Effect of Lyoprotectants on the Thermotropic Phase Behaviour of HSPC after 
Lyophilization 
 
A number of studies have been conducted to examine the interactions of trehalose with 
the phospholipid membrane at various hydration levels; there is a lack of data pertaining 
to how the interactions present in the hydrated state translate into those in the dehydrated 
state. In previous sections, we have examined the effects of trehalose on the transition 
behavior of HSPC before lyophilization in the presence of sugars. In this section, we 
examine how these interactions are manifest upon lyophilization. Upon dehydration, the 
phase transition temperature of HSPC increases from 52°C to 83°C. Removal of water 
leads to a decrease in the head group spacing of the lipids, thus allowing for increased 
van der Waals interactions between the lipid hydrocarbon chains.
306
 If the membrane (in 
the liquid crystalline phase) is dried in the presence of trehalose, the contraction of the 
phospholipids is avoided and the Tm decreases considerably.
307
 Figure 5.5 shows the 
thermograms for the lyophilized liposomes (~100 nm) containing various outer trehalose 
or sucrose concentrations. The lipid concentration for all of the samples is 50 mM, thus 
the lowest amount of trehalose or sucrose in any of these systems corresponds to 1:1 
ratio. During the freezing step of lyophilization, the membrane (prepared in the liquid 
crystalline phase) undergoes a phase transition to the gel phase. The tighter packing of the 
gel phase lipids results in a smaller number of trehalose molecules to interact (via water 
replacement) with the phospholipids during the drying process. Therefore, Tm is shifted 
towards high temperature, 83°C. For the sample containing 50 mM trehalose, the Tm is 
observed at approximately 73.5°C (Figure 5.5; lower panel),). The transition is decreased 
to 67.02°C upon increasing the trehalose concentration inside the vesicle to 100 mM, 
while it decreases to approximately 55.62°C for the samples containing 400 mM 
trehalose outside the vesicle. In the fully hydrated state, the decrease in Tm is mainly 
observed for the sample containing high trehalose concentration inside the vesicle.
304
 
 
Note that the shift in the Tm, observed at the various trehalose distributions, is amplified 
significantly upon dehydration.The largest Tm change, observed upon the addition of 400 
mM trehalose to liposomes, increases from 1°C in the fully hydrated state to 28°C in the 
dried state. Additionally, a second peak, or a shoulder, is observed for the dry sample 
containing 400 mM trehalose, mirroring the two transitions observed in the hydrated state 
(before lyophilization; Figure 5.3A). Collectively, our results demonstrate that the  
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Figure 5.5 Thermograms of lyophilized, rehydrated MPS-L
cRGD
 formulations 
containing increasing concentrations of sugar. 
 
The top panel represents that of thermograms with sucrose and the lower panel with 
trehalose. 
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trehalose distribution in the fully hydrated state is maintained upon lyophilization. More 
importantly, the direct interaction (via hydrogen bonding) between trehalose (400 mM 
trehalose) and phospholipid in the hydrated state is not only maintained, but amplified 
upon dehydration. Similar pattern was observed with sucrose. 
 
Explanation for the peak at right hand side of the main transition, 52°C could be that the 
lyophilization causes phase separation in the bilayer, resulting in highly ordered HSPC 
domains, which are difficult to rehydrate. Since the particle size distribution is conserved 
upon lyophilization and rehydration, the incomplete rehydration cannot be caused by 
formation of larger aggregates. Further investigations are necessary to verify the reason 
for the peak observed at 52°C. The results from this study show that sucrose is needed in 
higher concentrations than trehalose to protect MPS-L
cRGD
 during lyophilization and 
maintain a similar gel-to-liquid phase transition pattern after rehydration. This is in 
accordance with other studies
308
 and could be explained by a stronger interaction between 
the lipid membrane and trehalose than with sucrose.
303,309
 Another reason could be the 
larger hydration volume of trehalose compared to sucrose making it a better 
kosmotrope.
310
 
 
During freezing and drying this in turn leads to minimized damage by water 
crystallization.
311
 A final explanation could be the high Tg of trehalose in the dry state 
compared to other sugars
248,312
 making it a better vitrifier as it is less prone to 
crystallization than many other sugars.
248
 Crystallization of the sugars could cause a 
lowered Tg due to residual water, but this would also make the lyophilized cake collapse. 
Since no collapse was observed in formulations with more than 200 mM sugar, residual 
water is not believed to cause crystallization. Furthermore, since crystallization of the 
sugars is a slow process below Tg, there is no reason to believe that trehalose should be 
better to protect MPS-L
cRGD
 during lyophilization, because of its abilities as a vitrifier. It 
is therefore unlikely that the superior effect of trehalose compared to sucrose is due to its 
vitrifying effects. In this case, we consider direct interaction with HSPC to be the major 
reason for the protective effect of sucrose and trehalose. The beneficial effect of trehalose 
compared to sucrose could on the other hand be due to its quality as a kosmotrope and its 
strong direct interaction with HSPC. 
 
The data presented here prove that trehalose is able to protect surface modified 
liposomes. The mechanism of action is not yet fully understood, but these data suggest 
that the direct interaction with HSPC possibly plays a role, whereas the cosmotropic 
effect and vitrification of the sugars might be the main causes. Based on these physico- 
chemical data, we have demonstrated that trehalose in concentrations from 200 mM 
protects MPS-L
cRGD
 during lyophilization and enables rapid rehydration (within 10 min). 
 
 
5.3.5 Amino Acids as Lyoprotectants: Influence of Lyoprotectant Concentration 
 
To investigate the efficiency of amino acids as lyoprotectants, liposomes were prepared 
and subjected to lyophilization in the presence of various concentrations of the 
lyoprotectants ranging from 2-8 mol/mol of lipid. Liposomes formulated from 
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HSPC/CHOL/DSPE-PEG2000 (50:45:5 mol) were subjected to a freezing cycle at -45 C 
for 2 h followed by primary drying at -36 C for 36 h and, secondary drying at 10 C for 
24 h. Prior to lyophilization, liposomes were in the range, 100-120 nm. When lyophilized 
in the absence of lyoprotectants, liposomes of 2-3 m size were formed after rehydration, 
an almost 25 times over the original liposomes demonstrating aggregation/fusion of 
liposomes. Alternatively, formulations lyophilised in the presence of the aminoacids 
(lysine, histidine or arginine) showed lyoprotection with rehydrated liposomes smaller 
than the control size ( 2250 nm). Both aminoacid and its molar concentration influenced 
the lyoprotection efficiency. The lyoprotection profiles of the three amino acids were 
biphasic in nature, but maximal protection against liposome aggregation varied with the 
amino acids. At low [lyoprotectant/lipid: 2:1] concentration, lysine, histidine or arginine 
increased liposome size to 3-4 times over the pre-lyophilized liposomes (Table 5.1). With 
an increase in lyoprotectant/lipid ratio to 4:1, liposome size retention was observed with 
all the three amino acids. However, lysine offered better protection with liposome size 
similar to that of liposomes prior to lyophilization ( 110 nm). Histidine and arginine 
showed a small increase in size to around 200 nm compared to pre-lyophilized liposomes. 
TEM analysis of the rehydrated lysine incorporated lyophilized formulation revealed 
stable, spherical and uniform sized liposomes (Figure 5.6). 
 
Interestingly, a further increase in amino acid concentration resulted in the decrease of 
lyoprotection. Liposome lyophilized in the presence of lysine or histidine or arginine 
(8:1) demonstrated a significant (P<0.05) increase in liposome size (Table 5.1). Suzuki et 
al.
313
 reported the biphasic nature of lyoprotectants. During lyophilization, liposomes if 
unprotected will undergo membrane damage due to the formation of ice crystals and will 
ultimately flatten and fuse during dehydration and subsequent rehydration.
296
 As amino 
acids are charged molecules they are capable of interacting with the phosphate head 
group of the lipid molecule, which is an important feature exhibited by most of the 
saccharides.
247
 This offers the potential for the amino acids to form a layer on the 
liposome surface which could possibly be acting as a protective shield against ice crystal 
damage. In addition, all the amino acids used has a side chain functional group that reacts 
with a proton at pH 6-7 to form a charged ionic group which is capable of forming 
hydrogen bonds with the phosphate of the lipid head group. Histidine is characterized by 
the presence of a pentacyclic ring in its structure. Arginine and lysine have the longest 
side chains with lysine having a terminal amino group and arginine with a terminal 
guanidinium group. During lyophilization, it is possible that the amino acids interact with 
the phosphate group and form a barrier around the liposomes with layers of amino acids, 
possibly acting as cushions against any damage during lyophilization.
314
  
 
Saccharides as lyoprotectants suggested that interactions between the saccharide and the 
lipid molecules may depend on the hydrophobic/hydrophilic nature of the saccharide 
molecule, with more hydrophobic moieties promoting membrane fusion at higher 
concentrations. Therefore, the biphasic nature of the amino acid lyoprotection shown in 
Table 5.1 may be an outcome of high amino acid concentrations, promoting liposome 
fusion via either hydrophobic interactions or electrostatic interactions between the 
positively charged amino acids and the slightly anionic surface of the phospholipid 
membranes. 
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Table 5.1 The effect of lyoprotectant concentration on the mean diameter of empty 
liposomes (after lyophilization). 
 
 Mean liposome diameter (nm) 
Lyoprotectant/lipid ratio Control Lysine Histidine Arginine 
 2250 320 NA NA NA 
2:1  489 45 645 35 389 15 
4:1  127 15 190 8 184 14 
6:1  512 18 644 18 672 12 
8:1  985 47 751 18 653 12 
 
All measurements are a mean±SEM, n=2 samples. Prior to lyophilization, liposomes 
were in the 100-120 nm size range. 
 
 
 
 
 
Figure 5.6 Transmission electron micrographs of MPS-L before (A) and after (B) 
lyophilization with lysine as external lyoprotectant. 
 
Samples were diluted 40 times and subjected to 2% w/v uranyl acetate treatment before 
acquisition of images (50,000x magnification). 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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5.3.6 Influence of Freezing Temperature on the Performance of the Lyoprotectants 
 
To assess the influence of primary drying temperature on the lyoprotection, liposomes 
with [lyoprotectant/lipid] ratio at 4:1 were lyophilized. Results (Table 5.2) show that the 
primary drying temperature influences the liposome product characteristics; formulations 
subjected to program 1 and 2 were offered protection during lyophilization, with 
rehydrated liposome size remaining below 200 nm when any of the aminoacids were 
employed. In contrast, rehydrated MPS-L subjected to primary drying at -20 C followed 
by secondary drying at 10 C in the presence of lyoprotectant resulted in significant 
liposome aggregation/fusion, with resultant liposome sizes similar to liposomes 
lyophilized in the absence of lyoprotection. Crowe et al.
247
 showed that the lyoprotection 
offered by various solutes is influenced by various factors, including the phase transition 
temperature of the lipids (Tm) and the glass transition temperature (Tg‟) of the 
amorphous frozen matrix. 
 
In order to preserve the porous nature of the lyophilized cake, primary drying should be 
performed at approximately 4 C below the Tg‟ of the amorphous frozen matrix. For 
example, trehalose frozen matrix has a Tg‟ of -32 C and when the primary drying 
temperature was maintained below this temperature (program 1 and 2; Table 5.2), stable 
products were produced. However, when the frozen samples were subjected to a primary 
drying temperature around the Tg of the lyoprotectant (program 3; Table 5.2), liposome 
fusion occurs, possibly due to lack of formation of the glassy state which is responsible 
for inhibition of liposome aggregation.
247
 Investigation of the influence of duration of 
primary drying showed that there was no significant difference in the sizes of 
lyoprotected liposomes when primary drying was carried out at -36 C for 36 or 48 h. 
 
 
5.3.7 Influence of Lyoprotectants on MPS Leakage from MPS-L 
 
Investigations on the protection offered by the amino acids were also extended to 
determine MPS leakage from MPS-L. In the presence of the three amino acids, MPS-L 
particle size showed a similar biphasic pattern (Table 5.3) to that of the lyophilized 
„empty‟ liposome shown in Table 5.1. Thus, the presence of MPS within the liposomes 
did not influence the lyoprotection offered by amino acids suggesting that MPS does not 
interact with the cushioning effect of amino acids. The moisture levels of all the 
formulations were less than 3% w/w. The presence of low moisture content in the product 
confers improved stability and drug retention.
213
 This is also in line with the regulations 
laid down by the regulatory authorities that prefer a maximum water concentration of 3% 
w/w. 
 
To determine the particle size distribution pattern and MPS leakage from MPS-L, 
lyophilized MPS-L were stored at 2-8 C and 25 C for 4 weeks. With all the three 
aminoacids as lyoprotectants, a slight increase in liposome size (Figure 5.7) and MPS 
leakage (Figure 5.8) were observed. Among the three aminoacids, lysine offered 
protection with a minimal size increase and MPS leakage. It is evident that lyoprotection 
of liposomes is related to the structure-functional activity of aminoacids. An increase in 
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Table 5.2 The effect of lyophilization protocols on the mean diameter of liposomes. 
 
Size* Lyophilization protocol temperature ( C) Vesicle diameter after rehydration (nm) 
 Program Freezing Primary Drying Secondary Drying Control Lysine Histidine Arginine 
110 13 1 -45 -36 10 2564 124 199 21 142 17 157 8 
 2 -45 -20 10 3012 241 145 14 187 16 146 21 
 3 -45 -10 10 3845 108 3084 92 4012 402 3157 274 
 
Size prior to lyophilization (nm). All measurements were a mean±SEM, n=2 samples. Prior to lyophilization, liposomes were in the 
100-120 nm size range. 
 
 
Table 5.3 The effect of lyoprotectant concentration of the mean diameter of MPS-L. 
 
Lyoprotectant/lipid ratio Vesicle diameter (nm) 
 Control Lysine Histidine Arginine 
2:1 2850 124 437 13 538 25 389 15 
4:1  189 5 176 13 184 14 
6:1  486 91 644 18 672 12 
8:1  1356 91 751 18 653 12 
 
MPS-L (63% w/v loading efficiency) were prepared and mixed with increasing concentrations of lyoprotectants and lyophilized 
according to protocol 1 as outlined in Table 5.2. Control liposomes were subjected to the same lyophilization protocol in the absence 
of lyoprotectants. Mean diameter of liposomes was determined using a zeta sizer. All measurements were a mean±SEM, n=2 samples. 
Prior to lyophilization, liposomes were in the 100-120 nm size range. 
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Figure 5.7 Graph depicting the mean diameter of MPS-L as a function of aminoacids 
as external lyoprotectants used for lyophilization. 
 
Liposomes lyophilized with 4 moles of lyoprotectants/mole of the lipid were stored at 
25 C. At selected time intervals, 1, 3, 7, 14, 21, 28 days, samples were reconstituted and 
mean diameter of the liposomes was measured. All measurements are a mean±SEM, n=2 
samples. 
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Figure 5.8 Graph depicting the MPS leakage from MPS-L, lyophilized with 
aminoacids as external lyoprotectants. 
 
Liposomes lyophilized with 4 moles of lyoprotectants/mole of the lipid were stored at 
25 C. At selected time intervals, 1, 3, 7, 14, 21, 28 days, samples were reconstituted and 
MPS leakage from MPS-L was measured. All measurements are a mean±SEM, n=2 
samples. 
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liposome size and MPS leakage over time was observed with arginine or histidine as 
lyoprotectants. These observations may be attributed to liposome fusion promoted by 
weak interactions of the amino acids with the phosphate head groups. Therefore, the 
stability of liposomes was compromised, thus promoting high rates of MPS leakage.The 
results indicate that lysine appears to offer lyoprotection to liposomes similar to that of 
trehalose. The ability of amino acids to protect the formulation during lyophilization 
demonstrates another class of lyoprotectants. 
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CHAPTER 6. INHIBITION OF LUNG INFLAMMATION USING MPS-LCRGD 
 
 
6.1 Introduction 
 
Acute lung injury is a fatal syndrome in critically ill patients with a high mortality rate.
315
 
ALI syndrome is characterized by increased permeability of the alveolar-capillary barrier 
resulting in influx of protein rich edema fluid, and consequently impairment in arterial 
oxygenation. Low tidal-volume mechanical ventilation, a non-pharmacological approach 
is the only proven strategy to improve the survival of ALI patients. Despite an improved 
understanding of the pathogenesis of ALI, effective pharmacological therapies are 
currently not available. Numerous clinical trials involving pharmacological therapies (e.g. 
anti-inflammatory agents, anti-coagulants and pulmonary surfactants) aimed at different 
pathological targets turned unsuccessful. One of the attributed drawbacks is the 
underappreciation of drug delivery systems in the management of ALI.
316
 
 
During the early ALI phase, numerous pro-inflammatory mediators are released into the 
alveolar spaces in response to various inflammatory stimuli.
4
 Among them, IL-1  causes 
pulmonary epithelial and endothelial barrier dysfunction leading to an increase in lung 
permeability and edema.
317-319
 Ganter et al. reported that IL-1  mediates alveolar 
epithelial permeability via v 6 integrin dependent TGF-  activation.
21
 The v 6 
integrin receptors of the alveolar epithelium mediate interaction of the latent TGF-  with 
RGD domain of the LAP. As a result, the latent TGF-  undergoes activation leading to an 
increase in epithelial permeability.
19
 A transient blockade of v 6 integrin receptors 
would therefore be a potential strategy to prevent both TGF-  activation and an increase 
in epithelial permeability. 
 
IL-1  stimulates pro-inflammatory cytokine and chemokine release, and upregulates 
CAMs in alveolar epithelial cells.
320
 Due to a high chemokine gradient across the alveolar 
barrier, leukocytes (e.g. monocytes and neutrophils) infiltrate from blood circulation into 
alveoli, and exacerbate edema and lung inflammation.
321,322
 Of the various transcriptional 
factors, NF- B plays a central role in regulating the inflammatory genes encoding CAMs, 
chemokines and cytokines.
75,323
 NF- B is a heterodimeric protein present in the 
cytoplasm in an inactive form stabilized by binding to the inhibitory protein, I B .
74
 In 
response to IL-1  stimulation, I B  undergoes phosphorylation and proteolytic 
degradation. As a result, phosphorylated I B  (p-I B ) is ubiquitinated allowing nuclear 
translocation of NF- B, which binds to promoter regions of the target genes to initiate the 
transcription of CAMs, chemokines and pro-inflammatory cytokines.
324,325
 And inhibitors 
targeting the activated NF- B would suppress CAM expression and chemokines release, 
which eventually prevent migration of leukocytes.
326,327
 Glucocorticoids, cited as NF- B 
inhibitors mediate the effects through inhibition of NF- B transcriptional activity leading 
to suppression of pro-inflammatory genes.
328
 Taken together, IL-1β mediates: I) v 6 
integrin dependent epithelial permeability and II) induction of NF- B dependent pro-
inflammatory genes. In order to alleviate both pulmonary edema and inflammation 
associated with IL-1  stimulation, I used MPS-L
cRGD
. 
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In the present study, liposomes were chosen for their flexibility: I) to anchor cRGD-
peptide onto the surface of liposomes for targeting to v 6 integrin receptors located on 
alveolar epithelium and II) to encapsulate and deliver MPS, an anti-inflammatory 
glucocorticoid to alveolar epithelial cells for inhibition of pro-inflammatory cytokines 
(e.g. TNF-α and IL-6), chemokines (e.g. MCP-1) and CAMs (e.g. ICAM-1) expression. 
 
To evaluate the potential of MPS-L
cRGD
 treatment in modulating epithelial permeability, 
we examined IL-1  stimulated A549 cells. A significant decrease in albumin flux across 
A549 cells was observed. In addition, MPS-L
cRGD
 targeting the v 6 integrin receptors 
undergo cell internalization and suppress MCP-1 and ICAM-1 expression. To determine 
whether such an effect might have relevance to disease, we used IL-1  induced lung 
inflammation rat model. MPS-L
cRGD
 suspension was nebulized at a rate of 1 mL/min for 
5 min prior to instillation (i.t.) of IL-1  in male Sprague-Dawley rats. In vivo results 
demonstrated that MPS-L
cRGD
 treatment show a decrease in epithelial permeability, 
neutrophils migration and pro-inflammatory mediators‟ expression compared to IL-1  
instilled (i.t.) positive control. The results of this study present evidence that MPS-L
cRGD
 
reduces pulmonary edema by blocking v 6 integrin receptors; while MPS release from 
MPS-L
cRGD
 inhibits NF- B transcriptional activity, at least in part by increasing I B  
leading to suppression of MCP-1 and ICAM-1 production. 
 
 
6.2 Experimental Section 
 
 
6.2.1 Materials 
 
HSPC1, DSPE-PEG2000, DSPE-PEG2000-maleimide and 1-Oleoyl-2-[6-[(7-nitro-2-1,3-
benzoxadiazol-4-yl)amino]hexanoyl]-sn-Glycero-3-Phosphoethanolamine (NBD-PE) 
were obtained from Avanti Polar Lipids (Birmingham, AL). MPS and recombinant 
human interleukin-1  were purchased from Sigma (St.Louis, MO). cRGD-peptide was 
purchased from Peptide International Inc. (Louisville, KY). DMEM medium, PBS buffer, 
HEPES buffer, antibiotics and growth factors were purchased from Cellgro Inc. 
(Herndon, VA). RPMI 1640 medium was purchased from Gibco (Carlsbad, CA). 
Antibodies obtained include: Anti- v (P2W7; sc-9969; Santa Cruz Biotechnology Inc., 
Santa Cruz, CA), anti- 6 (H-110; sc-15329; Santa Cruz Biotechnology Inc), anti- 1 
(mAb13, Becton-Dickinson, Bedford, MA), anti- v 3 (LM609; Chemicon, Temecula, 
CA), anti- v 5 (P1F6; Chemicon) and IgG (Chemicon). Gel electrophoresis chemicals 
were obtained from Bio-Rad Inc. (Hercules, CA). All other chemicals of ACS grade or 
higher were purchased either from Sigma (St.Louis, MO) or Fisher Scientific (Suwannee, 
GA). 
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6.2.2 Methods 
 
 
6.2.2.1 Preparation of Liposomes 
 
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate 
gradient method. Liposomes were prepared with a lipid composition of HSPC, CHOL, 
DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45: 3: 2 molar ratios. Lipid (27.2 
mM total phospholipids) solution in chloroform-methanol solution (3:1% v/v) was 
subjected to vacuum drying at 40 C to form a thin dry film, which was hydrated with 
calcium acetate buffer (200 mM) at 65 C to form MLVs. These vesicles were extruded 
through 200/100 nm sandwiched polycarbonate membrane filters using LIPEX
TM
 
extruder. The MLVs were subjected to 6 extrusion passes to obtain liposomes with a 
mean diameter of 100-120 nm. For flow cytometry studies, lipid solution was spiked with 
3 mole% NBD-PE ( ex=488 nm, em=520 nm) dye during hydration. 
 
To create a transmembrane calcium acetate gradient across the liposomes, the 
extraliposomal calcium acetate buffer was replaced with 0.9% saline solution by dialysis 
(10,000 Da MWCO). Followed by generation of calcium acetate gradient, liposomes 
were mixed and incubated with MPS solution [19 mM] at 48°C for 6 min and then cooled 
to 4°C. Unencapsulated MPS and any traces of calcium acetate were removed by dialysis 
of MPS-L at 4°C. 
 
To prepare cRGD peptide conjugated liposomes, MPS-L were incubated with cRGD 
peptide solution (667 µg/30 L; pH 6.5) at 25 C for 12 h. The conjugation reaction was 
quenched with EDC solution. Unconjugated cRGD peptide and excess EDC were 
isolated by dialysis using equilibrium chambers separated by a 1000 Da MWCO 
membrane (Harvard Apparatus, Holliston, MA). The amount of cRGD peptide 
conjugated to MPS-L was estimated by subtraction of free cRGD peptide of the dialysate 
from the total cRGD peptide used for conjugation. The free cRGD peptide fraction was 
determined by RP-HPLC method. After dialysis, liposomal MPS and total phospholipids 
concentrations were 12.02 mM and 23.8 mM, respectively. Approximately, 34% (molar) 
cRGD peptide was conjugated to the maleimide group of MPS-L. 
 
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as 
described elsewhere. 
 
 
6.2.2.2 Cell Cultures 
 
A549 cells from the American Type Culture Collection (Manassas, VA) were grown in 
Dulbecco‟s modified Eagle‟s medium (DMEM) supplemented with 10% v/v heat-
inactivated FBS, antibiotics (10 µg/mL gentamicin and 0.25 µg/mL amphotericin), 1 
µg/mL hydrocortisone, 10 µg/mL human epidermal growth factor, 3 ng/mL fibroblast 
growth factor and 10 µg/mL heparin. The cell cultures were incubated in 5% CO2 at 
37°C. Cells were cultured in T-75 flasks (Beckton Dickinson, Franklin Lakes, NJ) before 
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transferring to plates for specific assays. For RT-PCR assays, cells were cultured in 
collagen-I coated 60 mm petri dishes (Beckton Dickinson) at a seeding density, 2x10
6
 
cells per mL. For cell based ELISA, cells were seeded at 2x10
4
 per well in collagen-I 
coated 96 well plates (Becton Dickinson). For monocytes or neutrophils adhesion assays, 
cells were passed from T-75 flasks and cultured in collagen-I coated 24 well Transwell® 
filters (8 µM pore membrane; Becton Dickinson) at a density, 5x10
4
 per well. For 
pemeability assays, cells were cultured in collagen-I coated Transwell® 6.5 mm filters 
(Costar, Cambridge, MA). Cells were then allowed to quiesce in DMEM incomplete 
medium overnight before subjecting to treatments. Cells between the passages, 2-4 were 
used for all studies. 
 
 
6.2.2.3 AlphaVBeta6 ( v 6) Integrin Expression in A549 Cells 
 
A549 cells were treated with IL-1  (10 ng/mL; 3 mL total volume) and DMEM 
incomplete medium (control; 3 mL) for 0, 3, 6 and 12 h at 37 C. Following treatments, 
cell monolayers were washed with PBS, fixed at 4˚C for 30 min in 2% v/v 
paraformaldehyde and washed again with PBS. Non-fat dry milk (5% w/v; 300 µL) was 
added to reduce non-specific binding. Cells were then incubated with primary 
monoclonal antibodies (100 µL; 100 µg/mL in 1% w/v BSA-PBS solution) for 1 h. The 
monolayers were washed with PBS-Tween20 (0.01% w/v; PBST) buffer and incubated 
with biotinylated anti-mouse secondary antibody (100 µL of 1 µg/mL) for 1 h. 
Subsequently, cells were washed as above and incubated with streptavidin horseradish 
peroxidase (100 µL; DAKO, Carpinteria, CA) for 30 min. After washing with PBST 
buffer, TMB peroxidase substrate (Sigma, MO) was added and incubated for 30 min. The 
reaction was halted by addition of 2N sulfuric acid (50 µL/well). All incubations were 
carried out at room temperature. The expression level of αvβ6 integrin receptors was 
determined by difference in absorbance at wavelengths 450 vs. 630 nm. An isotype 
matched control Ab (IgG) was used in place of primary antibody in three wells and 
background was subtracted from the signal. 
 
RT-PCR was performed to estimate mRNA expression of αvβ6 integrin receptors. Cells 
were grown and subjected to treatments as described elsewhere. Cells were lysed with 
TRIzol® reagent and total cell RNA was extracted according to manufacturer‟s 
instructions (Invitrogen, Carlsbad, CA). Equal aliquots (4 µg) of RNA were quantified at 
260 nm absorbance. RNA was reverse transcribed into cDNA synthesis with an oligo 
(dT) primer using the Superscript III First-Strand Synthesis System as described in the 
manufacturer‟s instructions. Primers were designed using Primer3 software 
(http://frodo.wi.mit.edu). The primers were purchased from Integrated DNA technologies 
(Coralville, IA). Primer sequences are listed in Table.6.1. The concentration of primers 
was 200 nM for forward and reverse primers. PCR amplification conditions were: 50 C 
for 30 min, 1 cycle; 94 C for 5 min, 1 cycle; 35 cycles of 94 C for 45 s, 55-58 C for 45 s 
and 72 C for 2 min; 68 C for 7 min, 1 cycle. Ten microliters of PCR amplification 
product and a 123-bp DNA ladder were separated using agarose (1.5% w/v) gel 
electrophoresis. Gels were stained with ethidium bromide and photographed under 
ultraviolet transillumination. 
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Table 6.1 Primer sequences for v, 6, MCP-1, ICAM-1 and -actin. 
 
Primer Primer sequence (5‟ 3‟) Product size (bp) Tm 
Genbank access 
No. 
V-integrin forward primer 5‟-TATGCTACATCTTGACCCACTA-3‟ 104 55.0 NM_002210 
V-integrin reverse primer 5‟-CCAATTAGCACTATCAGCAGTA-3‟    
6-integrin forward primer 5‟-TGAATACTCCATGTCAACTGTC-3‟ 150 55.14 NM_000888 
6-integrin reverse primer 5‟-GTAGCTCCAGGAATAAGTTTTG-3‟    
MCP-1 forward primer 5‟-AACTTATTTTCCCCTAGCTTTC-3‟ 172 55.26 NM_002982 
MCP-1 reverse primer 5‟-CCCCAAGTCTCTGTATCTAAAA-3‟    
ICAM-1 forward primer 5‟-TCAGTCAGATACAACAGCATTT-3‟ 223 55.07 NM_000201 
ICAM-1 reverse primer 5‟-ATAGGCAGCAAGTTTCAGTATT-3‟    
-actin forward primer 5‟-CATTGCTTTCGTGTAAATTATG-3‟ 213 55.0 NM_001101 
-actin reverse primer 5‟-TTATTCAACTGGTCTCAAGTCA-3‟    
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6.2.2.4 Confocal Laser Scanning Microscopy (CLSM) 
 
MPS-L
cRGD
 affinity to v 6 integrin receptors of A549 cells was determined by 
fluorescence microscopy using NBD-PE labeled, specific MPS-L
cRGD
 and non-specific 
liposomes (MPS-L). A549 cells were treated with either IL-1  or DMEM complete 
medium (control) for 6 h at 37 C. Followed by IL-1  treatment, A549 cells were treated 
with anti- v 3, anti- v 5 and anti- 1 integrin antibodies (10 µg/mL) to facilitate a high 
degree of binding of MPS-L
cRGD
 to v 6 integrins. After washing with DMEM 
incomplete medium, cells were incubated separately with the NBD-PE labeled liposome 
formulations (50 µM phospholipids/10
6
 cells) at 37 C for 1 h. The total volume of 
liposome formulation was 100 µL containing the following (in mM): NaCl (115), KCl 
(5), NaHCO3 (10), HEPES (25), MgCl2 (0.5), CaCl2 (1), glucose (5.6) and BSA (1 
mg/mL). Unbound liposomes were removed by washing the plates with ice-cold PBS 
buffer. Followed by treatments, the cells were fixed in paraformaldehyde and subjected to 
microscopy under 100,000x maginification. 
 
 
6.2.2.5 MCP-1 and ICAM-1 Expression in A549 Cells 
 
A549 cells were treated with IL-1  (10 ng/mL; 3 mL total volume) and DMEM 
incomplete medium (control; 3 mL) for 0, 3, 6 and 12 h at 37 C. In pretreatment 
protocol, A549 cells were pretreated with MPS-L or MPS-L
cRGD
 (equivalent to 0.03-30 
M MPS) or L
cRGD
 for 1 h followed by IL-1  (10 ng/mL) incubation for 6 h. Cells were 
analyzed for MCP-1 and ICAM-1 levels by Western Blot and RT-PCR procedures which 
were described elsewhere. Primer sequences and RT-PCR conditions are listed in Table 
6.1. 
 
 
6.2.2.6 Isolation of Monocytes and Neutrophils 
 
Blood collected from four healthy volunteers was subjected to dextran (Sigma, St.Louis, 
MO) sedimentation to obtain leukocyte rich plasma, which was layered onto 2.5 mL of 
Nycoprep, 1.068 (Invitrogen, Carlsbad, CA) and centrifuged (500xg, 20 min, 20°C). The 
plasma and cells were then collected into separate tubes and centrifuged (600xg, 10 min, 
20°C). The monocyte pellet was then resuspended in RPMI 1640 incomplete medium and 
centrifuged (90xg, 15 min, 20°C) again to remove platelets. This was repeated six times. 
The resulting cells were resuspended in RPMI 1640 containing 1% w/v PSG, 0.5% w/v 
BSA and 10% v/v FCS (Cellgro) at 1 x10
6
 per mL. Following this, cells were 90% pure. 
For isolation of neutrophils, the leukocyte rich plasma was centrifuged, (400xg, 10 min, 
4°C) and the supernatant was discarded. The cell pellet was resuspended in PBS and 
centrifuged for a second time as before. Following washing, the cell pellet was subjected 
to discontinuous Percoll gradient (Sigma). Using a discontinuous gradient consisting of 
three layers (81, 70 and 55% v/v); the cell pellet was resuspended in 3 mL of 55% v/v 
(the top layer), which was then overlaid onto the prepared gradient. The cells were then 
centrifuged (750xg, 20 min, 4°C) and neutrophils were harvested from the 70%/81% 
interface. The neutrophils were washed further in PBS for use in migration assays. 
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6.2.2.7 Monocytes and Neutrophils Adhesion Assays 
 
Isolated monocytes or neutrophils were suspended in RPMI 1640 (containing 1% w/v 
PSG, 0.5% w/v BSA and 10 mM HEPES, pH 7.2) medium and radiolabeled by 
incubating the cells (1x10
6
 per mL) with 0.05 µCi NaCrO4 (Perkin Elmer, Waltham, MA) 
at 37°C for 1 h. Radiolabeled monocytes or neutrophils were washed twice (250g; 5 min, 
20°C) with ice-cold incomplete medium to eliminate excess of unincorporated 
radioactivity and resuspended in RPMI 1640 incomplete medium, respectively. Twenty 
min later, monocytes or neutrophils were washed and adjusted to a final concentration of 
2x10
6
 per mL in RPMI 1640 incomplete medium, supplemented with CaCl2 (1.3 mM) 
and MgCl2 (1 mM). Prior to addition of radioactive monocytes or neutrophils, A549 cells 
were exposed to IL-1β (10 ng/mL) or incomplete medium (control) for 6 h. In a 
pretreatment protocol, A549 cells were exposed to MPS-L
cRGD
 or MPS-L (equivalent to 
0.03-30 µM MPS) or L
cRGD
 for 12 h followed by IL-1β (10 ng/mL) exposure for 6 h. 
Radiolabeled monocytes or neutrophils (5x10
5
/well) were then added to treated A549 
cells (monocytes or neutrophils /A549 cells: 10/1). After co-incubation at 37 C for 30 
min, the percentage of monocytes or neutrophils adhered to A549 cells were quantified. 
Non-adherent monocytes or neutrophils were removed by washing with 0.5% w/v BSA-
PBS solution. Adherent cells were lysed and counted in a gamma counter (Perkin Elmer, 
Waltham, MA). 
 
 
6.2.2.8 Epithelial Permeability Assay 
 
Cells were cultured as described elsewhere. A549 monolayers were grown to confluence 
until TEER reaches 30 .cm
2
 (EVOM; World Precision Instruments, Sarasota, FL). 
Briefly, monolayers were washed in PBS and equilibrated at 37 C for 30 min. A549 cells 
were exposed to IL-1β (10 ng/mL) or DMEM incomplete medium (control) for 6 h. In a 
pretreatment protocol, cells were incubated with MPS-L
cRGD
 or MPS-L (equivalent to 30 
µM MPS) or L
cRGD
 or antibodies (10 g/mL) and then stimulated with IL-1  (10 ng/mL) 
for 1 h. 
14
C-albumin (0.05 Ci) (Perkin Elmer, Waltham, MA) was added to upper 
compartment at 37°C for 1 h, after which contents from the lower compartment were 
collected and counted in scintillation counter. 
 
 
6.2.2.9 Animals 
 
Male Sprague-Dawley rats, weighing 150-200 g, were purchased from Harlan 
laboratories and used in all experiments. The protocols were approved by the Institution 
Animal Care and Use Committee (IACUC) of the University of Tennessee, Memphis. 
 
 
6.2.2.10 Nebulization of Liposome Formulations 
 
At least 30 min prior to IL-1β (i.t.) instillation, rats were nebulized with liposome (PL or 
MPS-L or MPS-L
cRGD
) formulations using micropump nebulizer (Aeroneb®, Aerogen, 
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Ireland). Nebulization chamber filled with formulations was placed on the snout of rats. 
Nebulization was actuated at a rate, 1 mL/min for 3 min. MPS-L or MPS-L
cRGD
 
formulations contain MPS dose, 6.3 mg/mL. (Estimation of MPS in Blood and BALF 
samples was done by RP-HPLC method). 
 
 
6.2.2.11 IL-1β Instillation and BALF Collection 
 
Male Sprague-Dawley rats, weighing 125-150 g were used in the study. Rats were fed 
normal diet before the experiment with free access to water. Anesthesia was induced by 
intra-peritoneal injection of ketamine/xylazine (87/13 mg/kg). Following anesthesia, a 
midline tracheal incision was made to expose the trachea. A 26 gauge needle was 
advanced endotracheally to instill IL-1  solution (200 µL, 100 µg/mL in PBS, pH 7.2) or 
PBS alone (control). Following the IL-1  instillation, tracheal opening was sutured and 
animals were returned to cage. Within 15 min of IL-1  instillation, anti-β1 or anti-αvβ3 
or anti-αvβ5 antibodies (1 mg/mL/kg) or a combination were administered intravenously 
(i.v.). Twenty four hours post IL-1  administration, the lung vascular bed was flushed 
twice by injecting 10 mL ice-cold PBS into right ventricle. Followed by overdose of 
pentobarbital (100 mg/kg, i.v), tracheal sutures were cut open to expose trachea. BALF 
collection was performed by inserting a 26 gauge needle into trachea and lungs were 
lavaged twice with PBS (3 mL). BALF was collected into cryovials and centrifuged at 
1100xg, 4 C for 10 min. The supernatant was stored at -70 C for cytokine and chemokine 
analysis and the cell pellet was subjected to neutrophils estimation. Aliquots of BALF 
were estimated for protein concentration by UV absorbance at 280 nm using albumin 
(Bio-Rad) as standard. 
 
 
6.2.2.12 Estimation of BALF Cytokines, Chemokines and Adhesion Molecules 
 
BALF supernatant collected and stored as described above was analyzed for cytokines 
(TNF- ), MCP-1 and ICAM-1 levels by ELISA method according to manufacturer 
(R&D Systems, Minneapolis, MN) instructions. 
 
 
6.2.2.13 Estimation of Lung Neutrophil Content 
 
Neutrophil content was assayed as described previously.
329
 Lung tissue from each lobe 
was pooled (500 mg) and freeze-dried. The samples were then homogenized in HEPES 
(50 mM, pH 8.0) at 0.5% w/v with tissue homogenizer (Fisher Scientific, Suwannee, 
GA). Homogenized samples were then centrifuged at 12,000xg at 4°C for 30 min and the 
supernatant was discarded. The process was repeated twice. The resulting pellet was 
homogenized in 0.5% w/v CTAC solution and clarified by repeat centrifugation. The 
resultant clear supernatant was analyzed for MPO activity. The same protocol was used to 
extract MPO from BALF cell pellets. The collected supernatant from HEPES/CTAC 
extracts of lung tissue was diluted 10 fold with 10 mM citrate buffer (pH 5.0) and 100 L 
of this solution was pipetted into 4 wells of a 96-well plate. As negative control, “stop 
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solution” (4N H2SO4) was added to two of the wells. Then, 100 L of the substrate 
solution (3 mM 3,5,5-tetramethylbenzidine dihydrochloride, 120 mM resorcinol and 2.2 
mM hydrogen peroxide in distilled water) was added to all the wells and the reaction was 
quenched with stop solution at 25°C after 2 min. 
 
A standard curve of MPO activity vs. neutrophils count was developed by homogenizing 
a known number of Percoll-purified neutrophils using the same technique used in MPO 
extraction from lung and BALF cells. Lung and BALF neutrophil count was estimated 
from the standard curve. 
 
 
6.2.2.14 Histological Examination of Lungs 
 
For histological examination (n = 3 each group), bronchial lavage was omitted and after 
vascular perfusion, 10 mL buffered formalin (3.7% v/v) was infused via the pulmonary 
artery to fix the lung. Lungs were isolated en bloc after tracheal ligation and preserved in 
10% v/v neutral buffered formalin for 24 h at 4 C. Wedge segments from each lobe were 
paraffin embedded and 5 mm sections were taken and stained with haematoxylin and 
eosin using standard protocol. 
 
 
6.2.2.15 Statistical Analysis 
 
All data reported are arithmetic means. Error bars represent one SEM. Differences 
between means of indicated groups were analyzed by ANOVA with Bonferroni 
corrections for multiple comparisons. A P value <0.05 was considered to be statistically 
significant. 
 
 
6.3 Results and Discussion 
 
The colloidal properties of MPS-L
cRGD
 and MPS-L determined by DLS method were 
stable over 14 days of shelf life. As shown in Table 6.2, mean diameter of MPS-L
cRGD
 
and MPS-L were comparable; however, the zeta potential of MPS-L
cRGD
 was slightly 
higher than MPS-L due to a partial negative charge of the targeting ligand, cRGD-
peptide. 
 
 
6.3.1 AlphaVBeta6 ( v 6) Integrin Receptor Expression in A549 Cells 
 
The v 6 integrin receptors are normally expressed at a low level in lung epithelium, but 
can be upregulated by injury and inflammation. To determine whether IL-1  treatment 
induces v 6 integrin up-regulation in A549 cells, we performed cell based Western Blot 
analysis was performed on A549 cells after treatment with either IL-1  or saline. A549 
cells were stimulated with IL-1  for various periods of time. After 3 h, 6 subunit protein 
expression increased by 1.8 folds (P<0.05) and after 6 h reached a maximum of 2.9 folds  
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Table 6.2 Physico-chemical properties of MPS-L
cRGD
 used in in vitro and in vivo 
studies. 
 
Liposomes Mean diameter, 
Zavg (nm) 
Zeta potential,  (mV) 
MPS incorporation 
efficiency (% w/v) 
PL 98±9 -22.7±4.3 NA 
PL
cRGD
 110±6 -17.1±3.8 NA 
PL
cRAD
 106±4 -20.8±6.1 NA 
MPS-L 113±5 -22.4±3.7 61 
MPS-L
cRGD
 117±8 -25.6±2.2 36 
 
Each value represents the mean±SEM (n = 3). NA indicates not applied. NA was applied 
to the liposome formulations devoid of MPS encapsulation. PL indicates plain liposomes 
and PL
cRAD
 indicates liposomes with RAD as the control targeting ligand, which has no 
specificity for integrin receptors. 
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(P<0.05) which persisted thereafter (Figure 6.1). The v integrin subunit also showed the 
same pattern. To determine whether v 6 integrin receptor protein levels reflected 
mRNA expression levels in IL-1β activated A549 cells, we performed RT-PCR analysis 
of the cell extracts. Figure 6.1 shows a representative agarose gel demonstrating v 6 
integrin expression after stimulation with IL-1  for 0, 3, 6 and 12 h. Stimulation with IL-
1  revealed an up-regulation of v 6 mRNA expression in A549 cells, with 6 subunit 
reached a peak level at 6 h (3.8 folds increase) which decreased thereafter. However, v 
integrin subunit mRNA expression persisted for 12 h. The protein expression levels of v 
and 6 subunits showed a gradual increase in response to IL-1  stimulation. Quiescent 
A549 cells showed constitutive v and 6 subunit integrin mRNA and protein 
expression. The increase in v and 6 expression levels at mRNA and protein levels 
signifify the role played by the integrin receptors in mediating the pulmonary edema. 
 
 
6.3.2 Cell Internalization of MPS-LcRGD: CLSM Studies 
 
To evaluate the cell internalization of MPS-L
cRGD
, A549 cells were analyzed by CLSM 
studies. Either quiescent or activated A549 cells were incubated with MPS-L
cRGD
 or 
MPS-L (1 mM lipid/10
6
 cells/mL) for 1 h at 37 C. As represented in Figure.6.2, 
activated A549 cells incubated with MPS-L
cRGD
 resulted in NBD fluorescence which is 
about 3-4 times higher than with MPS-L. In contrast, quiescent A549 cells incubated with 
MPS-L
cRGD
 showed a minimal level of NBD fluorescence over activated A549 cells. The 
fluorescence intensity of MPS-L emitted from either quiescent or IL-1  activated A549 
cells was comparable, but insignificant over the background. The results indicate the 
higher affinity of MPS-L
cRGD
 towards activated A549 cells. cRGD peptide is known to 
bind to many heterodimer integrins, such as v 3, v 5 and 5 1 while showing 
minimal effects on v 6 integrin receptors. Therefore, A549 cells were treated with 
integrin antibodies other than anti- v 6 integrin antibody prior to incubation with MPS-
L
cRGD
. 
 
 
6.3.3 Effect of MPS-LcRGD on MCP-1 Expression in A549 Cells 
 
MCP-1 expression in alveolar epithelial cells plays a critical role in monocyte recruitment 
from blood circulation into alveolar spaces. Earlier studies have shown that IL-1  is a 
potent stimulus for MCP-1 expression in both primary and transformed epithelial cells. 
To examine the MCP-1 expression in IL-1  activated A549 cells, ELISA was performed. 
As demonstrated in Figure 6.3, MCP-1 protein was constitutively expressed in quiescent 
cells. In IL-1β activated cells, a steady and significant (p<0.001) increase in MCP-1 
protein expression was observed till 6 h, and persisted thereafter (data not shown). To 
investigate whether the effect of IL-1  stimulation on MCP-1 expression would be 
inhibited by MPS, A549 cells were pretreated with different control and MPS 
encapsulated formulations containing an MPS equivalent to 30 M, before stimulation 
with IL-1  (10 ng/mL) for 12 h. 
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Figure 6.1 RT-PCR and Western Blot analyses of concentration dependent inhibition 
of v 6 integrin expression by MPS. 
 
After the indicated treatments as described in section, 6.2.2.3, cellular lysates from the 
experiments were subjected to Western Blot and RT-PCR analyses of integrin subunits 
and GADPH. For each set of conditions, three blots were conducted and representatives 
were shown. All the blots are a representative of n=3 samples. 
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Figure 6.2 Confocal laser fluorescence microscopy of cell internalization of MPS-L 
and MPS-L
cRGD
 in quiescent and IL-1  activated A549 cells. 
 
A549 cells were treated with IL-1  (10 ng/mL) prior to treatments with formulations. 
After the treatments, unbound liposomes were washed with citrate buffer and cells were 
observed under 100,000x magnification. All the liposome treatments were performed at 
37 C for 1 h. Top panel shows the fluorescence emitted from quiescent cells and lower 
panel shows that from IL-1  treated cells. 
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Figure 6.3 ELISA and RT-PCR analyses of MCP-1 expression in A549 cells as a 
function of MPS encapsulated formulations. 
 
A549 cells were pre-incubated with MPS-L and MPS-L
cRGD
 (30 M MPS equivalents). 
Followed by this, cells were treated with IL-1  at 37 C for 1 h. Supernatants were 
collected for chemokines analysis and cells were harvested for RT-PCR analysis. Data 
are plotted in nanograms per milliliter as mean SEM. *** indicates significant difference 
of MP-L
cRGD
 treatment effect at P<0.001 from the IL-1  stimulation alone.The top panel 
shows the ELISA results of MCP-1 expression, while the lower panel represents the RT-
PCR analysis of the data. 
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MPS-L
cRGD
 inhibited MCP-1 protein expression to 26% of the IL-1  stimulation alone. 
Similarly, MPS-L attenuated MCP-1 mRNA to 60% of IL-1  stimulated levels. The 
results suggest that MPS released from MPS-L
cRGD
 attenuates IL-1  activated MCP-1 
expression upon cell internalization. MPS-L
cRGD
 treatments showed no effect on cell 
viability in 0.3-30 M range (data not shown). The results from NF-  EMSA and 
Western Blot analysis also corroborate the evidence that MCP-1 gene, controlled by NF-
 was modulated using MPS formulation treatments, particularly, MPS-L
cRGD
. 
 
In summary, A549 cells instilled with IL-1  showed elevated mRNA and protein levels of 
MCP-1. Compared with the control, MPS containing formulations treatment reduced 
mRNA and protein levels of MCP-1 after IL-1  administration. 
 
 
6.3.4 Effect of MPS-LcRGD on Monocytes Adhesion to IL-1  Stimulated A549 
Monolayers 
 
An IL-1  concentration dependent monocytes adhesion to A549 cells was observed. 
Monocytes adhesion to activated A549 cells increase by 280% corresponding to 10 
ng/mL of IL-1  dose, respectively. To examine the effect of MPS on monocyte adhesion, 
A549 cells were pretreated with MPS-L
cRGD
 (equivalent to 30 µM MPS) for 12 h before 
IL-1  (10 ng/mL) stimulation for 6 h. MPS-L
cRGD
 treatment showed a significant 
decrease in monocyte adhesion to activated A549 cells. As shown in Figure 6.4, at 
concentration equivalent to 30 µM MPS, monocyte adhesion to activated A549 cells was 
reduced to near basal levels. To examine the effect of 1 or 6 antibodies, anti- 1 or anti-
6 were used, it is evident anti- 1 modulates monocytes adhesion to IL-1  in a mildly.  
 
 
6.3.5 Effect of MPS-LcRGD on ICAM-1 Expression in A549 Cells 
 
Cell adhesion mediated by ICAM-1 is critical for the transendothelial migration of 
neutrophils from blood circulation into alveolar spaces. In ALI, interaction between 
pathogens and macrophages or leukocytes results in release of cytokines, causing lung 
damage. In vivo, enhanced expression of lung ICAM-1 is presumed to be the result of 
direct inflammatory stimuli in concert with secondary effects (i.e., cytokines and 
chemokines) mediated by inflammatory cells. In this study, the direct effects of IL-1  on 
ICAM-1 expression in A549 epithelial cell line are evaluated. Alveolar epithelium shows 
constitutive ICAM-1 expression, which is upregulated in response to pro-inflammatory 
mediators, such as IL-1  and TNF-α. To examine the ICAM-1 expression, A549 cells 
were treated with IL-1  (10 ng/mL) for 0, 3, 6 and 12 h. IL-1  induced a gradual and 
significant (P<0.001) increase in mRNA and protein expression compared to the 
constitutive expression of quiescent cells (data not shown). Activated A549 cells showed 
a maximal, 243% increase in mRNA expression at 6 h followed by a slight decrease 
thereafter. 
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Figure 6.4 Histogram of the monocyte adhesion as a function of MPS encapsulated 
formulation treatments in IL-1  activated A549 cells. 
 
Monocyte adhesion is expressed as percentage of monocytes adhered to A549 cells in 
basal and stimulated conditions (IL-1 ). Data are plotted mean SEM, n=3 samples. ** 
indicates significant (P<0.01) inhibition of monocyte adhesion with MPS-L
cRGD
 in 
comparision with IL-1  stimulation alone. 
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To investigate the inhibitory potential of MPS on IL-1  induced ICAM-1 up-regulation, 
A549 cells were pre-incubated with MPS-L
cRGD
 (equivalent to 0.03-30 M of MPS) for 
12 h before stimulation with IL-1  (10 ng/mL) for 6 h. Figure 6.5 shows that MPS 
inhibited the up-regulation of ICAM-1 protein expression in a concentration-dependent 
manner. At 30 M concentration, MPS attenuated ICAM-1 production to 18% of IL-1  
stimulation alone. To further confirm the inhibitory effect of MPS-L
cRGD
 on IL-1  
induced ICAM-1 gene expression, the mRNA levels were analyzed by RT–PCR. A549 
cells were subjected to the similar treatment as described above. MPS released from 
MPS-L
cRGD
 abrogated IL-1  induced ICAM-1 mRNA expression in a dose dependent 
manner (data not shown). It was observed that at 30 M concentration, MPS attenuated 
82% of IL-1  activated mRNA up-regulation. From the results, it was found that MPS 
released from MPS-L
cRGD
 significantly attenuated IL-1  induced ICAM-1 production in 
A549 cells, both at the protein and mRNA levels. 
 
 
6.3.6 Effect of MPS-LcRGD on Neutrophil Adhesion to A549 Monolayers 
 
IL-1  stimulation mediates the adherence of neutrophils to epithelial cells through up-
regulation of ICAM-1 receptors. A549 cells were exposed to IL-1  for 6 h. After the 
monolayers were washed, neutrophils were added and incubated for 20 min. Non-
adherent neutrophils were washed away. Neutrophils adhesion increase by 48%, 210%, 
and 385% on exposure of A549 cells to 0.1, 1 and 10 ng/mL of IL-1 , respectively (data 
not shown). To investigate the effect of MPS on neutrophils adhesion, A549 cells were 
pretreated with MPS-L
cRGD
 (equivalent to 30 M of MPS) containing liposome 
formulations for 12 h before IL-1  treatment for 6 h. As shown in Figure 6.6, neutrophil 
adhesion was reduced to 33% of IL-1  stimulation alone. A combination of antibodies to 
1 and 6 significantly reduced the neutrophil adhesion to A549 cells. Anti- 1/ 6 
antibodies combination contributed a synergistic effect on inhibition of neutrophil 
adhesion. This study reveals the involvement of both 1 and 6 integrins in mediating the 
neutrophil migration into alveoli. 
 
 
6.3.7 Effect of MPS-LcRGD on Epithelial Permeability in IL-1  Induced A549 Cells 
 
IL-1  have been reported to mediate epithelial barrier dysfunction via v 6 integrins, we 
therefore analyzed the potential of MPS-L
cRGD
 on the modulation of epithelial cell 
permeability. Confluent A549 cells on permeable supports were incubated with IL-1  and 
transepithelial permeability was determined by measurement of 
14
C-albumin flux. IL-1  
increased permeability in A549 cells compared to control. The transepithelial albumin 
flux increased 220% following IL-1  treatment. However, MPS-L
cRGD
 (equivalent to 30 
M MPS) pretreatment reduced the transepithelial permeability of activated A549 cells to 
basal levels (P<0.001). To delineate the effect of L
cRGD
 from MPS on transepithelial 
permeability, A549 cells were pretreated with L
cRGD
 (equivalent to 33.4 g/mL of cRGD-
peptide), which significantly (P<0.05) reduced the 
14
C-albumin flux to near basal levels. 
It has been shown that IL-1  increases alveolar epithelial permeability by activating 
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Figure 6.5 Densitometric RT-PCR and Western Blot analyses of ICAM-1 expression 
in A549 cells, treated with MPS-L
cRGD
. 
 
MPS inhibits the expression of ICAM-1 induced by IL-1 . A549 cells were pre-
incubated with MPS-L
cRGD
 (1-100 M MPS equivalents). After 12 h, supernatants were 
collected for ICAM-1 analysis and cells were harvested for RT-PCR analysis. Lower 
panel represents the Western Blot analysis and top panel represents the densitometric RT-
PCR analysis of ICAM-1 expression. ** and *** indicate significant levels at P<0.01 and 
0.001, respectively from the IL-1  stimulated levels alone. 
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Figure 6.6 Histogram of neutrophil adhesion as a function of MPS encapsulated 
formulation treatments in IL-1  activated A549 cells. 
 
Freshly isolated neutrophils were isolated and incubated with quiescent and stimulated 
A549 cells. A549 cell monolayers were pretreated with MPS-L
cRGD
 (MPS equivalent to 
30 M) and antibody (10 g/mL). Data are shown as mean SEM. ** and *** indicate 
P<0.01 and P<0.001, respectively from IL-1  stimulated levels alone. 
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v 6 integrin receptors in alveolar type II cells. Therefore, we examined their role using 
anti- v 6 antibodies. A549 cells were pretreated with anti- v 6 (20 g/mL) antibodies 
before IL-1  treatment. 
14
C-albumin flux was reduced to basal levels across the A549 
cells (Figure 6.7). The data indicates the role of v 6 integrin receptors in mediating the 
epithelial cell permeability increase in IL-1  stimulated A549 cells. It is also evident that 
L
cRGD
 reduce the transepithelial albumin flux by blocking the v 6 integrin receptors. 
From the results, it is evident that the targeting ligand blocks the integrin receptors and 
seems to prevent the interaction with LAP doman of the TGF- -LAP complex. In both 
L
cRGD
 and MPS-L
cRGD
 formulations, a significant reduction was observed. However, a 
mild reduction in epithelial permeability was observed with MPS-L. The data signifies 
the importance of integrin receptors in mediating the IL-1  stimulated epithelial 
permeability. 
 
 
6.3.8 MPS-LcRGD Inhibits NF- B Nuclear Translocation in A549 Cells 
 
NF- B is a major transcription factor mediating IL-1β induced MCP-1 and ICAM-1 
expression through the NF- B binding sites located in the enhancer region of the MCP-1 
and ICAM-1 genes, respectively. To explore the inhibition potential of MPS-L
cRGD
, we 
used EMSA to determine whether MPS released from targeted liposomes could affect 
NF- B activation in A549 cells. Figure 6.8 demonstrates NF- B activity in response to 
IL-1  exposure. 
 
Since activation of NF- B in A549 cells is dependent on phosphorylation and subsequent 
degradation of I B , cytoplasmic extracts from IL-1  activated A549 cells in the 
presence or absence of MPS-L
cRGD
 was examined by Western blot analysis. In quiescent 
cells, low levels of phosphorylated I B  (p-I B ) were detected. However, p-I B  was 
readily detectable following IL-1  treatment. Prior incubation with MPS-L
cRGD
 led to a 
concentration dependent inhibition of p-I B . A549 cells pretreatment with MPS-L
cRGD
 
for 12 h caused a substantial accumulation of I B  (data not shown) and reduced p-I B  
levels compared with IL-1  alone. However, short interval pretreatment with MPS-L
cRGD
 
did not alter I B  (data not shown) and p-I B  levels. The data indicates that MPS 
released from MPS-L
cRGD
 inhibits NF- B transcriptional activity, at least in part, by 
increasing I B  due to reduced I B  phosphorylation and degradation. 
 
The data indicates that the targeting of NF-  dependent transcription by MPS represents 
a major mechanism of anti-inflammatory action. In support of this statement, MPS 
treatment modulated activated NF-  in A549 epithelial cells. Furthermore, we now 
report that the induction of NF-  dependent transcription A549 epithelial cells was 
affected by MPS in a concentration dependent manner. Therefore, higher concentrations 
of MPS or longer incubation times are necessary to exert the inhibitory effects on A549 
cells. Consistent with this, there was noticeable effect of MPS on the expression of MCP-
1 and ICAM-1, where inhibition of p-I  resulted in a profound repression of MCP-1 
and ICAM-1 expression. Thus, NF-  inhibitors seem to target processes related to  
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Figure 6.7 Histogram of 
14
C-albumin permeability across A549 cells, pretreated with 
MPS encapsulated formulations and antibodies. 
 
Data are shown as mean SEM. *** indicates P<0.001 from IL-1  stimulated levels 
alone. 
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Figure 6.8 EMSA (left panel) of NF-  elicitation and Western Bot analysis of I  
and p-I  expression pattern in A549 cells, pretreated with MPS-L
cRGD 
formulation. 
 
MPS attenuated stimulus loss of I . A549 cells were pretreated for 12 h with the 
MPS-L
cRGD
. Cells stimulated with IL-1  were harvested. NF-  activity was analyzed by 
EMSA (left panel) on nuclear extracts. A Western Blot analysis (right panel) of total 
I  and p-I  was performed on cytoplasmic extracts. All blots are representative of 
three experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  111 
corticosteroids in the repression of inflammatory gene expression. This finding may have 
a considerable impact in the context of steroid insensitive-ALI. 
 
In summary, we demonstrate that targeting NF-  inhibitors with small molecule 
inhibitors is effective at preventing the activation of NF-  in pulmonary epithelial cells. 
Furthermore, this manipulation results in the reduced expression of proinflammatory 
genes in both A549 cells. Based on the inflammatory roles of genes, such as ICAM-1, IL-
6 and MCP-1, and the key role of the alveolar epithelium in the pathogenesis of 
ALI/ARDS, we predict that inhibitors of NF-  may represent valuable anti-
inflammatory agents in management of ALI. 
 
 
6.3.9 Effect of MPS-LcRGD on BALF Protein Concentration in IL-1  Induced Rats 
 
Quantification of BALF protein concentration is considered as an indicator of increase in 
lung vascular and epithelial permeability resulting from inflammatory injury. In the 
present study, BALF protein concentration was quantified in control and treated groups. 
As represented in Figure 6.9, protein concentration in the BALF of IL-1  (i.t.) instilled 
group was nearly 3.6 folds that of rats receiving saline (i.t.) (IL-1  group, 0.43 0.07 
mg/mL; saline group, 0.12 0.02 mg/mL; P<0.001). A significant inhibition of BALF 
protein concentration was observed in rats pretreated with MPS-L
cRGD
 (0.18 0.03 
mg/mL; P<0.001) compared to IL-1  (i.t.) instilled group. To delineate the effects of 
MPS and cRGD-peptide conjugated liposomes on the inhibition of BALF protein, rats 
were pretreated with MPS-L or L
cRGD
, respectively. Reduction of BALF protein was 
observed in rats pretreated with either MPS-L (0.28 0.06 mg/mL; P<0.05) or L
cRGD
 
(0.21 0.02 mg/mL; P<0.01) formulation, but not as significant as MPS-L
cRGD
. The data 
suggests the additive effect of MPS-L
cRGD
 in reducing the BALF protein content. 
 
 
6.3.10 Effect of MPS-LcRGD on MCP-1 Production in BALF of IL-1  Induced Rats 
 
Since IL-1  induced macrophage and neutrophil migration is largely determined by 
MCP-1 expression, we measured the BALF levels at 24 h following IL-1  (i.t.) 
instillation in pretreated (MPS-L
cRGD
, MPS-L or L
cRGD
) rat groups. Saline and IL-1  
alone instilled groups were treated as negative and positive control groups. MPS-L
cRGD
 
treatment resulted in decrease of MCP-1 (1537.4 65.4 pg/mL in IL-1  alone instilled rats 
vs. 523.2 92.1 pg/mL in MPS-L
cRGD
 treated rats, P<0.001) and the levels were 
comparable to basal levels as that of saline instilled negative control group (Figure 6.10). 
MPS-L pretreated group also showed a significant decrease in MCP-1 (987.4 74.1 
pg/mL) in IL-1  instilled rats. While L
cRGD
 has no influence on MCP-1 production, 
whose levels were similar to that of IL-1  instilled positive control group. 
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Figure 6.9 Histogram depicting the inhibition of BALF protein after nebulization of 
MPS-L
cRGD
 in male Sprague-Dawley rats. 
 
BALF protein levels were measured by Bio-Rad micro-protein assay. Results are 
expressed as mean SEM of four experiments. * and ** indicate statistically signigicant 
levels at P<0.05 and 0.01 levels, respectively from IL-1  stimulated levels alone. 
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Figure 6.10 Histogram of the inhibition of BALF MCP-1 levels after nebulization of 
MPS-L
cRGD
 in male Sprague-Dawley rats. 
 
MCP-1 levels were measured by ELISA. Results are expressed as a mean SEM of four 
experiments. ** and *** indicate statistically signigicant levels at P<0.01 and P<0.001 
levels, respectively from IL-1  stimulated levels alone. 
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6.3.11 Effect of MPS-LcRGD on TNF-  Production in BALF of IL-1  Induced Rats 
 
As compared with saline-treated controls, IL-1  (i.t.) instillation induced a significant 
increase in BALF levels of TNF-  (Figure 6.11). After MPS-L
cRGD
 treatment, BALF 
levels of TNF-  were significantly (P<0.001) lower and comparable to saline treated rats. 
Animals pretreated with MPS solution had lower levels of TNF-  but not as significant 
(P<0.01) as animals pretreated with MPS-L
cRGD
. In contrast, BALF levels of TNF-  in 
animals pretreated with L
cRGD
 had no effect on TNF-  production and their levels were 
similar to IL-1  (i.t.) instilled positive control group. 
 
 
6.3.12 Effect of MPS-LcRGD on Neutrophil Migration of IL-1  Induced Rats 
 
A variety of stimuli induce neutrophil migration into the lung. Adhesion molecules and 
chemokines have been shown to be involved. Chemokines, such as MCP-1, promote 
neutrophil migration into the alveolar compartment. Also, ICAM-1 gradient across the 
alveolar barrier is thought to be required for neutrophil sequestration into the vascular 
compartment. For quantitative assessment of neutrophil migration into alveolar spaces, 
MPO assay of BALF was performed in pretreated rat groups (MPS-L
cRGD
, MPS-L or 
L
cRGD
) post IL-1  (i.t.) instillation. 
 
As illustrated in Figure 6.12, pretreatment of rats with MPS-L inhibited the neutrophil 
migration into alveolar spaces of rats receiving IL-1  (i.t.) as compared with saline 
treated rats (1.9 0.1x10
6
; p<0.05 in MPS-L treated group vs 2 0.2x10
5
; P<0.05 in saline 
treated group).Inhibition of neutrophil migration was further enhanced (1.1 0.05x10
6
; 
P<0.01) with MPS-L
cRGD
 as compared to MPS-L solution or L
cRGD
 pretreated groups. 
Further, inhibition of BALF neutrophils significantly increased in rats pretreated with 
anti- 1/ 6 (1.4 0.05x10
6
; P<0.01). As estimated by MPO assays, BALF neutrophil 
content was not significantly different from the neutrophil number in BALF determined 
by Histopaque® assay. 
 
The reduction of lung neutrophil recruitment observed under conditions could in part be 
attributed to inhibition of ICAM-1 and MCP-1 levels, which possesses chemotactic 
activity for neutrophils. As well, reduced lung neutrophil accumulation mediated by 
ICAM-1 and MCP-1 may be a result of reduced intra-pulmonary production of TNF- . 
Instillation of IL-1  induced lung injury is the primary stimulus for the upregulation of 
the adhesion molecules on alveolar epithelium or endothelium. In this model, both 
ICAM-1 and MCP-1 are required for lung neutrophil recruitment. Thus, it is likely that 
reduced lung neutrophil recruitment is due to reduced pulmonary production of TNF-  
and subsequent reduction in the up-regulation of adhesion molecules in the pulmonary 
vasculature. 
 
 
 
 
  114 
C
on
tr
ol
 (P
B
S
)
P
B
S P
L
cR
G
D
L M
P
S
-L
cR
G
D
M
P
S
-L
0
5.0×102
1.0×103
1.5×103
2.0×103
2.5×103
3.0×103
*
**
IL-1  (i.t.)+Pre-treatment
B
A
L
F
 T
N
F
-
 (
p
g
/m
L
)
 
 
 
Figure 6.11 Histogram of inhibition of BALF TNF-  levels after nebulization of MPS-
L
cRGD
. 
 
TNF-  levels were measured by ELISA. Results are expressed a mean SEM of four 
experiments. * and ** indicate significant difference at P<0.05 and P<0.01, respectively 
from IL-1  stimulated (PBS) alone. 
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Figure 6.12 Histogram of inhibition of BALF levels of neutrophils after nebulization 
of MPS-L
cRGD
 in male Sprague-Dawley rats. 
 
Neutrophils levels were analyzed by Histopaque and MPO assays. Results are expressed 
as a mean SEM of four experiments. Statistically significant differences (* P<0.05, ** 
P<0.01 and *** P<0.001) compared with IL-1  treatment alone in each experiment. 
  115 
6.3.13 Effect of MPS-LcRGD on Neutrophil Accumulation in Lung Parenchyma 
 
Rats received IL-1  (i.t.) or saline as a control and were sacrificed 24 h later. As shown in 
Figure 6.13, rats receiving IL-1  showed a 6 fold increase (P<0.001) in lung parenchyma 
neutrophil content to 1.8 0.1x10
7
 over saline control. Besides, BALF neutrophils in IL-
1  (i.t.) treated rats increased 14 folds (P<0.001) to 2.8 0.1x10
6
 over control group. To 
investigate the effect of MPS-L
cRGD
 on neutrophil migration into the lung during ALI, 
neutrophil accumulation which occurs prior to migration into alveoli was estimated by 
MPO assay of the lung tissue. Besides, haematoxylin staining techniques was adopted to 
visualize the neutrophil accumulation in paraffin embedded lung parenchyma sections. 
From the staining, it is evident that MPS-L
cRGD
 attenuated neutrophil accumulation in 
lungs compared to MPS-L or L
cRGD
. 
 
 
6.4 Summary 
 
In summary, these studies demonstrate a critical role for the v 6 integrins in mediating 
development of alveolar edema caused by IL-1 , which is among the most biologically 
important inflammatory mediators in the airspace of patients with early ALI. We 
specifically used MPS encapsulated v 6 specific integrin liposomes to deliver the drug 
to alveolar epithelial cells, the site of inflammation. In addition to inhibition of integrin 
receptors, MPS-L
cRGD
 inhibited inflammation and neutrophil migration in IL-1  instilled 
ALI model model. The inhibition of v 6 integrins blocked the IL-1  mediated protein 
permeability across the distal lung epithelium and prevented, in large part, the 
development of pulmonary edema. The findings reported here have potential clinical 
relevance as this mode of treatment may provide new causal therapies for pulmonary 
edema from ALI. 
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Figure 6.13 Histological sections of lung parenchyma after haematoxylin treatment to 
stain neutrophils.  
 
Lung parenchyma sections represent the edema and neutrophil modulation pattern after 
MPS-L
cRGD
 pretreatment.Control (A) shows neat parenchyma cells without edema and a 
few neutrophils. IL-1  (B) instilled lung sections shows profuse edema and neutrophil 
migration. Non-specific liposomes (C) exhibit profuse edema and a mild reduction in 
neutrophil infiltration. Among the lower panel, both MPS-L
cRGD
 (D) and L
cRGD
 (E) 
showed reduction in neutrophil levels in alveoli. However, MPS-L
cRGD
 significantly 
reduced edema also. All the sections are a representative of n=3 samples. 
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CHAPTER 7. INHIBITION OF LUNG INFLAMMATION USING MPS-LAB 
 
 
7.1 Introduction 
 
Acute lung injury and its more severe form, acute respiratory distress syndrome is 
characterized by inflammation at the alveolar-blood capillary interface, resulting in 
alveolar influx of protein rich edema fluid and consequently impairment in arterial 
oxygenation.
4
 ALI/ARDS is usually a major cause of acute respiratory failure with high 
morbidity and mortality in critically ill patients, affected by various predisposing 
insults.
4,330
 ALI usually arises within 4-72 h of the inciting insults and this period offers 
an opportunity for detection of inflammation and initiation of an effective treatment.
331
 
 
The hallmark event in the pathophysiology of ALI/ARDS is the recruitment of a large 
number of neutrophils into alveoli with concomitant production of pro-inflammatory 
cytokines.
16
 Neutrophil recruitment from blood vasculature into alveolar spaces is 
orchestrated by sequential up-regulation of cell adhesion molecules (e.g. selectins, 
integrins and immunoglobulin supergene adhesion molecules) and their ligands, located 
on both vascular endothelial cells and neutrophils.
332
 The initial tethering and rolling of 
neutrophils over the endothelial cells is mediated by selectins and their ligands present on 
the apposing cells. During the rolling process, the integrin receptors on neutrophil surface 
undergo activation as a result of interaction with chemokines on the inflamed 
endothelium. The activated integrins further interact with immunoglobulin adhesion 
molecules (e.g. ICAM-1, VCAM-1), upregulated on the inflamed endothelium. These 
interactions result in firm adhesion of neutrophils to the endothelium. This is followed by 
the transendothelial migration of neutrophils from blood circulation into the alveolar sites 
of inflammation.
333-335
 
 
In this multi-step process of neutrophil migration, firm adhesion is predominantly 
mediated by neutrophil 2 integrins in conjunction with ICAM-1 of the endothelium.
336
 
ICAM-1 is constitutively expressed on endothelial cells and its levels are upregulated in 
response to inflammatory stimuli, such as LPS, TNF-α and IL-1 .337 The upregulation of 
ICAM-1 is usually long lasting with a maximum level at 4-6 h and remains elevated for 
24 h.
338
 This offers a potential opportunity for targeting to the endothelial ICAM-1 
molecules using anti-ICAM-1 antibody as a specific targeting ligand. This strategy has 
been applied by conjugating anti-ICAM-1 monoclonal antibody onto the surface of 
liposomes. 
 
IL-1  stimulates pro-inflammatory cytokine and chemokine release and upregulates 
CAMs in alveolar epithelial cells.
320
 Due to a high chemokine gradient across the alveolar 
barrier, leukocytes infiltrate from blood circulation into alveoli, and exacerbate edema 
and lung inflammation.
321,322
 Of the various transcriptional factors, NF- B plays a central 
role in regulating the inflammatory genes encoding CAMs, chemokines and 
cytokines.
75,323
 NF- B is a heterodimeric protein present in the cytoplasm in an inactive 
form stabilized by binding to the inhibitory protein, I B .
74
 In response to IL-1  
stimulation, I B  undergoes phosphorylation and proteolytic degradation. As a result, p- 
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I B  is ubiquitinated allowing nuclear translocation of NF- B, which binds to promoter 
regions of the target genes to initiate the transcription of CAMs, chemokines and pro-
inflammatory cytokines.
324,325
 And inhibitors targeting the activated NF- B would 
suppress CAM expression and chemokines release, which eventually prevent migration 
of leukocytes.
326,327
 Glucocorticoids, cited as NF- B inhibitors mediate the effects 
through inhibition of NF- B transcriptional activity leading to suppression of pro-
inflammatory genes.
328
 Taken together, IL-1β mediates: I) 2 integrin dependent 
neutrophil migration and II) induction of NF- B dependent pro-inflammatory genes. In 
order to reduce both neutrophil migration and inflammation associated with IL-1  
stimulation, we used MPS encapsulated and anti-ICAM-1 antibody conjugated liposomes 
(MPS-L
Ab
). In the present study, liposomes were chosen for their flexibility: I) to anchor 
anti-ICAM-1 Ab onto the surface of liposomes for targeting to 2 integrin receptors 
located on alveolar epithelium and II) to encapsulate and deliver MPS to alveolar 
endothelial cells for inhibition of pro-inflammatory cytokines (e.g. TNF-α and IL-6), 
chemokines (e.g. MCP-1) and CAMs (e.g. ICAM-1) expression. 
 
To determine the effects of the targeting system in vivo, we used IL-1  induced lung 
inflammation rat model. MPS-L
Ab
 suspension was administered by intravenous route 
prior to intra-tracheal (i.t.) instillation of IL-1  in male Sprague-Dawley rats. In vivo 
results demonstrated that MPS-L
Ab
 treatment show a decrease in neutrophils migration 
and pro-inflammatory mediators‟ expression compared to IL-1  instilled (i.t.) positive 
control. The results of this study present evidence that MPS-L
Ab
 reduces neutrophil 
migration by blocking 2 integrin receptors; while MPS release from MPS-L
Ab
 exhibited 
mild reduction in pulmonary edema. 
 
 
7.2 Experimental Section 
 
 
7.2.1 Materials 
 
HSPC, DSPE-PEG2000, DSPE-PEG2000-maleimide were obtained from Avanti Polar 
Lipids (Birmingham, AL). MPS and recombinant human interleukin-1  were purchased 
from Sigma (St.Louis, MO). Antibodies obtained include: Anti- v (P2W7; sc-9969; 
Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti- 6 (H-110; sc-15329; Santa Cruz 
Biotechnology Inc), anti- 1 (mAb13, Becton-Dickinson, Bedford, MA), anti- v 3 
(LM609; Chemicon, Temecula, CA), anti- v 5 (P1F6; Chemicon) and IgG (Chemicon). 
Gel electrophoresis chemicals were obtained from Bio-Rad Inc. (Hercules, CA). All other 
chemicals of ACS grade or higher were purchased either from Sigma (St.Louis, MO) or 
Fisher Scientific (Suwannee, GA).  
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7.2.2 Methods 
 
 
7.2.2.1 Preparation of Liposomes 
 
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate 
gradient method described in Chapter 4. Liposomes were prepared with a lipid 
composition of HSPC, CHOL, DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45: 
3: 2 molar ratios. Lipid (30 mM total phospholipids) solution in chloroform-methanol 
solution (3:1% v/v) was subjected to vacuum drying at 40 C to form a thin dry film, 
which was hydrated with calcium acetate buffer (200 mM) at 65 C to form MLVs. These 
vesicles were extruded through 200/100 nm sandwiched polycarbonate membrane filters 
using LIPEX
TM
 extruder. The MLVs were subjected to 6 extrusion passes to obtain 
liposomes with a mean diameter of 100-120 nm. 
 
To create a transmembrane calcium acetate gradient across the liposomes, the 
extraliposomal calcium acetate buffer was replaced with 0.9% saline solution by dialysis 
(10,000 Da MWCO). Followed by generation of calcium acetate gradient, liposomes 
were mixed and incubated with MPS solution [19 mM] at 48°C for 6 min and then cooled 
to 4°C. Non-encapsulated MPS and any traces of calcium acetate were removed by 
dialysis of MPS-L at 4°C for 6 h. 
 
As shown in Figure 7.1, anti-ICAM-1 anti-body solution (1 mg/mL) was incubated with 
mercapto-ethylamine (MEA; 3 mg/mL, pH 6.0) at 30 C for 20 min. Followed by 
incubation; the anti-body solution was de-salted to remove MEA using de-salted 
columns. The de-salting process was repeated 3 times to remove any traces of MEA. 
Now, the anti-body fragments were subjected to fractionation to isolate anti-body 
fragments. Fraction number, 6-8 obtained mFAb‟2 fragments and fractions, 16-17 
obtained mFab fragments. The isolated mFab‟ fragments were used for conjugation with 
DSPE-PEG2000-maleimide in 500 L of HEPES buffer, pH 6.8 for 2 h at 30 C, under a 
nitrogen atmosphere. The reaction was stopped with N-ethyl maleimide solution (8 mM). 
Now, the lipid-mFab‟ conjugate was dialyzed for 6 h at 4°C to remove N-ethyl 
maleimide. The amount of mFab‟ coupled to DSPE-PEG2000-maleimide was estimated 
qualitatively by SDS-PAGE and quantitatively by using Bio-Rad protein assay kit. 
Approximately, 27% (molar) yield was obtained. 
 
 
7.2.2.2 SDS-PAGE 
 
Immunoliposomes were run SDS-PAGE under non-reducing conditions to avoid further 
fragmentation of anti-body. In this process, reducing agents were not added during the 
preparation of both samples. As a result, the resolution of the immunoliposomes is based 
on both molecular weight and charge resided on the surface of liposomes (Figure 7.2). 
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Figure 7.1 Schematic representation of the coupling of anti-ICAM-1 antibody 
fragment tethered to the surface of liposomes. 
 
In step A, antibody fragments were synthesized by using MEA buffer. In step B, 
following the cleavage of antibody, antibody fragments were coupled to DSPE-PEG2000-
maleimide by Michael addition reaction. 
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Figure 7.2 SDS-PAGE analysis of DSPE-PEG2000-mFab‟ fragment under non-
reducing conditions. 
 
The molecular weight heavy chain is 50,000 Da and that of light chain is 23,000 Da. And 
the molecular weight of the lipid is 20,000 Da. Total molecular weight of the conjugate is 
93,000 Da which is red circled on lane 3. The bands on lane 1 correspond to standard 
molecular weight markers (high molecular weight mixture; Bio-Rad). The bands on lane 
2 correspond to light chain and heavy chains. 
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7.2.2.3 Insertion of Lipid-antibody Conjugates into Lipid Bilayers of Liposomes 
 
Lipid-antibody was inserted into the bilayers of liposomes by post-insertion method as 
described in Chapter 4. 
 
 
7.2.2.4 Particle Colloidal Properties 
 
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as 
described elsewhere. 
 
 
7.2.2.5 Animals 
 
Male Sprague-Dawley rats were used in all experiments. The experimental protocols 
were approved by IACUC of the University of Tennessee, Memphis. 
 
 
7.2.2.6 Systemic Administration of Liposome Formulations 
 
At least 30 min prior to IL-1β (i.t.) instillation, rats were administered with liposome (PL 
or MPS-L or MPS-L
Ab
) formulations at 2 mg/kg. Dose selection was based on initial dose 
escalation studies to see the pharmacodynamic effects. Twenty-four hours after the 
treatment, animals from all groups were sacrificed and lung tissue samples from each 
animal were fixed in 10% v/v buffered formalin. 
 
 
7.2.2.7 IL-1β Instillation and BALF Collection 
 
Male Sprague-Dawley rats, weighing 125-150 g were used in the study. Rats were fed 
normal diet before the experiment with free access to water. Following anesthesia 
(ketamine/xylazine, 87/13 mg/kg), a midline tracheal incision was made to expose the 
trachea. A 26 gauge needle was advanced endotracheally to instill IL-1  solution (200 
µL, 100 µg/mL in PBS, pH 7.2) or PBS alone (control). Following the IL-1  instillation, 
tracheal opening was sutured and animals were returned to cage. 
 
Twenty four hours post IL-1  administration, the lung vascular bed was flushed twice by 
injecting 10 mL ice-cold PBS into right ventricle. Followed by overdose of pentobarbital 
(100 mg/kg, i.v), tracheal sutures were cut open to expose trachea. BALF collection was 
performed by inserting a 26 gauge needle into trachea and lungs were lavaged twice with 
PBS (3 mL). BALF was collected into cryovials and centrifuged at 1100xg, 4 C for 10 
min. The supernatant was stored at -70 C for cytokines and chemokines analysis and the 
cell pellet was subjected to neutrophils estimation. Aliquots of BALF were estimated for 
protein concentration by UV absorbance at 280 nm using albumin (Bio-Rad) as standard. 
Also, post IL-1  administration, blood was collected at different time intervals for 
estimation of MPS levels. 
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7.2.2.8 Estimation of BALF Cytokines and Chemokines 
 
BALF supernatant collected and stored as described above was analyzed for cytokines 
(TNF- ) by ELISA method according to manufacturer (R&D Systems, Minneapolis, 
MN) instructions. 
 
 
7.2.2.9 Estimation of Lung Neutrophil Content 
 
Neutrophil content was assayed as described previously.
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7.2.2.10 Histological Examination of Lungs 
 
Histological examination was performed as described in Chapter 6. 
 
 
7.2.2.11 Statistical Analysis 
 
All data reported are arithmetic means. Error bars represent one SEM Differences 
between means of indicated groups were analyzed by ANOVA with Bonferroni 
corrections for multiple comparisons. A P value <0.05 was considered to be statistically 
significant. 
 
 
7.3 Results and Discussion 
 
 
7.3.1 Physico-chemical Characterization of MPS-LAb 
 
The colloidal properties of MPS-L
Ab
 and MPS-L determined by DLS method were stable 
over 14 days of shelf life. As shown in Table.7.1, mean particle size and polydispersity 
index of MPS-L
Ab
 is large than MPS-L. This could be attributed due to the large 
molecular weight of the ligand on the surface of liposomes. Zeta potential of MPS-L
Ab
 
was lower than MPS-L due to a large content of positive charged amino acids residing on 
surface of the antibody. 
 
 
7.3.2 Effect of MPS-LAb on BALF Protein Concentration in IL-1  Induced Rats 
 
Quantification of BALF protein concentration is considered as an indicator of increase in 
lung vascular and epithelial permeability resulting from inflammatory injury. In the 
present study, BALF protein concentration was quantified in control and treated groups. 
As represented in Figure 7.3, protein concentration in the BALF of IL-1  (i.t.) instilled 
group was nearly 2.75 folds that of rats receiving saline (i.t.) (IL-1  group, 0.52 0.03 
mg/mL; saline group, 0.18 0.02 mg/mL; p<0.001). A significant inhibition of BALF 
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Table 7.1 Physico-chemical properties of MPS-L
Ab
 used in in vivo studies. 
 
Liposomes 
Mean diameter, Zavg (nm) Zeta potential,  (mV) 
MPS incorporation 
efficiency (% w/v) 
PL 113±5 -22.7±2.8 NA 
MPS-L 110±18 -20.4±1.4 59 
MPS-L
Ab
 135±14 -9.1±3.7 24 
 
Each value represents the mean±SEM (n = 3). Mean diameter and zeta potential of 
liposome formulations were determined at 25 C. NA indicates not applied. NA was 
applied to the liposome formulations devoid of MPS encapsulation. 
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Figure 7.3 Histogram of inhibition of BALF protein in male Sprague-Dawley rats 
after systemic administration of MPS-L
Ab
. 
 
BALF protein levels were measured by Bio-Rad micro-protein assay. Results are 
expressed as mean SEM of 3 samples. Statistically significant differences (* P<0.05) 
compared with IL-1  treatment alone in each experiment. 
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protein concentration was observed in rats pretreated with MPS-L
Ab
 (0.26 0.01 mg/mL; 
p<0.05) compared to IL-1  (i.t.) instilled group. To delineate the effects of MPS and L
Ab
 
on the inhibition of BALF protein, rats were pretreated with MPS-L or L
Ab
, respectively. 
A mild reduction of BALF protein was observed in rats pretreated with MPS-L 
(0.32 0.02 mg/mL; P>0.05) and L
Ab
 (0.44 0.02 mg/mL; P>0.05), which indicate 
formulations had no effect on alveolar endothelial permeability. The data suggests that 
protein permeability is mediated by pathways other than 2 integrins. The inhibition of 
protein permeability observed with MPS-L
Ab
 could be due to the synergistic effect of 
MPS delivery and anti-ICAM-1 Ab targeting. 
 
 
7.3.3 Effect of MPS-LAb on MCP-1 Production in BALF of IL-1  Induced Rats 
 
BALF levels at 24 h following IL-1  (i.t.) instillation in pretreated (MPS-L
Ab
, MPS-L or 
L
Ab
) rat groups were measured. Saline and IL-1  alone instilled groups were treated as 
negative and positive control groups. As shown in Figure 7.4, MPS-L
Ab
 treatment 
resulted in a decrease of MCP-1 (1499.2 85.2 pg/mL in IL-1  alone instilled rats vs. 
540.7 61.2 pg/mL in MPS-L
Ab
 treated rats, P<0.05). MPS-L also exerted the similar 
effects of MCP-1 inhibition as MPS-L
Ab
. L
Ab
 has no influence on MCP-1 production, 
whose levels were similar to that of IL-1  instilled positive control group. 
 
 
7.3.4 Effect of MPS-LAb on TNF-  Production in BALF of IL-1  Induced Rats 
 
As compared with saline-treated controls, IL-1  (i.t.) instillation induced a significant 
increase in BALF levels of TNF-  (Figure 7.5). After MPS-L
Ab
 and MPLS-L treatment, 
BALF levels of TNF-  were significantly (P<0.05) lower. In contrast, BALF levels of 
TNF-  in animals pretreated with L
Ab
 had no effect on TNF-  production. 
 
 
7.3.5 Effect of MPS-LAb on Neutrophil Migration of IL-1  Induced Rats 
 
For quantitative assessment of neutrophil migration into alveolar spaces, MPO assay of 
BALF was performed in pretreated rat groups (MPS-L
Ab
, MPS-L or L
Ab
) post IL-1  (i.t.) 
instillation. As illustrated in Figure 7.6, pretreatment of rats with L
Ab
 inhibited the 
neutrophil migration into alveolar spaces of rats receiving IL-1  (i.t.) as compared with 
saline treated rats (1.2 0.2x10
6
; p<0.05 in L
Ab
 treated group vs. 2.4 0.5x10
6
; P<0.05 in 
saline treated group). Inhibition of neutrophil migration was similar to L
Ab
 pretreatment. 
Only, a mild reduction of BALF neutrophil content was observed with MPS-L. 
 
 
7.3.6 Effect of MPS-LAb on Neutrophil Accumulation in Lung Parenchyma 
 
Rats received IL-1  (i.t.) or saline as a control, and were sacrificed 24 h later. As shown 
in Figure 7.7, rats receiving IL-1  showed a 11.3 fold increase (P<0.001) in lung  
  126 
Control PBS L
Ab
MPS-L MPS-L
Ab
0
500
1000
1500
2000
**
IL-1 (i.t.)+Pre-treatment
B
A
L
F
 M
C
P
-1
 (
p
g
/m
L
)
 
 
 
Figure 7.4 Histogram of inhibition of BALF MCP-1 levels in male Sprague-Dawley 
rats after systemic administration of MPS-L
Ab
. 
 
Results are expressed as a mean SEM of 3 samples. Statistically significant differences 
(* P<0.05) compared with IL-1  treatment alone in each experiment. 
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Figure 7.5 Histogram of inhibition of BALF TNF-  levels in male Sprague-Dawley 
rats after systemic administration of MPS-L
Ab
. 
 
TNF-  levels were measured by ELISA. Results are expressed as a mean SEM of 3 
samples. Statistically significant differences (* P<0.05) compared with IL-1  treatment 
alone in each experiment. 
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Figure 7.6 Histogram of inhibition of BALF levels of neutrophils after nebulization 
of MPS-L
Ab
 in male Spague-Dawley rats. 
 
Neutrophil levels were analyzed by Histopaque and MPO assays. Results are expressed 
as a mean SEM of 3 samples. Statistically significant differences (* P<0.05, ** P<0.01) 
compared with IL-1  treatment alone in each experiment. 
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Figure 7.7 Histological sections of lung parenchyma after haematoxylin treatment to 
stain neutrophils. 
 
Lung parenchyma sections represent the edema and neutrophil modulation pattern after 
MPS-L
Ab
 pretreatment. IL-1  instilled lung sections shows profuse edema and neutrophil 
migration. Both MPS-L
Ab 
and L
Ab
 showed neutrophil reduction in alveoli. However, 
MPS-L
Ab
 significantly reduced edema also. All the sections are representative of n=3 
samples. 
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parenchyma neutrophil content to 3.2 0.8x10
8
 over saline control. To investigate the 
effect of MPS-L
Ab
 on neutrophil migration into the lung during ALI, neutrophil 
accumulation which occurs prior to migration into alveoli was estimated by MPO assay 
of the lung tissue. Besides, haematoxylin staining technique was adopted to visualize the 
neutrophil accumulation in paraffin embedded lung parenchyma sections. From the 
staining, it is evident that MPS-L
Ab
 (P<0.01) completely attenuated neutrophil 
accumulation compared to saline control. Also, L
Ab
 (P<0.05) exerted a significant 
inhibition on lung parenchymal accumulation, which runs in correlation with BALF 
neutrophil content. 
 
 
7.4 Summary 
 
In summary, these studies demonstrate that 2 integrins mediate the neutrophil migration 
into alveoli in response to IL-1  stimulation. To disrupt the interaction between 2 
integrins and ICAM-1 receptors of alveolar endothelium, anti-ICAM-1 antibody 
conjugated liposomes were administered by systemic route. This strategy was adopted as 
ICAM-1 receptors could be accessed from the circulation rather than from the alveoli. 
MPS-L
Ab
 completely attenuated neutrophil migration. However, only a mild reduction in 
pulmonary edema and inhibition on inflammatory response were observed. This could 
possibly be due to the fact that IL-1  stimulates v 5 and v 6 integrins and mediates 
pulmonary edema. Anti-ICAM-1 antibody is not specific to either of the integrins and 
hence could exert no inhibitory effects on integrin receptors. In such cases, multiple 
ligand targeting strategy or combination approaches using integrin and ICAM-1 receptor 
specific targeting agents may favor the inhibition of pulmonary edema and neutrophil 
migration. 
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CHAPTER 8. SUMMARY AND CONCLUSIONS 
 
 
The alveolar epithelium and endothelium are prime targets for intervention of lung 
inflammation. ALI inflammation is characterized by pulmonary edema, pro-inflammatory 
inflammatory mediators‟ production and leukocyte migration into alveoli. Underlying the 
inflammation, integrin receptors play a critical role in the mediation of various 
pathological events of ALI. Proinflammatory cytokines like TNF-α and IL-1β activate 
alveolar epithelium and endothelium via NF-κB pathway. The activated EC excrete 
cytokines and chemokines, which in concert with cellular adhesion molecules promote 
leukocyte recruitment and migration. Blockade of these processes has attained an 
immense attention in recent years, and many new signal transduction inhibitors against 
NF-κB were developed. 
 
In this thesis, I developed novel surface modified liposomes aiming at the inhibition of 
proinflammatory stimuli in the lung. The first part of the thesis concerns the development 
and stabilization of surface modified nano-sized targeted liposomes. In the second part of 
the presented work, the drug targeting concept was applied to anti-inflammatory agents, 
in order to selectively deliver therapeutic moieties to the affected disease sites. I applied a 
cyclic arginine-glycine-D-aspartic acid tri-peptide and anti-ICAM-1 antibody as targeting 
ligands. The cRGD-peptide selectively binds to subsets of integrin receptor that are 
upregulated on activated epithelium and endothelium, but hardly expressed on quiescent 
cells. Anti-ICAM-1 antibody selectively binds to ICAM-1 receptors upregulated on 
alveolar endothelium. The task of a carrier is to carry the drug to the disease site. For this 
purpose, natural and synthetic polymers, antibodies (ligand and carrier), nanoparticles 
and even erythrocytes have been used. I chose liposomes for it is flexible enough for drug 
encapsulation, and imparts long circulation and targeting properties. Using functionalized 
lipids, I modified the surface of liposomes with cRGD-peptide and anti-ICAM-1 Ab, 
leading to a receptor binding drug carriers with high avidity. 
 
However, liposomes are thermodynamically unstable structures and undergo 
aggregation/fusion resulting in the loss of colloidal properties of the drug delivery 
systems. I addressed the concerns related to the stability of these uniquely designed 
targeted drug delivery systems. Lyophilization approach was adopted to improve the 
shelf-life of the liposomes. However, lyophilization itself is an aggressive process, which 
may be detrimental to the liposomes. Disaccharides and aminoacids were investigated to 
exert lyoprotection on these colloidal systems. Our studies showed that trehalose and 
sucrose among the sugars, and lysine among the aminoacids protected the liposomes 
from aggregation and leakage of the encapsulated drug moieties. 
 
This thesis reports how improved the delivery of the drug to the targeted sites with 
cRGD-peptide and anti-ICAM-1 Ab conjugated systems in comparison to the non-
targeted systems. The drug targeting systems showed high cell internalization and 
adequate drug release, since the uptake eventually led to release of the drug. To enhance 
overall delivery of the targeted liposomes, I explored different routes of administration to 
take advantage of the spatial and temporal expression of the receptors. Nebulization and 
  131 
systemic routes of administration were investigated. Since v 6 integrins are expressed 
on the apical side of the alveolar epithelium, I adopted nebulization approach for 
targeting to the integrin receptors. Nebulization of MPS-L
cRGD
 was performed prior to IL-
1  instillation in rats. MPS-L
cRGD
 liposome drug targeting system inhibited the 
inflammation and neutrophil migration associated with IL-1  instilled ALI model. The 
inhibition of v 6 integrins blocked the IL-1  mediated protein permeability across the 
distal lung epithelium, and prevented, in large part, the development of pulmonary 
edema. MPS released from the MPS-L
cRGD
 modulated the NF-  transcription, and 
attenuated the production of pro-inflammatory TNF-  and MCP-1 levels. Neutrophil 
migration and accumulation in lungs were inhibited. This study demonstrated that route 
of administration and targeted delivery system potentiate anti-inflammatory efficacy of 
MPS-L
cRGD
 targeted delivery system. 
 
I demonstrated that MPS-L
Ab
 could be targeted to ICAM-1 receptors, and thereby reduce 
the neutrophil migration into alveoli. MPS-L
Ab
 was able to inhibit the pro-inflammatory 
cytokines and chemokines production. However, only mild effects on edema were 
observed. 
 
In conclusion, I developed receptor specific surface modified nanoparticles to lung in an 
attempt to inhibit ALI pathogenesis. I demonstrated that route of administration of the 
delivery system plays a critical role to exert beneficial effects on ALI treatment. 
Furthermore, I stabilized the targeted liposomes, whose shelf-life was improved. The 
research works strengthened the development of novel nanoparticulate systems, in 
particular, liposomes for achieving anti-inflammatory drugs with high efficiency and 
specificity. Our studies demonstrated that the demands of many of these listed parameters 
were met, but the mild outcome for MPS-L
Ab
 demands that further work is required to 
see the benefits. Nevertheless, our drug targeting approach must be transferred to new 
drug moieties. Thereby, we can exploit our experience on targeting surface modified 
liposomes as shown in this thesis. The novel drug encapsulation and conjugation 
strategies, along with the strategic delivery facilitated improved results.
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